P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
1.889e-12 | -27.00 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 18 | 16828 | 49 |
NRXN1,MEIS2,MAML2,CADM1,RYR3,NPAS3,NRG3,PARD3B,NTRK2,PCDH9,CTNND2,ITPR2,PARD3,PTPRZ1,NEBL,ABLIM1,GPC5,QKI |
1.218e-11 | -25.13 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 28 | 16828 | 49 |
FBXL7,LSAMP,SLC1A3,NKAIN3,GPM6A,AHCYL2,RORA,CTNND2,PARD3,PTPRZ1,CDH20,ZBTB20,ATP13A4,RANBP3L,MEIS2,SFXN5,CADM1,MAML2,NRG3,RYR3,ITPR2,PCDH9,ZNRF3,SOX5,PREX2,TNIK,GPC5,QKI |
2.238e-11 | -24.52 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 16 | 16828 | 49 |
NEBL,PTPRZ1,PARD3,ABLIM1,MAML2,CADM1,MEIS2,NRXN1,PCDH9,ITPR2,CTNND2,RYR3,NPAS3,PARD3B,NTRK2,NRG3 |
2.289e-11 | -24.50 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 16 | 16828 | 49 |
PARD3,PTPRZ1,NEBL,ABLIM1,MEIS2,NRXN1,MAML2,CADM1,NPAS3,RYR3,NRG3,NTRK2,PARD3B,PCDH9,CTNND2,ITPR2 |
3.886e-11 | -23.97 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 30 | 16828 | 49 |
SLC1A3,LSAMP,FBXL7,GPM6A,NKAIN3,RORA,AHCYL2,CTNND2,PARD3,PTPRZ1,CDH20,ZBTB20,ATP13A4,MEIS2,RANBP3L,MAML2,CADM1,SFXN5,NPAS3,RYR3,NRG3,PCDH9,ITPR2,ZNRF3,PREX2,SOX5,GPC5,SLC1A2,TNIK,QKI |
4.918e-11 | -23.74 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 23 | 16828 | 49 |
ATP13A4,TRPS1,NEBL,DTNA,PARD3,CTNND2,PARD3B,GPM6A,LSAMP,SLC1A3,TNIK,GPC5,SOX5,PCDH9,ITPR2,RYR3,NRG3,NTRK2,MAML2,SFXN5,CADM1,RANBP3L,MEIS2 |
2.337e-10 | -22.18 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 32 | 16828 | 49 |
SLC4A4,PREX2,SOX5,SLC1A2,GPC5,TNIK,MEIS2,MAML2,NTM,CADM1,GLIS3,RYR3,NFIA,NTRK2,NRG3,PCDH9,ITPR2,PTPRZ1,PARD3,BMPR1B,NEBL,PAMR1,ZBTB20,ATP13A4,SLC1A3,LSAMP,NRXN1,FBXL7,GPM6A,NKAIN3,RORA,CTNND2 |
2.337e-10 | -22.18 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 32 | 16828 | 49 |
TNIK,SLC1A2,GPC5,SLC4A4,SOX5,PREX2,NRG3,NTRK2,NFIA,RYR3,GLIS3,ITPR2,PCDH9,MEIS2,CADM1,NTM,MAML2,ZBTB20,PAMR1,ATP13A4,PTPRZ1,PARD3,NEBL,BMPR1B,RORA,CTNND2,FBXL7,NRXN1,LSAMP,SLC1A3,NKAIN3,GPM6A |
6.000e-10 | -21.23 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 46 | 16828 | 49 |
PCDH9,NRG3,NTRK2,SFXN5,MSI2,NTM,MAML2,QKI,TNIK,SLC1A2,GPC5,SOX5,PREX2,SLC4A4,PITPNC1,AHCYL2,RORA,NKAIN3,SPARCL1,GPM6A,NRXN1,TRPS1,ABLIM1,BMPR1B,PARD3,MACF1,ITPR2,NFIA,GLIS3,NPAS3,RYR3,CADM1,MEIS2,ZNRF3,CTNND2,PARD3B,FBXL7,LSAMP,SLC1A3,NHSL1,ATP13A4,ZBTB20,DTNA,CDH20,NEBL,PTPRZ1 |
6.230e-10 | -21.20 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 42 | 16828 | 49 |
NEBL,PTPRZ1,PARD3,NHSL1,ATP13A4,TRPS1,ABLIM1,PAMR1,ZBTB20,GPM6A,NKAIN3,LSAMP,SLC1A3,FBXL7,NRXN1,CTNND2,RORA,PITPNC1,AHCYL2,PARD3B,PREX2,SOX5,SLC4A4,QKI,TNIK,GPC5,SLC1A2,NTM,MAML2,SFXN5,CADM1,RANBP3L,MEIS2,PCDH9,MACF1,ITPR2,NFIA,NPAS3,GLIS3,RYR3,NRG3,NTRK2 |
1.522e-09 | -20.30 | nervous system development | biological process | GO:0007399 | 2185 | 23 | 18204 | 49 |
BMPR1B,ATP1A2,PREX2,MSI2,PARD3,MEIS2,GPM6A,SLC1A2,NRG3,NRXN1,NFIA,PTPRZ1,NTM,LSAMP,SOX5,PCDH9,SLC1A3,RORA,QKI,CTNND2,NTRK2,TNIK,CTNNA2 |
2.096e-09 | -19.98 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 32 | 16828 | 49 |
NRG3,NTRK2,RYR3,MACF1,ITPR2,PCDH9,RANBP3L,MEIS2,CADM1,MAML2,TNIK,SLC1A2,GPC5,QKI,SOX5,PREX2,AHCYL2,RORA,CTNND2,ATP1A2,FBXL7,LSAMP,SLC1A3,NKAIN3,SPARCL1,GPM6A,TRPS1,ATP13A4,PARD3,DTNA,CDH20,NEBL |
2.612e-09 | -19.76 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 20 | 16828 | 49 |
MEIS2,FBXL7,SLC1A3,LSAMP,CADM1,NKAIN3,MAML2,NTRK2,NRG3,RORA,RYR3,ITPR2,CTNND2,PCDH9,PARD3,SOX5,NEBL,PREX2,GPC5,QKI |
2.612e-09 | -19.76 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 20 | 16828 | 49 |
NTRK2,NRG3,RORA,RYR3,ITPR2,CTNND2,PCDH9,MEIS2,FBXL7,SLC1A3,LSAMP,CADM1,NKAIN3,MAML2,GPC5,QKI,PARD3,SOX5,NEBL,PREX2 |
3.883e-09 | -19.37 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 23 | 16828 | 49 |
MAML2,CADM1,PCDH9,ITPR2,RYR3,NPAS3,NTRK2,NRG3,PREX2,SOX5,SLC1A2,GPC5,GPM6A,NKAIN3,SLC1A3,LSAMP,FBXL7,CTNND2,AHCYL2,BMPR1B,PARD3,ATP13A4,NHSL1 |
3.883e-09 | -19.37 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 23 | 16828 | 49 |
ATP13A4,NHSL1,GPC5,SLC1A2,BMPR1B,PREX2,SOX5,PARD3,PCDH9,ITPR2,CTNND2,NPAS3,RYR3,NTRK2,AHCYL2,NRG3,GPM6A,MAML2,CADM1,NKAIN3,SLC1A3,LSAMP,FBXL7 |
8.150e-09 | -18.63 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 12 | 16828 | 49 |
LSAMP,MEIS2,GPM6A,MAML2,CADM1,SFXN5,RYR3,GPC5,NRG3,PCDH9,ATP13A4,CTNND2 |
1.464e-08 | -18.04 | multicellular organism development | biological process | GO:0007275 | 3957 | 29 | 18204 | 49 |
RANBP3L,NRG3,CADM1,NEBL,NRXN1,NFIA,TRPS1,ATP1A2,MSI2,PREX2,CDH20,BMPR1B,SLC1A2,PARD3,MEIS2,GPM6A,QKI,CTNND2,SLC1A3,RORA,TNIK,CTNNA2,NTRK2,LSAMP,NTM,SOX5,PTPRZ1,PCDH9,ZNRF3 |
2.157e-08 | -17.65 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 14 | 16828 | 49 |
PARD3,SOX5,PREX2,SLC1A2,GPC5,FBXL7,LSAMP,NKAIN3,MAML2,NTRK2,NRG3,RYR3,ATP1A2,PCDH9 |
2.998e-08 | -17.32 | system development | biological process | GO:0048731 | 3533 | 27 | 18204 | 49 |
NRXN1,NFIA,RANBP3L,NRG3,NEBL,CADM1,SLC1A2,MEIS2,PARD3,GPM6A,ATP1A2,TRPS1,PREX2,MSI2,BMPR1B,CTNNA2,TNIK,NTRK2,QKI,CTNND2,SLC1A3,RORA,PCDH9,NTM,LSAMP,SOX5,PTPRZ1 |
4.380e-08 | -16.94 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 22 | 16828 | 49 |
SLC1A2,GPC5,PARD3,PTPRZ1,PREX2,CDH20,NEBL,SOX5,RYR3,NRG3,NTRK2,PCDH9,CTNND2,ITPR2,LSAMP,SLC1A3,FBXL7,MEIS2,MAML2,GPM6A,NKAIN3,CADM1 |
4.380e-08 | -16.94 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 22 | 16828 | 49 |
GPC5,SLC1A2,NEBL,CDH20,PREX2,SOX5,PARD3,PTPRZ1,PCDH9,ITPR2,CTNND2,RYR3,NTRK2,NRG3,MAML2,GPM6A,CADM1,NKAIN3,SLC1A3,LSAMP,MEIS2,FBXL7 |
4.446e-08 | -16.93 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 25 | 16828 | 49 |
SLC1A2,GPC5,TRPS1,ATP13A4,ZNRF3,PARD3,SOX5,NEBL,PREX2,PARD3B,NTRK2,NRG3,RYR3,ITPR2,CTNND2,PCDH9,MEIS2,FBXL7,SLC1A3,LSAMP,CADM1,NKAIN3,SFXN5,GPM6A,MAML2 |
5.128e-08 | -16.79 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 22 | 16828 | 49 |
CDH20,NEBL,PARD3,PTPRZ1,CTNND2,NKAIN3,GPM6A,FBXL7,SLC1A3,LSAMP,GPC5,SLC1A2,SOX5,PREX2,ITPR2,PCDH9,NTRK2,NRG3,RYR3,CADM1,MAML2,MEIS2 |
5.448e-08 | -16.73 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 28 | 16828 | 49 |
ATP1A2,CTNND2,AHCYL2,RORA,NKAIN3,GPM6A,SPARCL1,FBXL7,LSAMP,ATP13A4,CDH20,NEBL,PARD3,ITPR2,MACF1,PCDH9,NRG3,RYR3,CADM1,MAML2,MEIS2,RANBP3L,QKI,GPC5,SLC1A2,TNIK,SOX5,PREX2 |
7.535e-08 | -16.40 | PRNP (prion protein (Kanno blood group)) | protein interactions | 5621 | 1118 | 15 | 19454 | 50 |
QKI,NHSL1,SLC1A3,MACF1,ABLIM1,AHCYL2,TRPS1,SPARCL1,MAML2,GPM6A,MSI2,PTPRZ1,SLC4A4,LSAMP,ATP1A2 |
1.027e-07 | -16.09 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 24 | 16828 | 49 |
ITPR2,CTNND2,PCDH9,NTRK2,PARD3B,NRG3,RYR3,CADM1,SFXN5,NKAIN3,MAML2,GPM6A,MEIS2,FBXL7,SLC1A3,LSAMP,TRPS1,GPC5,SLC1A2,SOX5,NEBL,PREX2,ZNRF3,PARD3 |
1.593e-07 | -15.65 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 49 | 16828 | 49 |
ZNRF3,MEIS2,CADM1,NFIA,NPAS3,GLIS3,RYR3,MACF1,ITPR2,PTPRZ1,DTNA,CDH20,NEBL,ZBTB20,PAMR1,NHSL1,ATP13A4,FBXL7,LSAMP,SLC1A3,PARD3B,CTNND2,ATP1A2,SLC4A4,SOX5,PREX2,TNIK,SLC1A2,GPC5,QKI,RANBP3L,SFXN5,MSI2,NTM,MAML2,NRG3,NTRK2,PCDH9,PARD3,BMPR1B,ABLIM1,TRPS1,NRXN1,NKAIN3,SPARCL1,GPM6A,AHCYL2,PITPNC1,RORA |
1.885e-07 | -15.48 | cell junction | cellular component | GO:0030054 | 2224 | 20 | 19108 | 49 |
PARD3B,NFIA,NRXN1,PTPRZ1,CTNND2,PCDH9,DTNA,SPARCL1,NRG3,NTRK2,CADM1,PARD3,QKI,SLC1A2,CDH20,CTNNA2,TNIK,GPM6A,ATP1A2,SLC1A3 |
1.940e-07 | -15.46 | cell morphogenesis | biological process | GO:0000902 | 687 | 12 | 18204 | 49 |
SLC1A3,CTNND2,CTNNA2,NRXN1,TNIK,NFIA,PTPRZ1,BMPR1B,CDH20,PREX2,PARD3,GPM6A |
2.088e-07 | -15.38 | neurogenesis | biological process | GO:0022008 | 1334 | 16 | 18204 | 49 |
RORA,SLC1A3,CTNND2,QKI,NTRK2,NFIA,TNIK,NRXN1,CTNNA2,BMPR1B,PTPRZ1,PREX2,SOX5,NTM,GPM6A,PARD3 |
2.090e-07 | -15.38 | generation of neurons | biological process | GO:0048699 | 1158 | 15 | 18204 | 49 |
NTM,SOX5,PREX2,PTPRZ1,BMPR1B,PARD3,GPM6A,CTNND2,SLC1A3,RORA,CTNNA2,TNIK,NRXN1,NFIA,NTRK2 |
2.559e-07 | -15.18 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 38 | 16828 | 49 |
ABLIM1,ZBTB20,PAMR1,ATP13A4,NHSL1,TRPS1,PTPRZ1,PARD3,NEBL,CDH20,DTNA,RORA,PARD3B,PITPNC1,ATP1A2,CTNND2,LSAMP,NRXN1,FBXL7,GPM6A,SLC1A2,GPC5,TNIK,QKI,ZNRF3,SLC4A4,PREX2,SOX5,RYR3,NRG3,PCDH9,ITPR2,MACF1,RANBP3L,MAML2,NTM,CADM1,SFXN5 |
2.894e-07 | -15.06 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 11 | 16828 | 49 |
GPC5,SOX5,PCDH9,CTNND2,RYR3,AHCYL2,NRG3,GPM6A,NKAIN3,SFXN5,LSAMP |
4.196e-07 | -14.68 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 20 | 18204 | 49 |
SLC1A3,NEBL,RORA,QKI,NRG3,CTNND2,NTRK2,NRXN1,TNIK,CTNNA2,ABLIM1,NFIA,PTPRZ1,CDH20,BMPR1B,SOX5,PREX2,PARD3,MEIS2,GPM6A |
4.672e-07 | -14.58 | anatomical structure development | biological process | GO:0048856 | 5207 | 31 | 18204 | 49 |
CTNNA2,TNIK,NTRK2,CTNND2,QKI,RORA,SLC1A3,ZNRF3,PCDH9,SOX5,NTM,LSAMP,PTPRZ1,NFIA,ABLIM1,SPARCL1,NRXN1,RANBP3L,NRG3,NEBL,CADM1,SLC1A2,GPM6A,MEIS2,PARD3,MSI2,PREX2,ATP1A2,TRPS1,BMPR1B,CDH20 |
5.939e-07 | -14.34 | neuron differentiation | biological process | GO:0030182 | 1081 | 14 | 18204 | 49 |
PTPRZ1,BMPR1B,NTM,PREX2,PARD3,GPM6A,SLC1A3,RORA,CTNND2,NTRK2,CTNNA2,TNIK,NRXN1,NFIA |
6.811e-07 | -14.20 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 15 | 16828 | 49 |
NTRK2,NRG3,RYR3,NPAS3,NFIA,ATP1A2,FBXL7,LSAMP,NKAIN3,SLC1A2,TNIK,PARD3,SOX5,BMPR1B,PREX2 |
6.811e-07 | -14.20 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 15 | 16828 | 49 |
TNIK,SLC1A2,PARD3,SOX5,PREX2,BMPR1B,NRG3,NTRK2,NFIA,RYR3,NPAS3,ATP1A2,FBXL7,LSAMP,NKAIN3 |
1.073e-06 | -13.75 | developmental process | biological process | GO:0032502 | 5716 | 32 | 18204 | 49 |
ZNRF3,PCDH9,SOX5,LSAMP,NTM,PTPRZ1,TNIK,CTNNA2,NTRK2,CTNND2,QKI,NHSL1,RORA,SLC1A3,SLC1A2,GPM6A,PARD3,MEIS2,PREX2,MSI2,TRPS1,ATP1A2,CDH20,BMPR1B,ABLIM1,NFIA,NRXN1,SPARCL1,NRG3,RANBP3L,CADM1,NEBL |
1.623e-06 | -13.33 | CTNNA1 (catenin alpha 1) | protein interactions | 1495 | 325 | 8 | 19454 | 50 |
ABLIM1,MACF1,CTNNA2,NEBL,DTNA,TNIK,NHSL1,PARD3 |
1.809e-06 | -13.22 | multicellular organismal process | biological process | GO:0032501 | 6177 | 33 | 18204 | 49 |
MSI2,PREX2,ATP1A2,TRPS1,BMPR1B,CDH20,SLC4A4,SLC1A2,GPM6A,MEIS2,DTNA,PARD3,NRG3,RANBP3L,NEBL,CADM1,NFIA,ABLIM1,NRXN1,SOX5,LSAMP,NTM,PTPRZ1,RYR3,ZNRF3,PCDH9,CTNND2,QKI,RORA,SLC1A3,CTNNA2,TNIK,NTRK2 |
2.071e-06 | -13.09 | neuron development | biological process | GO:0048666 | 859 | 12 | 18204 | 49 |
NRXN1,TNIK,CTNNA2,GPM6A,NTRK2,PARD3,PREX2,CTNND2,NTM,BMPR1B,SLC1A3,PTPRZ1 |
2.806e-06 | -12.78 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 25 | 16828 | 49 |
PAMR1,PARD3,PTPRZ1,BMPR1B,DTNA,PARD3B,PITPNC1,CTNND2,SLC1A3,LSAMP,FBXL7,GPC5,TNIK,ZNRF3,SLC4A4,PREX2,RYR3,NPAS3,NTRK2,NRG3,PCDH9,MACF1,MEIS2,RANBP3L,MSI2 |
2.806e-06 | -12.78 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 25 | 16828 | 49 |
PITPNC1,PARD3B,CTNND2,LSAMP,SLC1A3,FBXL7,PAMR1,PARD3,PTPRZ1,BMPR1B,DTNA,RYR3,NPAS3,NRG3,NTRK2,PCDH9,MACF1,RANBP3L,MEIS2,MSI2,TNIK,GPC5,SLC4A4,ZNRF3,PREX2 |
3.019e-06 | -12.71 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 33 | 16828 | 49 |
CTNND2,RORA,PARD3B,GPM6A,SPARCL1,NKAIN3,SLC1A3,LSAMP,FBXL7,NHSL1,TRPS1,PAMR1,CDH20,NEBL,PARD3,PTPRZ1,PCDH9,ITPR2,MACF1,GLIS3,RYR3,NPAS3,NFIA,NTRK2,NRG3,MAML2,CADM1,MEIS2,SLC1A2,GPC5,PREX2,SOX5,ZNRF3 |
4.244e-06 | -12.37 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 18 | 16828 | 49 |
MAML2,GPM6A,NRXN1,PCDH9,ITPR2,MACF1,NPAS3,RYR3,RORA,PARD3B,AHCYL2,NEBL,BMPR1B,SOX5,ZNRF3,SLC4A4,ZBTB20,TNIK |
4.307e-06 | -12.36 | larynx | COSMIC cancer mutations | larynx | 1948 | 18 | 16828 | 49 |
GPM6A,MAML2,NRXN1,MACF1,ITPR2,PCDH9,AHCYL2,PARD3B,NPAS3,RYR3,RORA,SOX5,BMPR1B,NEBL,SLC4A4,ZNRF3,TNIK,ZBTB20 |
4.959e-06 | -12.21 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 37 | 16828 | 49 |
GPM6A,SPARCL1,NKAIN3,SLC1A3,LSAMP,FBXL7,CTNND2,RORA,PARD3B,AHCYL2,NEBL,CDH20,BMPR1B,PTPRZ1,PARD3,ATP13A4,NHSL1,ABLIM1,PAMR1,MAML2,CADM1,SFXN5,MEIS2,RANBP3L,PCDH9,ITPR2,MACF1,RYR3,GLIS3,NTRK2,NRG3,PREX2,SOX5,QKI,GPC5,SLC1A2,TNIK |
5.085e-06 | -12.19 | neuron projection morphogenesis | biological process | GO:0048812 | 486 | 9 | 18204 | 49 |
NRXN1,TNIK,CTNNA2,GPM6A,PARD3,PREX2,CTNND2,BMPR1B,PTPRZ1 |
5.525e-06 | -12.11 | plasma membrane bounded cell projection morphogenesis | biological process | GO:0120039 | 491 | 9 | 18204 | 49 |
PREX2,CTNND2,BMPR1B,PTPRZ1,TNIK,NRXN1,CTNNA2,GPM6A,PARD3 |
5.996e-06 | -12.02 | cell projection morphogenesis | biological process | GO:0048858 | 496 | 9 | 18204 | 49 |
GPM6A,PARD3,CTNNA2,TNIK,NRXN1,BMPR1B,PTPRZ1,CTNND2,PREX2 |
6.705e-06 | -11.91 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 38 | 16828 | 49 |
GPM6A,NKAIN3,LSAMP,SLC1A3,FBXL7,CTNND2,ATP1A2,RORA,AHCYL2,NEBL,BMPR1B,CDH20,PARD3,PTPRZ1,NHSL1,ATP13A4,TRPS1,ABLIM1,PAMR1,MAML2,SFXN5,CADM1,RANBP3L,MEIS2,PCDH9,MACF1,ITPR2,RYR3,GLIS3,NRG3,NTRK2,PREX2,SOX5,SLC4A4,QKI,TNIK,GPC5,SLC1A2 |
7.143e-06 | -11.85 | Par3/HAL_N | interpro domains | IPR021922 | 2 | 2 | 18521 | 50 |
PARD3B,PARD3 |
7.388e-06 | -11.82 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 21 | 16828 | 49 |
PREX2,DTNA,PTPRZ1,SLC4A4,NHSL1,QKI,ATP13A4,GPC5,SLC1A2,SFXN5,PCDH9,CTNND2,MACF1,ATP1A2,NFIA,NPAS3,RYR3,NRG3,PITPNC1,PARD3B,NTRK2 |
7.428e-06 | -11.81 | Par3_HAL_N_term | pfam domains | PF12053 | 2 | 2 | 17795 | 49 |
PARD3B,PARD3 |
8.905e-06 | -11.63 | mouth | COSMIC cancer mutations | mouth | 9004 | 41 | 16828 | 49 |
MAML2,NTM,CADM1,SFXN5,RANBP3L,PCDH9,ITPR2,MACF1,NPAS3,RYR3,NTRK2,NRG3,PREX2,SOX5,ZNRF3,SLC4A4,QKI,GPC5,SLC1A2,TNIK,GPM6A,SLC1A3,LSAMP,NRXN1,FBXL7,ATP1A2,CTNND2,RORA,PARD3B,PITPNC1,NEBL,CDH20,DTNA,PARD3,PTPRZ1,ATP13A4,NHSL1,TRPS1,ABLIM1,ZBTB20,PAMR1 |
9.371e-06 | -11.58 | central nervous system development | biological process | GO:0007417 | 995 | 12 | 18204 | 49 |
CTNNA2,NTRK2,NRG3,QKI,RORA,SLC1A2,PCDH9,MEIS2,MSI2,ATP1A2,BMPR1B,PTPRZ1 |
1.006e-05 | -11.51 | plasma membrane | cellular component | GO:0005886 | 5538 | 29 | 19108 | 49 |
ATP1A2,GPM6A,TNIK,CTNNA2,CDH20,SLC1A2,MACF1,LSAMP,ZNRF3,NTRK2,BMPR1B,CADM1,PREX2,ITPR2,DTNA,PCDH9,NTM,SLC4A4,NRXN1,SLC1A3,NKAIN3,GPC5,PARD3,NRG3,CTNND2,PTPRZ1,ATP13A4,RYR3,PARD3B |
1.071e-05 | -11.44 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 44 | 16828 | 49 |
LSAMP,SLC1A3,FBXL7,CTNND2,ATP1A2,PARD3B,CDH20,NEBL,DTNA,PTPRZ1,ATP13A4,PAMR1,ZBTB20,CADM1,MEIS2,MACF1,ITPR2,NFIA,GLIS3,NPAS3,RYR3,ZNRF3,GPM6A,NKAIN3,NRXN1,RORA,AHCYL2,PITPNC1,BMPR1B,PARD3,TRPS1,ABLIM1,NTM,SFXN5,RANBP3L,PCDH9,NRG3,NTRK2,PREX2,SOX5,SLC4A4,TNIK,GPC5,SLC1A2 |
1.071e-05 | -11.44 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 44 | 16828 | 49 |
NTRK2,NRG3,RYR3,GLIS3,NPAS3,NFIA,ITPR2,MACF1,PCDH9,MEIS2,RANBP3L,CADM1,SFXN5,NTM,GPC5,SLC1A2,TNIK,ZNRF3,SLC4A4,SOX5,PREX2,PARD3B,AHCYL2,PITPNC1,RORA,ATP1A2,CTNND2,NRXN1,FBXL7,SLC1A3,LSAMP,NKAIN3,GPM6A,ZBTB20,PAMR1,ABLIM1,TRPS1,ATP13A4,PARD3,PTPRZ1,DTNA,CDH20,NEBL,BMPR1B |
1.272e-05 | -11.27 | synapse | cellular component | GO:0045202 | 1473 | 14 | 19108 | 49 |
NTRK2,CADM1,QKI,SLC1A2,TNIK,GPM6A,SLC1A3,ATP1A2,PTPRZ1,NRXN1,CTNND2,SPARCL1,DTNA,NRG3 |
1.364e-05 | -11.20 | trunk | COSMIC cancer mutations | trunk | 3554 | 24 | 16828 | 49 |
SOX5,PREX2,MAML2,MEIS2,MACF1,PCDH9,NRG3,NTRK2,GLIS3,NPAS3,RYR3,NEBL,CDH20,PARD3,PTPRZ1,TRPS1,ATP13A4,ABLIM1,SPARCL1,NRXN1,LSAMP,SLC1A3,CTNND2,ATP1A2 |
1.707e-05 | -10.98 | cell periphery | cellular component | GO:0071944 | 6020 | 30 | 19108 | 49 |
SPARCL1,CTNND2,NRG3,PARD3B,RYR3,ATP13A4,PTPRZ1,SLC1A3,PARD3,GPC5,NKAIN3,PCDH9,DTNA,ITPR2,SLC4A4,NRXN1,NTM,CDH20,CTNNA2,GPM6A,TNIK,ATP1A2,PREX2,ZNRF3,NTRK2,BMPR1B,CADM1,LSAMP,MACF1,SLC1A2 |
2.112e-05 | -10.77 | neuron projection | cellular component | GO:0043005 | 1331 | 13 | 19108 | 49 |
CTNND2,PCDH9,DTNA,ATP1A2,SLC1A3,AHCYL2,CTNNA2,GPM6A,SLC1A2,NTRK2,BMPR1B,CADM1,PARD3 |
2.170e-05 | -10.74 | cell morphogenesis involved in neuron differentiation | biological process | GO:0048667 | 443 | 8 | 18204 | 49 |
CTNND2,PREX2,PTPRZ1,SLC1A3,BMPR1B,CTNNA2,NRXN1,PARD3 |
2.256e-05 | -10.70 | MAPT (microtubule associated protein tau) | protein interactions | 4137 | 948 | 11 | 19454 | 50 |
ATP1A2,LSAMP,CTNNA2,CTNND2,TNIK,GPM6A,SLC1A2,ABLIM1,NEBL,NTM,SLC1A3 |
2.908e-05 | -10.45 | bone | COSMIC cancer mutations | bone | 8157 | 38 | 16828 | 49 |
AHCYL2,PARD3B,RORA,CTNND2,ATP1A2,NRXN1,LSAMP,SLC1A3,NKAIN3,SPARCL1,GPM6A,ZBTB20,PAMR1,ABLIM1,TRPS1,ATP13A4,PTPRZ1,PARD3,DTNA,NEBL,NRG3,NTRK2,RYR3,NPAS3,GLIS3,MACF1,ITPR2,PCDH9,RANBP3L,SFXN5,CADM1,MAML2,TNIK,GPC5,QKI,SLC4A4,SOX5,PREX2 |
3.199e-05 | -10.35 | cell adhesion | biological process | GO:0007155 | 942 | 11 | 18204 | 49 |
SPARCL1,NRXN1,CTNNA2,PARD3,PCDH9,CTNND2,LSAMP,NTM,PARD3B,CDH20,CADM1 |
3.969e-05 | -10.13 | Neurotransmitter uptake and Metabolism In Glial Cells | REACTOME pathways | R-HSA-112313 | 4 | 2 | 10285 | 27 |
SLC1A2,SLC1A3 |
3.969e-05 | -10.13 | Astrocytic Glutamate-Glutamine Uptake And Metabolism | REACTOME pathways | R-HSA-210455 | 4 | 2 | 10285 | 27 |
SLC1A3,SLC1A2 |
4.105e-05 | -10.10 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 33 | 16828 | 49 |
SPARCL1,GPM6A,FBXL7,NRXN1,CTNND2,ATP1A2,PITPNC1,PARD3B,BMPR1B,NEBL,PARD3,PTPRZ1,TRPS1,ATP13A4,ZBTB20,ABLIM1,SFXN5,CADM1,MAML2,RANBP3L,MEIS2,MACF1,ITPR2,PCDH9,NRG3,RYR3,GLIS3,NPAS3,SOX5,PREX2,SLC4A4,TNIK,GPC5 |
4.376e-05 | -10.04 | cell-cell junction | cellular component | GO:0005911 | 513 | 8 | 19108 | 49 |
PARD3,CADM1,PARD3B,CTNNA2,CDH20,PCDH9,CTNND2,ATP1A2 |
4.392e-05 | -10.03 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 46 | 16828 | 49 |
PREX2,SOX5,SLC4A4,ZNRF3,QKI,TNIK,SLC1A2,GPC5,NTM,MAML2,SFXN5,CADM1,RANBP3L,MEIS2,PCDH9,MACF1,ITPR2,NFIA,GLIS3,RYR3,NPAS3,NRG3,NTRK2,CDH20,NEBL,BMPR1B,DTNA,PTPRZ1,PARD3,NHSL1,ATP13A4,TRPS1,ABLIM1,ZBTB20,PAMR1,SPARCL1,GPM6A,LSAMP,SLC1A3,FBXL7,NRXN1,CTNND2,ATP1A2,RORA,PITPNC1,PARD3B |
4.451e-05 | -10.02 | cervix | COSMIC cancer mutations | cervix | 11793 | 46 | 16828 | 49 |
TRPS1,ABLIM1,BMPR1B,PARD3,RORA,PITPNC1,GPM6A,SPARCL1,NRXN1,QKI,GPC5,SLC1A2,TNIK,PREX2,SOX5,SLC4A4,PCDH9,NTRK2,NRG3,MAML2,NTM,SFXN5,RANBP3L,ATP13A4,NHSL1,PAMR1,ZBTB20,NEBL,CDH20,DTNA,PTPRZ1,ATP1A2,CTNND2,PARD3B,SLC1A3,LSAMP,FBXL7,ZNRF3,ITPR2,MACF1,GLIS3,NPAS3,RYR3,NFIA,CADM1,MEIS2 |
4.606e-05 | -9.99 | plasma_cell_myeloma | COSMIC cancer mutations | plasma_cell_myeloma | 1263 | 13 | 16828 | 49 |
ABLIM1,TNIK,PAMR1,ATP13A4,TRPS1,NEBL,RYR3,NTRK2,NRG3,CTNND2,MACF1,GPM6A,NTM |
4.606e-05 | -9.99 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | 1263 | 13 | 16828 | 49 |
ATP13A4,MACF1,TRPS1,CTNND2,ABLIM1,RYR3,NRG3,TNIK,PAMR1,NTRK2,NTM,NEBL,GPM6A |
4.821e-05 | -9.94 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 10 | 16828 | 49 |
NTRK2,ITPR2,CTNND2,TRPS1,SLC1A3,RANBP3L,PARD3,NEBL,SOX5,DTNA |
5.020e-05 | -9.90 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 35 | 16828 | 49 |
FBXL7,NRXN1,LSAMP,PITPNC1,PARD3B,RORA,CTNND2,ATP1A2,PARD3,PTPRZ1,CDH20,NEBL,ZBTB20,TRPS1,NHSL1,ATP13A4,RANBP3L,MEIS2,SFXN5,NTM,MAML2,NRG3,NTRK2,NFIA,NPAS3,RYR3,MACF1,ITPR2,PCDH9,SLC4A4,ZNRF3,SOX5,PREX2,SLC1A2,QKI |
5.020e-05 | -9.90 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 35 | 16828 | 49 |
LSAMP,NRXN1,FBXL7,ATP1A2,CTNND2,RORA,PARD3B,PITPNC1,CDH20,NEBL,PTPRZ1,PARD3,ATP13A4,NHSL1,TRPS1,ZBTB20,MAML2,NTM,SFXN5,MEIS2,RANBP3L,PCDH9,ITPR2,MACF1,RYR3,NPAS3,NFIA,NTRK2,NRG3,PREX2,SOX5,ZNRF3,SLC4A4,QKI,SLC1A2 |
5.476e-05 | -9.81 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 35 | 16828 | 49 |
SOX5,PREX2,SLC4A4,QKI,SLC1A2,GPC5,CADM1,SFXN5,MAML2,MEIS2,RANBP3L,ITPR2,MACF1,PCDH9,NTRK2,NRG3,RYR3,GLIS3,BMPR1B,NEBL,CDH20,PARD3,ATP13A4,NHSL1,PAMR1,ABLIM1,NKAIN3,GPM6A,FBXL7,SLC1A3,LSAMP,ATP1A2,CTNND2,AHCYL2,RORA |
5.783e-05 | -9.76 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 13 | 16828 | 49 |
PTPRZ1,NEBL,CDH20,PREX2,ABLIM1,ATP13A4,SPARCL1,NPAS3,GLIS3,NTRK2,ATP1A2,CTNND2,MACF1 |
6.856e-05 | -9.59 | high-affinity L-glutamate transmembrane transporter activity | molecular function | GO:0005314 | 5 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
6.856e-05 | -9.59 | glutamate:sodium symporter activity | molecular function | GO:0015501 | 5 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
7.061e-05 | -9.56 | D-aspartate import across plasma membrane | biological process | GO:0070779 | 5 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
7.061e-05 | -9.56 | D-aspartate transmembrane transport | biological process | GO:0070777 | 5 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
7.070e-05 | -9.56 | neurotransmitter uptake | biological process | GO:0001504 | 30 | 3 | 18204 | 49 |
SLC1A2,ATP1A2,SLC1A3 |
7.145e-05 | -9.55 | nodular | COSMIC cancer mutations | nodular | 1515 | 14 | 16828 | 49 |
PREX2,CDH20,NEBL,SLC4A4,PTPRZ1,ATP13A4,ABLIM1,SPARCL1,MACF1,CTNND2,ATP1A2,NPAS3,GLIS3,NTRK2 |
7.798e-05 | -9.46 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 30 | 16828 | 49 |
LSAMP,SLC1A3,FBXL7,GPM6A,NKAIN3,AHCYL2,PARD3B,CTNND2,ATP1A2,PTPRZ1,PARD3,NEBL,CDH20,DTNA,PAMR1,ATP13A4,TRPS1,MEIS2,NTM,MAML2,RYR3,NPAS3,NRG3,NTRK2,MACF1,ITPR2,SLC4A4,ZNRF3,SOX5,GPC5 |
7.798e-05 | -9.46 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 30 | 16828 | 49 |
TRPS1,ATP13A4,PAMR1,DTNA,CDH20,NEBL,PARD3,PTPRZ1,CTNND2,ATP1A2,AHCYL2,PARD3B,NKAIN3,GPM6A,FBXL7,LSAMP,SLC1A3,GPC5,SOX5,SLC4A4,ZNRF3,MACF1,ITPR2,NRG3,NTRK2,NPAS3,RYR3,NTM,MAML2,MEIS2 |
7.923e-05 | -9.44 | cell junction organization | biological process | GO:0034330 | 532 | 8 | 18204 | 49 |
GPM6A,CDH20,PARD3,CTNND2,NRG3,NFIA,NRXN1,SPARCL1 |
7.937e-05 | -9.44 | prostate | COSMIC cancer mutations | prostate | 13883 | 49 | 16828 | 49 |
TRPS1,ABLIM1,BMPR1B,PARD3,RORA,AHCYL2,PITPNC1,SPARCL1,GPM6A,NKAIN3,NRXN1,QKI,TNIK,GPC5,SLC1A2,PREX2,SOX5,SLC4A4,PCDH9,NRG3,NTRK2,NTM,MAML2,SFXN5,MSI2,RANBP3L,NHSL1,ATP13A4,ZBTB20,PAMR1,CDH20,NEBL,DTNA,PTPRZ1,CTNND2,ATP1A2,PARD3B,LSAMP,SLC1A3,FBXL7,ZNRF3,MACF1,ITPR2,NFIA,NPAS3,RYR3,GLIS3,CADM1,MEIS2 |
8.255e-05 | -9.40 | NTM (neurotrimin) | protein interactions | 50863 | 33 | 3 | 19454 | 50 |
GPM6A,LSAMP,NTM |
8.356e-05 | -9.39 | neuron projection development | biological process | GO:0031175 | 693 | 9 | 18204 | 49 |
CTNNA2,NRXN1,TNIK,GPM6A,PARD3,CTNND2,PREX2,BMPR1B,PTPRZ1 |
8.364e-05 | -9.39 | vascular transport | biological process | GO:0010232 | 86 | 4 | 18204 | 49 |
SLC1A2,ATP1A2,SLC1A3,SLC4A4 |
8.364e-05 | -9.39 | transport across blood-brain barrier | biological process | GO:0150104 | 86 | 4 | 18204 | 49 |
SLC1A3,SLC4A4,SLC1A2,ATP1A2 |
9.447e-05 | -9.27 | response to auditory stimulus | biological process | GO:0010996 | 33 | 3 | 18204 | 49 |
NRXN1,ATP1A2,SLC1A3 |
1.012e-04 | -9.20 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 25 | 16828 | 49 |
PARD3B,CTNND2,FBXL7,GPM6A,ZBTB20,TRPS1,NHSL1,ATP13A4,PTPRZ1,PARD3,CDH20,NRG3,NTRK2,NFIA,RYR3,MACF1,ITPR2,PCDH9,RANBP3L,CADM1,NTM,TNIK,SLC4A4,SOX5,PREX2 |
1.057e-04 | -9.15 | L-aspartate import across plasma membrane | biological process | GO:0140009 | 6 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
1.057e-04 | -9.15 | D-amino acid transport | biological process | GO:0042940 | 6 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
1.064e-04 | -9.15 | RIH_dom | interpro domains | IPR000699 | 6 | 2 | 18521 | 50 |
RYR3,ITPR2 |
1.064e-04 | -9.15 | Ins145_P3_rcpt | interpro domains | IPR014821 | 6 | 2 | 18521 | 50 |
ITPR2,RYR3 |
1.064e-04 | -9.15 | Ryanodine_IP3_receptor | interpro domains | IPR015925 | 6 | 2 | 18521 | 50 |
ITPR2,RYR3 |
1.064e-04 | -9.15 | RIH_assoc-dom | interpro domains | IPR013662 | 6 | 2 | 18521 | 50 |
ITPR2,RYR3 |
1.064e-04 | -9.15 | RyR/IP3R_RIH_dom_sf | interpro domains | IPR035910 | 6 | 2 | 18521 | 50 |
RYR3,ITPR2 |
1.080e-04 | -9.13 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 24 | 16828 | 49 |
FBXL7,GPM6A,MAML2,NFIA,GLIS3,NPAS3,RYR3,PITPNC1,PARD3B,NTRK2,PCDH9,MACF1,CTNND2,ATP1A2,PTPRZ1,PARD3,SLC4A4,ZNRF3,PREX2,NEBL,TNIK,SLC1A2,NHSL1,TRPS1 |
1.106e-04 | -9.11 | RIH_assoc | pfam domains | PF08454 | 6 | 2 | 17795 | 49 |
RYR3,ITPR2 |
1.106e-04 | -9.11 | RYDR_ITPR | pfam domains | PF01365 | 6 | 2 | 17795 | 49 |
RYR3,ITPR2 |
1.106e-04 | -9.11 | Ins145_P3_rec | pfam domains | PF08709 | 6 | 2 | 17795 | 49 |
RYR3,ITPR2 |
1.136e-04 | -9.08 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 44 | 16828 | 49 |
RORA,PARD3B,AHCYL2,ATP1A2,CTNND2,SLC1A3,LSAMP,NRXN1,FBXL7,SPARCL1,NKAIN3,ABLIM1,PAMR1,ATP13A4,NHSL1,PTPRZ1,PARD3,NEBL,CDH20,BMPR1B,DTNA,NPAS3,RYR3,GLIS3,NFIA,NTRK2,NRG3,PCDH9,ITPR2,MACF1,MEIS2,RANBP3L,MAML2,NTM,CADM1,MSI2,SFXN5,SLC1A2,GPC5,TNIK,QKI,SLC4A4,PREX2,SOX5 |
1.173e-04 | -9.05 | adherens junction | cellular component | GO:0005912 | 188 | 5 | 19108 | 49 |
CTNNA2,CDH20,PARD3B,CTNND2,PARD3 |
1.219e-04 | -9.01 | tibia | COSMIC cancer mutations | tibia | 836 | 10 | 16828 | 49 |
GPM6A,PREX2,NKAIN3,LSAMP,RANBP3L,QKI,CTNND2,MACF1,ABLIM1,TNIK |
1.317e-04 | -8.94 | skin-face-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-squamous_cell_carcinoma | 2036 | 16 | 16828 | 49 |
LSAMP,MSI2,GPM6A,NRG3,RORA,ITPR2,MACF1,PCDH9,ZNRF3,PTPRZ1,PARD3,NEBL,PREX2,GPC5,ABLIM1,TRPS1 |
1.345e-04 | -8.91 | IP3 receptor type 1 binding core, RIH domain | gene3d domains | 1.25.10.30 | 6 | 2 | 14470 | 44 |
RYR3,ITPR2 |
1.367e-04 | -8.90 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 12 | 16828 | 49 |
PARD3,SOX5,TNIK,GPC5,LSAMP,RANBP3L,NKAIN3,RORA,NRG3,PCDH9,CTNND2,ITPR2 |
1.374e-04 | -8.89 | C11orf52 (chromosome 11 open reading frame 52) | protein interactions | 91894 | 310 | 6 | 19454 | 50 |
TNIK,ABLIM1,MACF1,DTNA,PARD3,AHCYL2 |
1.378e-04 | -8.89 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 9 | 18094 | 48 |
SLC1A3,ATP13A4,RYR3,GPM6A,ATP1A2,SLC4A4,SFXN5,ITPR2,SLC1A2 |
1.487e-04 | -8.81 | Na:dicarbo_symporter_sf | interpro domains | IPR036458 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter | interpro domains | IPR001991 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter_CS | interpro domains | IPR018107 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.495e-04 | -8.81 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 43 | 16828 | 49 |
MEIS2,CADM1,NPAS3,RYR3,GLIS3,ITPR2,MACF1,ZNRF3,FBXL7,SLC1A3,LSAMP,PARD3B,ATP1A2,CTNND2,PTPRZ1,DTNA,CDH20,NEBL,PAMR1,ZBTB20,ATP13A4,NHSL1,RANBP3L,MSI2,SFXN5,MAML2,NTM,NTRK2,NRG3,PCDH9,SLC4A4,SOX5,PREX2,GPC5,SLC1A2,TNIK,QKI,NRXN1,AHCYL2,RORA,PARD3,BMPR1B,TRPS1 |
1.534e-04 | -8.78 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 7 | 18094 | 48 |
RYR3,GPM6A,ATP1A2,SLC1A3,ITPR2,SLC1A2,SLC4A4 |
1.546e-04 | -8.77 | SDF | pfam domains | PF00375 | 7 | 2 | 17795 | 49 |
SLC1A2,SLC1A3 |
1.565e-04 | -8.76 | cellular response to alkaloid | biological process | GO:0071312 | 39 | 3 | 18204 | 49 |
SLC1A2,RYR3,SLC1A3 |
1.578e-04 | -8.75 | cell development | biological process | GO:0048468 | 2236 | 16 | 18204 | 49 |
GPM6A,PARD3,PREX2,MSI2,NTM,BMPR1B,PTPRZ1,TNIK,NRXN1,CTNNA2,NTRK2,CTNND2,QKI,RORA,SLC1A3,NEBL |
1.616e-04 | -8.73 | Transport of inorganic cations/anions and amino acids/oligopeptides | REACTOME pathways | R-HSA-425393 | 107 | 4 | 10285 | 27 |
SLC1A3,AHCYL2,SLC1A2,SLC4A4 |
1.628e-04 | -8.72 | humerus | COSMIC cancer mutations | humerus | 546 | 8 | 16828 | 49 |
GPC5,PARD3B,AHCYL2,GPM6A,NEBL,SOX5,SFXN5,NKAIN3 |
1.743e-04 | -8.65 | CASK (calcium/calmodulin dependent serine protein kinase) | protein interactions | 8573 | 204 | 5 | 19454 | 50 |
NRXN1,ABLIM1,PARD3B,CADM1,DTNA |
1.810e-04 | -8.62 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 41 | 16828 | 49 |
CDH20,BMPR1B,NEBL,DTNA,PTPRZ1,PARD3,ATP13A4,TRPS1,ABLIM1,PAMR1,SPARCL1,GPM6A,NKAIN3,FBXL7,NRXN1,CTNND2,ATP1A2,RORA,AHCYL2,PITPNC1,PARD3B,PREX2,SOX5,SLC4A4,ZNRF3,QKI,TNIK,GPC5,NTM,MAML2,MSI2,RANBP3L,MEIS2,PCDH9,MACF1,ITPR2,NFIA,NPAS3,RYR3,NRG3,NTRK2 |
1.838e-04 | -8.60 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 41 | 16828 | 49 |
ABLIM1,PAMR1,ATP13A4,TRPS1,PARD3,PTPRZ1,BMPR1B,CDH20,NEBL,DTNA,RORA,PARD3B,AHCYL2,PITPNC1,ATP1A2,CTNND2,NRXN1,FBXL7,GPM6A,SPARCL1,NKAIN3,GPC5,TNIK,QKI,ZNRF3,SLC4A4,PREX2,SOX5,RYR3,NPAS3,NFIA,NTRK2,NRG3,PCDH9,ITPR2,MACF1,MEIS2,RANBP3L,MAML2,NTM,MSI2 |
1.841e-04 | -8.60 | beta-catenin binding | molecular function | GO:0008013 | 107 | 4 | 18094 | 48 |
CTNND2,CDH20,CTNNA2,RORA |
1.874e-04 | -8.58 | bone-tibia-other-chondroblastoma | COSMIC cancer mutations | bone-tibia-other-chondroblastoma | 98 | 4 | 16828 | 49 |
LSAMP,CTNND2,NKAIN3,GPM6A |
1.879e-04 | -8.58 | Sodium:dicarboxylate symporter | gene3d domains | 1.10.3860.10 | 7 | 2 | 14470 | 44 |
SLC1A2,SLC1A3 |
2.008e-04 | -8.51 | scalp | COSMIC cancer mutations | scalp | 2110 | 16 | 16828 | 49 |
PREX2,NEBL,SOX5,PTPRZ1,SLC4A4,ATP13A4,TRPS1,GPC5,NTM,CADM1,LSAMP,NRXN1,MACF1,ATP1A2,NFIA,RORA |
2.035e-04 | -8.50 | cell projection | cellular component | GO:0042995 | 2398 | 16 | 19108 | 49 |
CTNND2,DTNA,PCDH9,NRXN1,CTNNA2,GPM6A,ATP1A2,AHCYL2,SLC1A3,BMPR1B,CADM1,NTRK2,PARD3,ABLIM1,MACF1,SLC1A2 |
2.247e-04 | -8.40 | behavior | biological process | GO:0007610 | 619 | 8 | 18204 | 49 |
PREX2,ATP1A2,SLC1A3,PTPRZ1,SLC1A2,NRXN1,NTRK2,MEIS2 |
2.276e-04 | -8.39 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 8 | 18094 | 48 |
RYR3,ATP1A2,GPM6A,SLC1A3,ATP13A4,SLC1A2,ITPR2,SLC4A4 |
2.280e-04 | -8.39 | cell differentiation | biological process | GO:0030154 | 3645 | 21 | 18204 | 49 |
NTM,MSI2,PREX2,SOX5,PTPRZ1,BMPR1B,PARD3,GPM6A,NHSL1,QKI,RANBP3L,CTNND2,NEBL,SLC1A3,CADM1,RORA,CTNNA2,TNIK,NRXN1,NFIA,NTRK2 |
2.282e-04 | -8.39 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 6 | 16828 | 49 |
GPM6A,SOX5,SFXN5,NKAIN3,GPC5,AHCYL2 |
2.304e-04 | -8.38 | NEGR1 (neuronal growth regulator 1) | protein interactions | 257194 | 9 | 2 | 19454 | 50 |
LSAMP,NTM |
2.304e-04 | -8.38 | LSAMP (limbic system associated membrane protein) | protein interactions | 4045 | 9 | 2 | 19454 | 50 |
LSAMP,NTM |
2.307e-04 | -8.37 | cellular developmental process | biological process | GO:0048869 | 3648 | 21 | 18204 | 49 |
NTM,MSI2,PREX2,SOX5,PTPRZ1,BMPR1B,PARD3,GPM6A,QKI,NHSL1,CTNND2,RANBP3L,SLC1A3,NEBL,CADM1,RORA,CTNNA2,TNIK,NRXN1,NFIA,NTRK2 |
2.353e-04 | -8.35 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 42 | 16828 | 49 |
PAMR1,ABLIM1,ATP13A4,NHSL1,PTPRZ1,PARD3,CDH20,NEBL,PARD3B,AHCYL2,RORA,ATP1A2,CTNND2,NRXN1,FBXL7,SLC1A3,LSAMP,NKAIN3,SPARCL1,SLC1A2,GPC5,TNIK,QKI,SLC4A4,SOX5,PREX2,NTRK2,NRG3,NPAS3,RYR3,GLIS3,NFIA,ITPR2,MACF1,PCDH9,MEIS2,RANBP3L,CADM1,MSI2,SFXN5,MAML2,NTM |
2.353e-04 | -8.35 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 42 | 16828 | 49 |
NHSL1,ATP13A4,PAMR1,ABLIM1,CDH20,NEBL,PARD3,PTPRZ1,CTNND2,ATP1A2,AHCYL2,PARD3B,RORA,NKAIN3,SPARCL1,FBXL7,NRXN1,LSAMP,SLC1A3,QKI,TNIK,SLC1A2,GPC5,SOX5,PREX2,SLC4A4,MACF1,ITPR2,PCDH9,NRG3,NTRK2,NFIA,NPAS3,GLIS3,RYR3,SFXN5,MSI2,CADM1,NTM,MAML2,RANBP3L,MEIS2 |
2.355e-04 | -8.35 | face | COSMIC cancer mutations | face | 2139 | 16 | 16828 | 49 |
LSAMP,MSI2,GPM6A,NRG3,RORA,ITPR2,MACF1,PCDH9,ZNRF3,PARD3,PTPRZ1,NEBL,PREX2,GPC5,ABLIM1,TRPS1 |
2.402e-04 | -8.33 | acidic amino acid transport | biological process | GO:0015800 | 45 | 3 | 18204 | 49 |
SLC1A2,SLC1A3,NTRK2 |
2.443e-04 | -8.32 | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | 105 | 4 | 16828 | 49 |
GPC5,PARD3,NRG3,QKI |
2.526e-04 | -8.28 | NA_DICARBOXYL_SYMP_2 | prosite domains | PS00714 | 7 | 2 | 12186 | 43 |
SLC1A3,SLC1A2 |
2.526e-04 | -8.28 | NA_DICARBOXYL_SYMP_1 | prosite domains | PS00713 | 7 | 2 | 12186 | 43 |
SLC1A3,SLC1A2 |
2.561e-04 | -8.27 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 9 | 18204 | 49 |
ITPR2,ATP1A2,SLC4A4,ATP13A4,SLC1A3,RYR3,SLC1A2,SFXN5,GPM6A |
2.582e-04 | -8.26 | synapse organization | biological process | GO:0050808 | 333 | 6 | 18204 | 49 |
GPM6A,NRXN1,SPARCL1,NFIA,NRG3,CTNND2 |
2.601e-04 | -8.25 | EDTRNSPORT | prints domains | PR00173 | 7 | 2 | 5227 | 19 |
SLC1A2,SLC1A3 |
2.764e-04 | -8.19 | skin-trunk-malignant_melanoma | COSMIC cancer mutations | skin-trunk-malignant_melanoma | 2647 | 18 | 16828 | 49 |
NEBL,CDH20,PREX2,SOX5,PARD3,PTPRZ1,ATP13A4,TRPS1,MAML2,SLC1A3,LSAMP,MEIS2,NRXN1,PCDH9,ATP1A2,CTNND2,RYR3,NRG3 |
2.894e-04 | -8.15 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 23 | 16828 | 49 |
TRPS1,SLC1A2,TNIK,NEBL,PREX2,ZNRF3,PTPRZ1,PARD3,SLC4A4,PCDH9,ATP1A2,CTNND2,MACF1,NPAS3,RYR3,GLIS3,NFIA,PARD3B,NTRK2,PITPNC1,MAML2,GPM6A,FBXL7 |
2.905e-04 | -8.14 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 23 | 16828 | 49 |
PREX2,ZNRF3,SLC4A4,SLC1A2,TNIK,MAML2,PCDH9,MACF1,GLIS3,RYR3,NPAS3,NFIA,NTRK2,NEBL,PARD3,PTPRZ1,TRPS1,GPM6A,FBXL7,ATP1A2,CTNND2,PARD3B,PITPNC1 |
2.948e-04 | -8.13 | Bicarbonate transporters | REACTOME pathways | R-HSA-425381 | 10 | 2 | 10285 | 27 |
SLC4A4,AHCYL2 |
2.984e-04 | -8.12 | glial cell differentiation | biological process | GO:0010001 | 219 | 5 | 18204 | 49 |
PTPRZ1,PARD3,NTRK2,QKI,NFIA |
3.150e-04 | -8.06 | neuronal action potential propagation | biological process | GO:0019227 | 10 | 2 | 18204 | 49 |
ATP1A2,NTRK2 |
3.150e-04 | -8.06 | cellular response to cocaine | biological process | GO:0071314 | 10 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
3.150e-04 | -8.06 | action potential propagation | biological process | GO:0098870 | 10 | 2 | 18204 | 49 |
NTRK2,ATP1A2 |
3.150e-04 | -8.06 | establishment of centrosome localization | biological process | GO:0051660 | 10 | 2 | 18204 | 49 |
PARD3B,PARD3 |
3.155e-04 | -8.06 | plasma membrane region | cellular component | GO:0098590 | 1278 | 11 | 19108 | 49 |
SLC4A4,NRXN1,PARD3B,SLC1A3,ATP1A2,GPM6A,TNIK,SLC1A2,MACF1,PARD3,CADM1 |
3.162e-04 | -8.06 | EPB41L4A (erythrocyte membrane protein band 4.1 like 4A) | protein interactions | 64097 | 127 | 4 | 19454 | 50 |
MACF1,ABLIM1,PARD3,DTNA |
3.170e-04 | -8.06 | MIR_motif | interpro domains | IPR016093 | 10 | 2 | 18521 | 50 |
RYR3,ITPR2 |
3.170e-04 | -8.06 | MIR_dom_sf | interpro domains | IPR036300 | 10 | 2 | 18521 | 50 |
RYR3,ITPR2 |
3.296e-04 | -8.02 | MIR | pfam domains | PF02815 | 10 | 2 | 17795 | 49 |
ITPR2,RYR3 |
3.346e-04 | -8.00 | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | 114 | 4 | 16828 | 49 |
RYR3,SLC1A2,PREX2,SOX5 |
3.471e-04 | -7.97 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 43 | 16828 | 49 |
SLC1A3,LSAMP,NRXN1,FBXL7,ATP1A2,CTNND2,RORA,PARD3B,AHCYL2,NEBL,CDH20,BMPR1B,DTNA,PARD3,PTPRZ1,ATP13A4,NHSL1,TRPS1,ZBTB20,PAMR1,MAML2,NTM,MSI2,CADM1,SFXN5,MEIS2,RANBP3L,PCDH9,ITPR2,MACF1,NPAS3,RYR3,GLIS3,NTRK2,NRG3,PREX2,SOX5,ZNRF3,SLC4A4,QKI,GPC5,SLC1A2,TNIK |
3.844e-04 | -7.86 | L-aspartate transmembrane transport | biological process | GO:0070778 | 11 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
3.844e-04 | -7.86 | L-glutamate import across plasma membrane | biological process | GO:0098712 | 11 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
3.906e-04 | -7.85 | regulation of chondrocyte differentiation | biological process | GO:0032330 | 53 | 3 | 18204 | 49 |
BMPR1B,TRPS1,SOX5 |
3.958e-04 | -7.83 | positive regulation of multicellular organismal process | biological process | GO:0051240 | 1691 | 13 | 18204 | 49 |
NRXN1,SFXN5,NTRK2,ZBTB20,QKI,RORA,MACF1,CADM1,PARD3,SOX5,ATP1A2,BMPR1B,PTPRZ1 |
3.988e-04 | -7.83 | NTRK2 (neurotrophic receptor tyrosine kinase 2) | protein interactions | 4915 | 135 | 4 | 19454 | 50 |
DTNA,NTRK2,PARD3,ABLIM1 |
4.077e-04 | -7.81 | Ion homeostasis | REACTOME pathways | R-HSA-5578775 | 56 | 3 | 10285 | 27 |
ITPR2,RYR3,ATP1A2 |
4.129e-04 | -7.79 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 15 | 19108 | 49 |
DTNA,PCDH9,CTNND2,PARD3,NTRK2,BMPR1B,CADM1,MACF1,SLC1A2,ABLIM1,GPM6A,CTNNA2,AHCYL2,SLC1A3,ATP1A2 |
4.282e-04 | -7.76 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 49 | 16828 | 49 |
FBXL7,SLC1A3,LSAMP,ATP1A2,CTNND2,PARD3B,DTNA,NEBL,CDH20,PTPRZ1,ATP13A4,NHSL1,PAMR1,ZBTB20,CADM1,MEIS2,ITPR2,MACF1,NPAS3,GLIS3,RYR3,NFIA,ZNRF3,NKAIN3,GPM6A,SPARCL1,NRXN1,AHCYL2,PITPNC1,RORA,BMPR1B,PARD3,TRPS1,ABLIM1,MSI2,SFXN5,MAML2,NTM,RANBP3L,PCDH9,NTRK2,NRG3,SOX5,PREX2,SLC4A4,QKI,GPC5,SLC1A2,TNIK |
4.347e-04 | -7.74 | amino acid transport | biological process | GO:0006865 | 132 | 4 | 18204 | 49 |
NTRK2,SFXN5,SLC1A3,SLC1A2 |
4.439e-04 | -7.72 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 10 | 16828 | 49 |
NKAIN3,SOX5,PARD3,LSAMP,CTNND2,ITPR2,PCDH9,NRG3,GPC5,RORA |
4.439e-04 | -7.72 | NAKATPASE | prints domains | PR00121 | 9 | 2 | 5227 | 19 |
ATP13A4,ATP1A2 |
4.465e-04 | -7.71 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 21 | 16828 | 49 |
ABLIM1,GPC5,TNIK,ZBTB20,PAMR1,NHSL1,SLC4A4,PARD3,PTPRZ1,NEBL,PREX2,SOX5,RYR3,NRG3,PCDH9,ATP1A2,CTNND2,MACF1,MAML2,GPM6A,SPARCL1 |
4.501e-04 | -7.71 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 21 | 16828 | 49 |
NRG3,RYR3,CTNND2,MACF1,ATP1A2,PCDH9,SPARCL1,GPM6A,MAML2,TNIK,PAMR1,ZBTB20,GPC5,ABLIM1,NHSL1,PTPRZ1,SLC4A4,PARD3,SOX5,PREX2,NEBL |
4.605e-04 | -7.68 | auditory behavior | biological process | GO:0031223 | 12 | 2 | 18204 | 49 |
SLC1A3,NRXN1 |
4.842e-04 | -7.63 | visual behavior | biological process | GO:0007632 | 57 | 3 | 18204 | 49 |
SLC1A2,ATP1A2,MEIS2 |
5.060e-04 | -7.59 | cell body | cellular component | GO:0044297 | 556 | 7 | 19108 | 49 |
BMPR1B,SLC1A2,NRXN1,GPM6A,CTNND2,SLC1A3,ATP1A2 |
5.376e-04 | -7.53 | MIR | prosite domains | PS50919 | 10 | 2 | 12186 | 43 |
ITPR2,RYR3 |
5.428e-04 | -7.52 | neurotransmitter transport | biological process | GO:0006836 | 140 | 4 | 18204 | 49 |
ATP1A2,NRXN1,SLC1A2,SLC1A3 |
6.052e-04 | -7.41 | cell-cell adhesion | biological process | GO:0098609 | 546 | 7 | 18204 | 49 |
CDH20,CADM1,CTNND2,PCDH9,SPARCL1,NRXN1,CTNNA2 |
6.145e-04 | -7.39 | L-glutamate transmembrane transporter activity | molecular function | GO:0005313 | 14 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
6.239e-04 | -7.38 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 12 | 16828 | 49 |
ATP1A2,CTNND2,ATP13A4,QKI,NHSL1,NTRK2,SLC1A2,PITPNC1,NFIA,SFXN5,PREX2,SLC4A4 |
6.239e-04 | -7.38 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 12 | 16828 | 49 |
NFIA,NTRK2,PITPNC1,ATP1A2,CTNND2,SFXN5,SLC1A2,ATP13A4,QKI,NHSL1,SLC4A4,PREX2 |
6.327e-04 | -7.37 | mechanosensory behavior | biological process | GO:0007638 | 14 | 2 | 18204 | 49 |
NRXN1,SLC1A3 |
6.327e-04 | -7.37 | sodium ion export across plasma membrane | biological process | GO:0036376 | 14 | 2 | 18204 | 49 |
SLC4A4,ATP1A2 |
6.356e-04 | -7.36 | adult behavior | biological process | GO:0030534 | 146 | 4 | 18204 | 49 |
ATP1A2,NRXN1,SLC1A2,PREX2 |
6.366e-04 | -7.36 | Neurexin-like | interpro domains | IPR003585 | 14 | 2 | 18521 | 50 |
CADM1,NRXN1 |
6.401e-04 | -7.35 | brain development | biological process | GO:0007420 | 724 | 8 | 18204 | 49 |
SLC1A2,CTNNA2,MEIS2,PCDH9,NTRK2,NRG3,ATP1A2,RORA |
6.412e-04 | -7.35 | cell adhesion molecule binding | molecular function | GO:0050839 | 560 | 7 | 18094 | 48 |
CADM1,CDH20,PTPRZ1,CTNNA2,MACF1,NRXN1,CTNND2 |
6.542e-04 | -7.33 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 47 | 16828 | 49 |
ZNRF3,NFIA,GLIS3,NPAS3,RYR3,MACF1,ITPR2,CADM1,ZBTB20,PAMR1,NHSL1,ATP13A4,PTPRZ1,DTNA,NEBL,CDH20,PARD3B,CTNND2,ATP1A2,FBXL7,LSAMP,SLC1A3,TNIK,GPC5,SLC1A2,QKI,SLC4A4,SOX5,PREX2,NRG3,NTRK2,PCDH9,RANBP3L,SFXN5,MSI2,NTM,MAML2,ABLIM1,TRPS1,PARD3,BMPR1B,AHCYL2,PITPNC1,RORA,NRXN1,NKAIN3,GPM6A |
6.654e-04 | -7.32 | TIAM2 (TIAM Rac1 associated GEF 2) | protein interactions | 26230 | 15 | 2 | 19454 | 50 |
TNIK,PARD3 |
6.803e-04 | -7.29 | dendrite morphogenesis | biological process | GO:0048813 | 64 | 3 | 18204 | 49 |
CTNND2,PREX2,CTNNA2 |
7.080e-04 | -7.25 | astrocytoma_Grade_I | COSMIC cancer mutations | astrocytoma_Grade_I | 139 | 4 | 16828 | 49 |
QKI,GPC5,NRG3,PARD3 |
7.282e-04 | -7.22 | MIR | smart domains | SM00472 | 10 | 2 | 9717 | 40 |
ITPR2,RYR3 |
7.502e-04 | -7.20 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 5 | 16828 | 49 |
NRG3,GPC5,NFIA,NPAS3,PCDH9 |
7.502e-04 | -7.20 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 5 | 16828 | 49 |
NPAS3,NFIA,GPC5,NRG3,PCDH9 |
7.721e-04 | -7.17 | active monoatomic ion transmembrane transporter activity | molecular function | GO:0022853 | 274 | 5 | 18094 | 48 |
SLC4A4,SLC1A3,ATP13A4,SLC1A2,ATP1A2 |
7.762e-04 | -7.16 | learning | biological process | GO:0007612 | 154 | 4 | 18204 | 49 |
MEIS2,NTRK2,ATP1A2,NRXN1 |
8.077e-04 | -7.12 | sodium ion transmembrane transporter activity | molecular function | GO:0015081 | 158 | 4 | 18094 | 48 |
ATP1A2,SLC1A2,SLC1A3,SLC4A4 |
8.086e-04 | -7.12 | human chr3q13.31 | chromosome location | human chr3q13.31 | 22 | 2 | 26134 | 50 |
LSAMP,ZBTB20 |
8.145e-04 | -7.11 | retina development in camera-type eye | biological process | GO:0060041 | 156 | 4 | 18204 | 49 |
GPM6A,BMPR1B,NTRK2,NFIA |
8.315e-04 | -7.09 | asymmetric cell division | biological process | GO:0008356 | 16 | 2 | 18204 | 49 |
SOX5,PARD3 |
8.403e-04 | -7.08 | gliogenesis | biological process | GO:0042063 | 275 | 5 | 18204 | 49 |
PARD3,NTRK2,PTPRZ1,QKI,NFIA |
8.443e-04 | -7.08 | plasma membrane bounded cell projection organization | biological process | GO:0120036 | 1152 | 10 | 18204 | 49 |
ABLIM1,CTNNA2,TNIK,NRXN1,GPM6A,PARD3,CTNND2,PREX2,BMPR1B,PTPRZ1 |
8.541e-04 | -7.07 | learning or memory | biological process | GO:0007611 | 276 | 5 | 18204 | 49 |
NRXN1,ATP1A2,NTRK2,PTPRZ1,MEIS2 |
8.632e-04 | -7.05 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 7 | 18094 | 48 |
SLC1A3,GPM6A,ATP1A2,RYR3,SLC4A4,ITPR2,SLC1A2 |
9.557e-04 | -6.95 | monoatomic ion transport | biological process | GO:0006811 | 964 | 9 | 18204 | 49 |
SLC1A2,RYR3,GPM6A,SFXN5,ITPR2,ATP1A2,SLC4A4,ATP13A4,SLC1A3 |
9.860e-04 | -6.92 | cell junction assembly | biological process | GO:0034329 | 285 | 5 | 18204 | 49 |
NRXN1,NRG3,PARD3,GPM6A,CDH20 |
9.890e-04 | -6.92 | head development | biological process | GO:0060322 | 774 | 8 | 18204 | 49 |
NTRK2,PCDH9,MEIS2,CTNNA2,SLC1A2,RORA,ATP1A2,NRG3 |
9.985e-04 | -6.91 | regulation of cartilage development | biological process | GO:0061035 | 73 | 3 | 18204 | 49 |
SOX5,TRPS1,BMPR1B |
1.022e-03 | -6.89 | Htt (huntingtin) | protein interactions | 15194 | 77 | 3 | 19454 | 50 |
NTM,GPM6A,LSAMP |
1.026e-03 | -6.88 | intracellularly gated calcium channel activity | molecular function | GO:0015278 | 18 | 2 | 18094 | 48 |
RYR3,ITPR2 |
1.026e-03 | -6.88 | acidic amino acid transmembrane transporter activity | molecular function | GO:0015172 | 18 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
1.032e-03 | -6.88 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 48 | 16828 | 49 |
MEIS2,CADM1,GLIS3,NPAS3,RYR3,NFIA,ITPR2,MACF1,ZNRF3,FBXL7,SLC1A3,LSAMP,PARD3B,ATP1A2,CTNND2,PTPRZ1,DTNA,CDH20,NEBL,PAMR1,ZBTB20,ATP13A4,NHSL1,RANBP3L,MSI2,SFXN5,MAML2,NTRK2,NRG3,PCDH9,SLC4A4,SOX5,PREX2,SLC1A2,GPC5,TNIK,QKI,NRXN1,NKAIN3,GPM6A,SPARCL1,PITPNC1,AHCYL2,RORA,PARD3,BMPR1B,ABLIM1,TRPS1 |
1.032e-03 | -6.88 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 48 | 16828 | 49 |
PCDH9,NTRK2,NRG3,MAML2,MSI2,SFXN5,RANBP3L,QKI,SLC1A2,GPC5,TNIK,PREX2,SOX5,SLC4A4,RORA,PITPNC1,AHCYL2,GPM6A,SPARCL1,NKAIN3,NRXN1,TRPS1,ABLIM1,BMPR1B,PARD3,ITPR2,MACF1,NPAS3,RYR3,GLIS3,NFIA,CADM1,MEIS2,ZNRF3,ATP1A2,CTNND2,PARD3B,SLC1A3,LSAMP,FBXL7,ATP13A4,NHSL1,PAMR1,ZBTB20,CDH20,NEBL,DTNA,PTPRZ1 |
1.049e-03 | -6.86 | HNRNPL (heterogeneous nuclear ribonucleoprotein L) | protein interactions | 3191 | 1958 | 13 | 19454 | 50 |
AHCYL2,TRPS1,NRG3,BMPR1B,MSI2,DTNA,ZBTB20,PARD3,QKI,MACF1,PARD3B,ABLIM1,NFIA |
1.063e-03 | -6.85 | ATPase_P-typ_cation-transptr_N | interpro domains | IPR004014 | 18 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
1.096e-03 | -6.82 | transporter activity | molecular function | GO:0005215 | 1211 | 10 | 18094 | 48 |
ATP13A4,SLC1A3,GPM6A,ATP1A2,RYR3,SFXN5,SLC4A4,PITPNC1,SLC1A2,ITPR2 |
1.105e-03 | -6.81 | Cation_ATPase_N | pfam domains | PF00690 | 18 | 2 | 17795 | 49 |
ATP13A4,ATP1A2 |
1.154e-03 | -6.76 | cell projection organization | biological process | GO:0030030 | 1200 | 10 | 18204 | 49 |
BMPR1B,PTPRZ1,PREX2,CTNND2,GPM6A,PARD3,ABLIM1,TNIK,NRXN1,CTNNA2 |
1.165e-03 | -6.76 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 49 | 16828 | 49 |
PARD3B,ATP1A2,CTNND2,SLC1A3,LSAMP,FBXL7,PAMR1,ZBTB20,ATP13A4,NHSL1,PTPRZ1,NEBL,CDH20,DTNA,GLIS3,RYR3,NPAS3,NFIA,ITPR2,MACF1,MEIS2,CADM1,ZNRF3,RORA,PITPNC1,AHCYL2,NRXN1,GPM6A,SPARCL1,NKAIN3,ABLIM1,TRPS1,PARD3,BMPR1B,NTRK2,NRG3,PCDH9,RANBP3L,MAML2,NTM,MSI2,SFXN5,GPC5,SLC1A2,TNIK,QKI,SLC4A4,PREX2,SOX5 |
1.167e-03 | -6.75 | positive regulation of nervous system development | biological process | GO:0051962 | 296 | 5 | 18204 | 49 |
NTRK2,PTPRZ1,MACF1,NRXN1,QKI |
1.179e-03 | -6.74 | cartilage condensation | biological process | GO:0001502 | 19 | 2 | 18204 | 49 |
BMPR1B,SOX5 |
1.179e-03 | -6.74 | RHOB (ras homolog family member B) | protein interactions | 388 | 832 | 8 | 19454 | 50 |
TNIK,SLC1A3,AHCYL2,PARD3,ABLIM1,PARD3B,MACF1,DTNA |
1.194e-03 | -6.73 | PDZD2 (PDZ domain containing 2) | protein interactions | 23037 | 20 | 2 | 19454 | 50 |
CTNND2,NRXN1 |
1.210e-03 | -6.72 | dicarboxylic acid transport | biological process | GO:0006835 | 78 | 3 | 18204 | 49 |
SLC1A2,NTRK2,SLC1A3 |
1.226e-03 | -6.70 | GSC (goosecoid homeobox) | protein interactions | 145258 | 82 | 3 | 19454 | 50 |
TRPS1,NFIA,SOX5 |
1.246e-03 | -6.69 | somatodendritic compartment | cellular component | GO:0036477 | 842 | 8 | 19108 | 49 |
ATP1A2,SLC1A3,CTNND2,GPM6A,NRXN1,NTRK2,BMPR1B,CADM1 |
1.247e-03 | -6.69 | solute:sodium symporter activity | molecular function | GO:0015370 | 80 | 3 | 18094 | 48 |
SLC1A3,SLC4A4,SLC1A2 |
1.266e-03 | -6.67 | axon | cellular component | GO:0030424 | 650 | 7 | 19108 | 49 |
DTNA,PCDH9,CTNNA2,GPM6A,SLC1A2,NTRK2,PARD3 |
1.307e-03 | -6.64 | positive regulation of chondrocyte differentiation | biological process | GO:0032332 | 20 | 2 | 18204 | 49 |
BMPR1B,SOX5 |
1.307e-03 | -6.64 | aspartate transmembrane transport | biological process | GO:0015810 | 20 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
1.317e-03 | -6.63 | prostate-carcinoma-adenocarcinoma | COSMIC cancer mutations | prostate-carcinoma-adenocarcinoma | 12379 | 45 | 16828 | 49 |
AHCYL2,PITPNC1,RORA,NRXN1,NKAIN3,SPARCL1,GPM6A,ABLIM1,TRPS1,PARD3,BMPR1B,NRG3,NTRK2,PCDH9,RANBP3L,SFXN5,NTM,MAML2,TNIK,GPC5,SLC1A2,QKI,SOX5,PREX2,PARD3B,CTNND2,ATP1A2,FBXL7,LSAMP,SLC1A3,ZBTB20,PAMR1,NHSL1,ATP13A4,PTPRZ1,CDH20,NEBL,NFIA,NPAS3,GLIS3,RYR3,MACF1,ITPR2,MEIS2,CADM1 |
1.321e-03 | -6.63 | stomach-adenocarcinoma | COSMIC cancer mutations | stomach-adenocarcinoma | 4101 | 22 | 16828 | 49 |
PARD3,CDH20,NEBL,PAMR1,ABLIM1,TRPS1,ATP13A4,PARD3B,AHCYL2,RORA,ATP1A2,CTNND2,SLC4A4,PREX2,GPC5,SLC1A2,QKI,MEIS2,NRG3,ITPR2,MACF1,PCDH9 |
1.343e-03 | -6.61 | regulation of nervous system development | biological process | GO:0051960 | 456 | 6 | 18204 | 49 |
PARD3,NTRK2,NRXN1,MACF1,PTPRZ1,QKI |
1.442e-03 | -6.54 | Transmembrane transport of small molecules | REACTOME pathways | R-HSA-382551 | 677 | 7 | 10285 | 27 |
SLC1A2,AHCYL2,ATP1A2,ATP13A4,RYR3,SLC4A4,SLC1A3 |
1.443e-03 | -6.54 | positive regulation of purine nucleotide catabolic process | biological process | GO:0033123 | 21 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
1.443e-03 | -6.54 | positive regulation of nucleotide catabolic process | biological process | GO:0030813 | 21 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
1.443e-03 | -6.54 | cell aggregation | biological process | GO:0098743 | 21 | 2 | 18204 | 49 |
SOX5,BMPR1B |
1.443e-03 | -6.54 | positive regulation of glycolytic process | biological process | GO:0045821 | 21 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
1.457e-03 | -6.53 | 4.1m | smart domains | SM00294 | 14 | 2 | 9717 | 40 |
CADM1,NRXN1 |
1.467e-03 | -6.52 | cellular response to organic cyclic compound | biological process | GO:0071407 | 464 | 6 | 18204 | 49 |
SLC1A3,RORA,ATP1A2,RYR3,ITPR2,SLC1A2 |
1.474e-03 | -6.52 | monoatomic cation transmembrane transport | biological process | GO:0098655 | 636 | 7 | 18204 | 49 |
ATP13A4,SLC1A3,SLC4A4,ATP1A2,ITPR2,GPM6A,RYR3 |
1.499e-03 | -6.50 | neuronal cell body | cellular component | GO:0043025 | 489 | 6 | 19108 | 49 |
BMPR1B,GPM6A,CTNND2,SLC1A3,NRXN1,ATP1A2 |
1.582e-03 | -6.45 | Rbm38 (RNA binding motif protein 38) | protein interactions | 56190 | 23 | 2 | 19454 | 50 |
MSI2,QKI |
1.582e-03 | -6.45 | TIMM10B (translocase of inner mitochondrial membrane 10B) | protein interactions | 26515 | 23 | 2 | 19454 | 50 |
MSI2,MEIS2 |
1.584e-03 | -6.45 | intracellular sodium ion homeostasis | biological process | GO:0006883 | 22 | 2 | 18204 | 49 |
SLC1A3,ATP1A2 |
1.608e-03 | -6.43 | Salivary secretion | KEGG pathways | ko04970 | 90 | 3 | 7161 | 19 |
ATP1A2,RYR3,ITPR2 |
1.608e-03 | -6.43 | Salivary secretion | KEGG pathways | hsa04970 | 90 | 3 | 7161 | 19 |
RYR3,ITPR2,ATP1A2 |
1.620e-03 | -6.43 | OCLN (occludin) | protein interactions | 100506658 | 495 | 6 | 19454 | 50 |
PARD3,NTRK2,DTNA,MACF1,TNIK,ABLIM1 |
1.624e-03 | -6.42 | cognition | biological process | GO:0050890 | 319 | 5 | 18204 | 49 |
PTPRZ1,MEIS2,NTRK2,ATP1A2,NRXN1 |
1.632e-03 | -6.42 | Proximal tubule bicarbonate reclamation | KEGG pathways | ko04964 | 23 | 2 | 7161 | 19 |
ATP1A2,SLC4A4 |
1.632e-03 | -6.42 | Proximal tubule bicarbonate reclamation | KEGG pathways | hsa04964 | 23 | 2 | 7161 | 19 |
ATP1A2,SLC4A4 |
1.683e-03 | -6.39 | amino acid:sodium symporter activity | molecular function | GO:0005283 | 23 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
1.689e-03 | -6.38 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 12 | 16828 | 49 |
ATP1A2,MACF1,RORA,CADM1,NRXN1,LSAMP,TRPS1,ATP13A4,GPC5,SOX5,SLC4A4,PTPRZ1 |
1.715e-03 | -6.37 | human chr5p13.2 | chromosome location | human chr5p13.2 | 32 | 2 | 26134 | 50 |
RANBP3L,SLC1A3 |
1.748e-03 | -6.35 | parathyroid-carcinoma | COSMIC cancer mutations | parathyroid-carcinoma | 300 | 5 | 16828 | 49 |
MACF1,TRPS1,PAMR1,GPC5,RYR3 |
1.757e-03 | -6.34 | TIAM1 (TIAM Rac1 associated GEF 1) | protein interactions | 7074 | 201 | 4 | 19454 | 50 |
RYR3,ATP1A2,PARD3,DTNA |
1.768e-03 | -6.34 | Glutamate Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-210500 | 24 | 2 | 10285 | 27 |
SLC1A2,SLC1A3 |
1.792e-03 | -6.32 | gallbladder | COSMIC cancer mutations | gallbladder | 2821 | 17 | 16828 | 49 |
NKAIN3,SPARCL1,CTNND2,MACF1,ITPR2,PCDH9,NRG3,PITPNC1,RYR3,PREX2,SLC4A4,PTPRZ1,PARD3,ZNRF3,TRPS1,NHSL1,TNIK |
1.792e-03 | -6.32 | biliary_tract-gallbladder-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-gallbladder-carcinoma-adenocarcinoma | 2821 | 17 | 16828 | 49 |
NKAIN3,SPARCL1,PITPNC1,NRG3,RYR3,ITPR2,MACF1,CTNND2,PCDH9,ZNRF3,SLC4A4,PTPRZ1,PARD3,PREX2,TNIK,TRPS1,NHSL1 |
1.832e-03 | -6.30 | P-type transmembrane transporter activity | molecular function | GO:0140358 | 24 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
1.832e-03 | -6.30 | P-type ion transporter activity | molecular function | GO:0015662 | 24 | 2 | 18094 | 48 |
ATP13A4,ATP1A2 |
1.879e-03 | -6.28 | Pancreatic secretion | KEGG pathways | hsa04972 | 95 | 3 | 7161 | 19 |
ATP1A2,SLC4A4,ITPR2 |
1.879e-03 | -6.28 | Pancreatic secretion | KEGG pathways | ko04972 | 95 | 3 | 7161 | 19 |
ATP1A2,SLC4A4,ITPR2 |
1.912e-03 | -6.26 | Cation_ATPase_N | smart domains | SM00831 | 16 | 2 | 9717 | 40 |
ATP1A2,ATP13A4 |
1.912e-03 | -6.26 | SOX2 (SRY-box transcription factor 2) | protein interactions | 6657 | 1342 | 10 | 19454 | 50 |
MSI2,NFIA,MEIS2,MACF1,LSAMP,TRPS1,GLIS3,QKI,SOX5,ITPR2 |
1.913e-03 | -6.26 | human chr3q26.2-q26.31 | chromosome location | human chr3q26.2-q26.31 | 1 | 1 | 26134 | 50 |
TNIK |
1.913e-03 | -6.26 | human chr10p11.22-p11.21 | chromosome location | human chr10p11.22-p11.21 | 1 | 1 | 26134 | 50 |
PARD3 |
1.913e-03 | -6.26 | human chr15q13.3-q14 | chromosome location | human chr15q13.3-q14 | 1 | 1 | 26134 | 50 |
RYR3 |
1.928e-03 | -6.25 | anchoring junction | cellular component | GO:0070161 | 902 | 8 | 19108 | 49 |
CADM1,PARD3,PARD3B,ATP1A2,CTNND2,CDH20,CTNNA2,PCDH9 |
1.957e-03 | -6.24 | bone-femur-other-chondroblastoma | COSMIC cancer mutations | bone-femur-other-chondroblastoma | 183 | 4 | 16828 | 49 |
GPC5,NRG3,RYR3,PCDH9 |
2.026e-03 | -6.20 | calcium ion binding | molecular function | GO:0005509 | 683 | 7 | 18094 | 48 |
ITPR2,PCDH9,PAMR1,SPARCL1,MACF1,RYR3,NRXN1 |
2.047e-03 | -6.19 | L-glutamate transmembrane transport | biological process | GO:0015813 | 25 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
2.152e-03 | -6.14 | extrinsic component of plasma membrane | cellular component | GO:0019897 | 100 | 3 | 19108 | 49 |
DTNA,CTNNA2,CDH20 |
2.181e-03 | -6.13 | KCNJ12 (potassium inwardly rectifying channel subfamily J member 12) | protein interactions | 3768 | 27 | 2 | 19454 | 50 |
ABLIM1,DTNA |
2.181e-03 | -6.13 | MBNL2 (muscleblind like splicing regulator 2) | protein interactions | 10150 | 27 | 2 | 19454 | 50 |
MSI2,QKI |
2.185e-03 | -6.13 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 7 | 19454 | 50 |
SLC1A3,TNIK,PARD3,MACF1,ABLIM1,MSI2,DTNA |
2.200e-03 | -6.12 | EZR (ezrin) | protein interactions | 7430 | 526 | 6 | 19454 | 50 |
DTNA,AHCYL2,TNIK,ABLIM1,NEBL,MACF1 |
2.214e-03 | -6.11 | C4-dicarboxylate transport | biological process | GO:0015740 | 26 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
2.282e-03 | -6.08 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 9 | 18094 | 48 |
SLC4A4,SFXN5,SLC1A2,ITPR2,SLC1A3,ATP13A4,RYR3,GPM6A,ATP1A2 |
2.341e-03 | -6.06 | actin filament binding | molecular function | GO:0051015 | 211 | 4 | 18094 | 48 |
MACF1,ABLIM1,CTNNA2,NEBL |
2.352e-03 | -6.05 | animal organ development | biological process | GO:0048513 | 2846 | 16 | 18204 | 49 |
CADM1,NEBL,RORA,RANBP3L,NRG3,NTRK2,CTNNA2,ABLIM1,NFIA,BMPR1B,ATP1A2,SOX5,MEIS2,PCDH9,GPM6A,SLC1A2 |
2.362e-03 | -6.05 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 48 | 16828 | 49 |
CADM1,MEIS2,MACF1,ITPR2,NFIA,GLIS3,NPAS3,RYR3,ZNRF3,FBXL7,LSAMP,SLC1A3,CTNND2,ATP1A2,PARD3B,DTNA,NEBL,CDH20,PTPRZ1,NHSL1,ATP13A4,PAMR1,ZBTB20,SFXN5,NTM,MAML2,RANBP3L,PCDH9,NRG3,NTRK2,SOX5,PREX2,SLC4A4,QKI,TNIK,SLC1A2,GPC5,NKAIN3,SPARCL1,GPM6A,NRXN1,PITPNC1,AHCYL2,RORA,BMPR1B,PARD3,TRPS1,ABLIM1 |
2.455e-03 | -6.01 | NTRK3 (neurotrophic receptor tyrosine kinase 3) | protein interactions | 4916 | 367 | 5 | 19454 | 50 |
PARD3,AHCYL2,NTRK2,ABLIM1,TNIK |
2.467e-03 | -6.00 | response to alkaloid | biological process | GO:0043279 | 100 | 3 | 18204 | 49 |
RYR3,SLC1A2,SLC1A3 |
2.476e-03 | -6.00 | parathyroid | COSMIC cancer mutations | parathyroid | 476 | 6 | 16828 | 49 |
GPC5,PAMR1,RYR3,MACF1,TRPS1,GPM6A |
2.514e-03 | -5.99 | INSC (INSC spindle orientation adaptor protein) | protein interactions | 387755 | 29 | 2 | 19454 | 50 |
PARD3,PARD3B |
2.566e-03 | -5.97 | positive regulation of oligodendrocyte differentiation | biological process | GO:0048714 | 28 | 2 | 18204 | 49 |
QKI,PTPRZ1 |
2.570e-03 | -5.96 | Bdnf (brain derived neurotrophic factor) | protein interactions | 12064 | 1 | 1 | 19454 | 50 |
NTRK2 |
2.570e-03 | -5.96 | Dynlt1 (dynein light chain Tctex-type 1) | protein interactions | 83462 | 1 | 1 | 19454 | 50 |
NTRK2 |
2.570e-03 | -5.96 | Sytl1 (synaptotagmin-like 1) | protein interactions | 269589 | 1 | 1 | 19454 | 50 |
NRXN1 |
2.570e-03 | -5.96 | Lztr1 (leucine-zipper-like transcriptional regulator, 1) | protein interactions | 66863 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Hipk3 (homeodomain interacting protein kinase 3) | protein interactions | 15259 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | Dcaf7 (DDB1 and CUL4 associated factor 7) | protein interactions | 71833 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Agtrap (angiotensin II, type I receptor-associated protein) | protein interactions | 11610 | 1 | 1 | 19454 | 50 |
PITPNC1 |
2.570e-03 | -5.96 | Isl1 (ISL1 transcription factor, LIM/homeodomain) | protein interactions | 16392 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | 1700006A11Rik (RIKEN cDNA 1700006A11 gene) | protein interactions | 71824 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.593e-03 | -5.95 | Calcium-transporting ATPase, transmembrane domain | gene3d domains | 1.20.1110.10 | 25 | 2 | 14470 | 44 |
ATP1A2,ATP13A4 |
2.602e-03 | -5.95 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 7 | 18094 | 48 |
ATP1A2,GPM6A,RYR3,SLC1A3,SLC1A2,ITPR2,SLC4A4 |
2.653e-03 | -5.93 | brain-derived neurotrophic factor receptor activity | molecular function | GO:0060175 | 1 | 1 | 18094 | 48 |
NTRK2 |
2.653e-03 | -5.93 | internal N(7)-methylguanine-containing RNA reader activity | molecular function | GO:0160089 | 1 | 1 | 18094 | 48 |
QKI |
2.673e-03 | -5.92 | ligand-gated calcium channel activity | molecular function | GO:0099604 | 29 | 2 | 18094 | 48 |
ITPR2,RYR3 |
2.673e-03 | -5.92 | amino acid:monoatomic cation symporter activity | molecular function | GO:0005416 | 29 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
2.692e-03 | -5.92 | directional guidance of interneurons involved in migration from the subpallium to the cortex | biological process | GO:0021840 | 1 | 1 | 18204 | 49 |
NRG3 |
2.692e-03 | -5.92 | negative regulation of calcium:sodium antiporter activity | biological process | GO:1903280 | 1 | 1 | 18204 | 49 |
ATP1A2 |
2.692e-03 | -5.92 | chemorepulsion involved in interneuron migration from the subpallium to the cortex | biological process | GO:0021842 | 1 | 1 | 18204 | 49 |
NRG3 |
2.692e-03 | -5.92 | olfactory cortex development | biological process | GO:0021989 | 1 | 1 | 18204 | 49 |
ATP1A2 |
2.692e-03 | -5.92 | trans-synaptic signaling by neuropeptide, modulating synaptic transmission | biological process | GO:0099551 | 1 | 1 | 18204 | 49 |
NTRK2 |
2.692e-03 | -5.92 | trans-synaptic signaling by neuropeptide | biological process | GO:0099540 | 1 | 1 | 18204 | 49 |
NTRK2 |
2.698e-03 | -5.92 | EN1 (engrailed homeobox 1) | protein interactions | 2019 | 108 | 3 | 19454 | 50 |
AHCYL2,NFIA,TRPS1 |
2.700e-03 | -5.91 | NTRK2 | interpro domains | IPR020455 | 1 | 1 | 18521 | 50 |
NTRK2 |
2.700e-03 | -5.91 | Nebulette_SH3 | interpro domains | IPR035631 | 1 | 1 | 18521 | 50 |
NEBL |
2.700e-03 | -5.91 | Rex2_DEP_1 | interpro domains | IPR037367 | 1 | 1 | 18521 | 50 |
PREX2 |
2.700e-03 | -5.91 | TRPS1 | interpro domains | IPR028440 | 1 | 1 | 18521 | 50 |
TRPS1 |
2.700e-03 | -5.91 | Quaking_NLS | interpro domains | IPR032367 | 1 | 1 | 18521 | 50 |
QKI |
2.700e-03 | -5.91 | ZNRF3_Znf_RING | interpro domains | IPR045903 | 1 | 1 | 18521 | 50 |
ZNRF3 |
2.700e-03 | -5.91 | STAR_dimer | interpro domains | IPR032377 | 1 | 1 | 18521 | 50 |
QKI |
2.700e-03 | -5.91 | MAML2_TAD | interpro domains | IPR048452 | 1 | 1 | 18521 | 50 |
MAML2 |
2.700e-03 | -5.91 | SPARC-like_p1 | interpro domains | IPR016359 | 1 | 1 | 18521 | 50 |
SPARCL1 |
2.709e-03 | -5.91 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 48 | 16828 | 49 |
MEIS2,CADM1,GLIS3,NPAS3,RYR3,NFIA,ITPR2,MACF1,ZNRF3,FBXL7,SLC1A3,LSAMP,PARD3B,ATP1A2,CTNND2,PTPRZ1,DTNA,CDH20,NEBL,ZBTB20,PAMR1,ATP13A4,NHSL1,RANBP3L,SFXN5,MAML2,NTM,NTRK2,NRG3,PCDH9,SLC4A4,SOX5,PREX2,SLC1A2,GPC5,TNIK,QKI,NRXN1,NKAIN3,GPM6A,SPARCL1,AHCYL2,PITPNC1,RORA,PARD3,BMPR1B,ABLIM1,TRPS1 |
2.751e-03 | -5.90 | peripheral nervous system axon ensheathment | biological process | GO:0032292 | 29 | 2 | 18204 | 49 |
PARD3,NTRK2 |
2.751e-03 | -5.90 | myelination in peripheral nervous system | biological process | GO:0022011 | 29 | 2 | 18204 | 49 |
PARD3,NTRK2 |
2.754e-03 | -5.89 | MAML2_TAD | pfam domains | PF20804 | 1 | 1 | 17795 | 49 |
MAML2 |
2.754e-03 | -5.89 | STAR_dimer | pfam domains | PF16544 | 1 | 1 | 17795 | 49 |
QKI |
2.754e-03 | -5.89 | Quaking_NLS | pfam domains | PF16551 | 1 | 1 | 17795 | 49 |
QKI |
2.809e-03 | -5.87 | caecum | COSMIC cancer mutations | caecum | 14248 | 48 | 16828 | 49 |
ZNRF3,MEIS2,CADM1,RYR3,GLIS3,NPAS3,NFIA,ITPR2,MACF1,PTPRZ1,DTNA,NEBL,CDH20,ZBTB20,PAMR1,ATP13A4,NHSL1,FBXL7,SLC1A3,LSAMP,PARD3B,ATP1A2,CTNND2,SLC4A4,SOX5,PREX2,SLC1A2,GPC5,TNIK,QKI,RANBP3L,SFXN5,MAML2,NTM,NTRK2,NRG3,PCDH9,PARD3,BMPR1B,ABLIM1,TRPS1,NRXN1,NKAIN3,GPM6A,SPARCL1,PITPNC1,AHCYL2,RORA |
2.834e-03 | -5.87 | neural precursor cell proliferation | biological process | GO:0061351 | 105 | 3 | 18204 | 49 |
RORA,SOX5,NFIA |
2.857e-03 | -5.86 | catenin complex | cellular component | GO:0016342 | 31 | 2 | 19108 | 49 |
CDH20,CTNNA2 |
2.862e-03 | -5.86 | ACTB (actin beta) | protein interactions | 60 | 958 | 8 | 19454 | 50 |
MACF1,NEBL,MEIS2,ABLIM1,SFXN5,DTNA,NHSL1,AHCYL2 |
2.863e-03 | -5.86 | DST (dystonin) | protein interactions | 667 | 230 | 4 | 19454 | 50 |
TNIK,ATP1A2,NTRK2,PARD3 |
2.874e-03 | -5.85 | response to mechanical stimulus | biological process | GO:0009612 | 220 | 4 | 18204 | 49 |
SLC1A3,MEIS2,NRXN1,ATP1A2 |
2.942e-03 | -5.83 | L-glutamate import | biological process | GO:0051938 | 30 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
2.950e-03 | -5.83 | axonogenesis | biological process | GO:0007409 | 366 | 5 | 18204 | 49 |
BMPR1B,PARD3,PTPRZ1,NRXN1,CTNNA2 |
2.952e-03 | -5.83 | cellular response to endogenous stimulus | biological process | GO:0071495 | 1135 | 9 | 18204 | 49 |
NTRK2,SLC1A2,NFIA,RYR3,BMPR1B,SLC1A3,SOX5,ATP1A2,ITPR2 |
2.991e-03 | -5.81 | TBR1 (T-box brain transcription factor 1) | protein interactions | 10716 | 112 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
3.041e-03 | -5.80 | - | gene3d domains | 1.20.5.4010 | 1 | 1 | 14470 | 44 |
QKI |
3.051e-03 | -5.79 | intracellularly ligand-gated monoatomic ion channel activity | molecular function | GO:0005217 | 31 | 2 | 18094 | 48 |
ITPR2,RYR3 |
3.055e-03 | -5.79 | CDH1 (cadherin 1) | protein interactions | 999 | 757 | 7 | 19454 | 50 |
PARD3,CTNND2,NHSL1,CTNNA2,NEBL,MACF1,ABLIM1 |
3.057e-03 | -5.79 | NXPH2 (neurexophilin 2) | protein interactions | 11249 | 32 | 2 | 19454 | 50 |
NRXN1,PCDH9 |
3.093e-03 | -5.78 | MARK3 (microtubule affinity regulating kinase 3) | protein interactions | 4140 | 235 | 4 | 19454 | 50 |
MACF1,NTRK2,PARD3,DTNA |
3.144e-03 | -5.76 | ORF3b (ORF3b protein) | protein interactions | 1489670 | 114 | 3 | 19454 | 50 |
MACF1,PCDH9,ZBTB20 |
3.162e-03 | -5.76 | Glutamatergic synapse | KEGG pathways | ko04724 | 114 | 3 | 7161 | 19 |
SLC1A3,ITPR2,SLC1A2 |
3.162e-03 | -5.76 | Glutamatergic synapse | KEGG pathways | hsa04724 | 114 | 3 | 7161 | 19 |
SLC1A2,ITPR2,SLC1A3 |
3.222e-03 | -5.74 | SMAD7 (SMAD family member 7) | protein interactions | 4092 | 115 | 3 | 19454 | 50 |
PARD3,SOX5,BMPR1B |
3.224e-03 | -5.74 | human chr11p13 | chromosome location | human chr11p13 | 44 | 2 | 26134 | 50 |
SLC1A2,PAMR1 |
3.282e-03 | -5.72 | E1-E2_ATPase | pfam domains | PF00122 | 31 | 2 | 17795 | 49 |
ATP13A4,ATP1A2 |
3.289e-03 | -5.72 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 22 | 16828 | 49 |
SLC1A3,MEIS2,RANBP3L,GPM6A,CADM1,GLIS3,RYR3,NRG3,PCDH9,ATP1A2,MACF1,CTNND2,ZNRF3,PTPRZ1,PARD3,PREX2,SOX5,DTNA,ABLIM1,QKI,NHSL1,TRPS1 |
3.289e-03 | -5.72 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 22 | 16828 | 49 |
PARD3,PTPRZ1,ZNRF3,DTNA,SOX5,PREX2,ABLIM1,TRPS1,NHSL1,QKI,RANBP3L,MEIS2,SLC1A3,CADM1,GPM6A,NRG3,RYR3,GLIS3,MACF1,CTNND2,ATP1A2,PCDH9 |
3.336e-03 | -5.70 | GJA1 (gap junction protein alpha 1) | protein interactions | 2697 | 572 | 6 | 19454 | 50 |
PCDH9,ITPR2,MACF1,TNIK,PARD3,DTNA |
3.344e-03 | -5.70 | centrosome localization | biological process | GO:0051642 | 32 | 2 | 18204 | 49 |
PARD3B,PARD3 |
3.344e-03 | -5.70 | transepithelial transport | biological process | GO:0070633 | 32 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
3.344e-03 | -5.70 | positive regulation of ATP metabolic process | biological process | GO:1903580 | 32 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
3.344e-03 | -5.70 | microtubule organizing center localization | biological process | GO:0061842 | 32 | 2 | 18204 | 49 |
PARD3B,PARD3 |
3.344e-03 | -5.70 | positive regulation of cartilage development | biological process | GO:0061036 | 32 | 2 | 18204 | 49 |
SOX5,BMPR1B |
3.486e-03 | -5.66 | dendrite development | biological process | GO:0016358 | 113 | 3 | 18204 | 49 |
CTNNA2,PREX2,CTNND2 |
3.495e-03 | -5.66 | Cation_ATPase | pfam domains | PF13246 | 32 | 2 | 17795 | 49 |
ATP1A2,ATP13A4 |
3.504e-03 | -5.65 | eye development | biological process | GO:0001654 | 381 | 5 | 18204 | 49 |
BMPR1B,GPM6A,NTRK2,MEIS2,NFIA |
3.635e-03 | -5.62 | NTKRECEPTOR2 | prints domains | PR01941 | 1 | 1 | 5227 | 19 |
NTRK2 |
3.649e-03 | -5.61 | TPRA1 (transmembrane protein adipocyte associated 1) | protein interactions | 131601 | 35 | 2 | 19454 | 50 |
ITPR2,BMPR1B |
3.653e-03 | -5.61 | response to endogenous stimulus | biological process | GO:0009719 | 1402 | 10 | 18204 | 49 |
SLC1A3,BMPR1B,ATP1A2,ITPR2,SOX5,MEIS2,NTRK2,RYR3,NFIA,SLC1A2 |
3.656e-03 | -5.61 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 21 | 16828 | 49 |
ZNRF3,PTPRZ1,PARD3,SOX5,DTNA,GPC5,TNIK,TRPS1,ATP13A4,NRXN1,LSAMP,CADM1,SPARCL1,GLIS3,RYR3,NFIA,ATP1A2,ITPR2,MACF1,CTNND2,PCDH9 |
3.663e-03 | -5.61 | visual system development | biological process | GO:0150063 | 385 | 5 | 18204 | 49 |
NFIA,BMPR1B,GPM6A,NTRK2,MEIS2 |
3.688e-03 | -5.60 | calcium channel activity | molecular function | GO:0005262 | 117 | 3 | 18094 | 48 |
RYR3,ITPR2,GPM6A |
3.688e-03 | -5.60 | solute:monoatomic cation symporter activity | molecular function | GO:0015294 | 117 | 3 | 18094 | 48 |
SLC4A4,SLC1A3,SLC1A2 |
3.878e-03 | -5.55 | organic acid:sodium symporter activity | molecular function | GO:0005343 | 35 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
3.912e-03 | -5.54 | sensory system development | biological process | GO:0048880 | 391 | 5 | 18204 | 49 |
NTRK2,MEIS2,GPM6A,BMPR1B,NFIA |
3.912e-03 | -5.54 | Ig_sub2 | interpro domains | IPR003598 | 239 | 4 | 18521 | 50 |
LSAMP,NTRK2,CADM1,NTM |
3.930e-03 | -5.54 | oesophagus-lower_third-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-adenocarcinoma | 6302 | 28 | 16828 | 49 |
ZBTB20,PAMR1,TRPS1,ATP13A4,PARD3,PTPRZ1,CDH20,NEBL,PARD3B,AHCYL2,RORA,CTNND2,NRXN1,GPC5,QKI,ZNRF3,SOX5,PREX2,NTRK2,NRG3,RYR3,NPAS3,ITPR2,MACF1,PCDH9,MEIS2,RANBP3L,CADM1 |
3.937e-03 | -5.54 | synapse assembly | biological process | GO:0007416 | 118 | 3 | 18204 | 49 |
NRXN1,NRG3,GPM6A |
3.979e-03 | -5.53 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 5 | 19108 | 49 |
NRG3,SLC1A2,SPARCL1,TNIK,GPM6A |
4.071e-03 | -5.50 | TRNAU1AP (tRNA selenocysteine 1 associated protein 1) | protein interactions | 54952 | 37 | 2 | 19454 | 50 |
ZBTB20,QKI |
4.116e-03 | -5.49 | DELLA | smart domains | SM01129 | 1 | 1 | 9717 | 40 |
MACF1 |
4.127e-03 | -5.49 | striated muscle contraction | biological process | GO:0006941 | 120 | 3 | 18204 | 49 |
DTNA,RYR3,ATP1A2 |
4.183e-03 | -5.48 | monoatomic cation transport | biological process | GO:0006812 | 766 | 7 | 18204 | 49 |
ATP13A4,SLC1A3,SLC4A4,GPM6A,RYR3,ATP1A2,ITPR2 |
4.217e-03 | -5.47 | organic anion transport | biological process | GO:0015711 | 398 | 5 | 18204 | 49 |
SLC4A4,NTRK2,SLC1A3,SFXN5,SLC1A2 |
4.244e-03 | -5.46 | P_typ_ATPase | interpro domains | IPR001757 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | ATPase_P-typ_P_site | interpro domains | IPR018303 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | ATPase_P-typ_transduc_dom_A_sf | interpro domains | IPR008250 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | ATPase_P-typ_cyto_dom_N | interpro domains | IPR023299 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | P_typ_ATPase_HD_dom | interpro domains | IPR044492 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.258e-03 | -5.46 | PAX9 (paired box 9) | protein interactions | 5083 | 127 | 3 | 19454 | 50 |
TRPS1,QKI,NFIA |
4.281e-03 | -5.45 | regulation of synapse organization | biological process | GO:0050807 | 246 | 4 | 18204 | 49 |
CTNNA2,NRXN1,NTRK2,GPM6A |
4.281e-03 | -5.45 | positive regulation of neurogenesis | biological process | GO:0050769 | 246 | 4 | 18204 | 49 |
QKI,MACF1,PTPRZ1,NTRK2 |
4.290e-03 | -5.45 | Pcbp1 (poly(rC) binding protein 1) | protein interactions | 23983 | 38 | 2 | 19454 | 50 |
MSI2,QKI |
4.335e-03 | -5.44 | kidney-other-neoplasm | COSMIC cancer mutations | kidney-other-neoplasm | 10653 | 40 | 16828 | 49 |
CDH20,NEBL,DTNA,PARD3,PTPRZ1,NHSL1,ATP13A4,TRPS1,ABLIM1,ZBTB20,PAMR1,SPARCL1,GPM6A,NKAIN3,LSAMP,SLC1A3,FBXL7,NRXN1,CTNND2,ATP1A2,RORA,AHCYL2,PREX2,SOX5,QKI,TNIK,SLC1A2,GPC5,MAML2,SFXN5,CADM1,RANBP3L,MEIS2,PCDH9,MACF1,ITPR2,NPAS3,RYR3,NRG3,NTRK2 |
4.352e-03 | -5.44 | ATF7IP (activating transcription factor 7 interacting protein) | protein interactions | 55729 | 128 | 3 | 19454 | 50 |
SOX5,MACF1,CADM1 |
4.448e-03 | -5.42 | Lima1 (LIM domain and actin binding 1) | protein interactions | 65970 | 129 | 3 | 19454 | 50 |
ABLIM1,ZBTB20,ITPR2 |
4.451e-03 | -5.41 | positive regulation of purine nucleotide metabolic process | biological process | GO:1900544 | 37 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
4.451e-03 | -5.41 | positive regulation of nucleotide metabolic process | biological process | GO:0045981 | 37 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
4.470e-03 | -5.41 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 1117 | 9 | 16828 | 49 |
RYR3,SLC1A2,GPC5,NRG3,ATP13A4,QKI,PARD3,CDH20,SOX5 |
4.478e-03 | -5.41 | ATPase_P-typ_TM_dom_sf | interpro domains | IPR023298 | 37 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.491e-03 | -5.41 | intracellular chemical homeostasis | biological process | GO:0055082 | 581 | 6 | 18204 | 49 |
RYR3,ZBTB20,ATP1A2,SLC4A4,ATP13A4,SLC1A3 |
4.602e-03 | -5.38 | FGFR1 (fibroblast growth factor receptor 1) | protein interactions | 2260 | 611 | 6 | 19454 | 50 |
PARD3,AHCYL2,DTNA,NHSL1,ABLIM1,TNIK |
4.604e-03 | -5.38 | PDZ | pfam domains | PF00595 | 122 | 3 | 17795 | 49 |
PARD3B,PREX2,PARD3 |
4.607e-03 | -5.38 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 27 | 16828 | 49 |
SFXN5,CADM1,PCDH9,MACF1,ITPR2,NFIA,GLIS3,NRG3,NTRK2,PREX2,SLC4A4,GPC5,SPARCL1,GPM6A,SLC1A3,NRXN1,ATP1A2,PARD3B,NEBL,CDH20,DTNA,PARD3,PTPRZ1,ATP13A4,TRPS1,ABLIM1,ZBTB20 |
4.631e-03 | -5.37 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 27 | 16828 | 49 |
SLC4A4,PREX2,GPC5,CADM1,SFXN5,NTRK2,NRG3,GLIS3,NFIA,ITPR2,MACF1,PCDH9,PARD3,PTPRZ1,DTNA,CDH20,NEBL,ZBTB20,ABLIM1,TRPS1,ATP13A4,NRXN1,SLC1A3,GPM6A,SPARCL1,PARD3B,ATP1A2 |
4.662e-03 | -5.37 | regulation of synapse structure or activity | biological process | GO:0050803 | 252 | 4 | 18204 | 49 |
NTRK2,GPM6A,CTNNA2,NRXN1 |
4.682e-03 | -5.36 | forebrain development | biological process | GO:0030900 | 408 | 5 | 18204 | 49 |
ATP1A2,SLC1A2,NRG3,NTRK2,PCDH9 |
4.691e-03 | -5.36 | amino acid import across plasma membrane | biological process | GO:0089718 | 38 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
4.744e-03 | -5.35 | DZIP1 (DAZ interacting zinc finger protein 1) | protein interactions | 22873 | 40 | 2 | 19454 | 50 |
NTRK2,PARD3 |
4.868e-03 | -5.33 | dendrite | cellular component | GO:0030425 | 620 | 6 | 19108 | 49 |
GPM6A,CADM1,NTRK2,BMPR1B,CTNND2,ATP1A2 |
4.936e-03 | -5.31 | sodium ion homeostasis | biological process | GO:0055078 | 39 | 2 | 18204 | 49 |
ATP1A2,SLC1A3 |
4.942e-03 | -5.31 | myelination | biological process | GO:0042552 | 128 | 3 | 18204 | 49 |
PARD3,NTRK2,QKI |
4.944e-03 | -5.31 | dendritic tree | cellular component | GO:0097447 | 622 | 6 | 19108 | 49 |
NTRK2,BMPR1B,CADM1,ATP1A2,CTNND2,GPM6A |
5.049e-03 | -5.29 | Myo1c (myosin IC) | protein interactions | 17913 | 135 | 3 | 19454 | 50 |
ABLIM1,ITPR2,TRPS1 |
5.127e-03 | -5.27 | EF-hand-dom_pair | interpro domains | IPR011992 | 258 | 4 | 18521 | 50 |
MACF1,RYR3,DTNA,SPARCL1 |
5.134e-03 | -5.27 | Fbxo34 (F-box protein 34) | protein interactions | 78938 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fkbp1b (FK506 binding protein 1b) | protein interactions | 14226 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fkbp1a (FK506 binding protein 1a) | protein interactions | 14225 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Ppp3cc (protein phosphatase 3, catalytic subunit, gamma isoform) | protein interactions | 19057 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Bcr (BCR activator of RhoGEF and GTPase) | protein interactions | 110279 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Bmpr2 (bone morphogenetic protein receptor type 2) | protein interactions | 12168 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Irf7 (interferon regulatory factor 7) | protein interactions | 54123 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Mknk2 (MAP kinase-interacting serine/threonine kinase 2) | protein interactions | 17347 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Kdm4c (lysine (K)-specific demethylase 4C) | protein interactions | 76804 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | Klhl1 (kelch-like 1) | protein interactions | 93688 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Zmym2 (zinc finger, MYM-type 2) | protein interactions | 76007 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | Sh3kbp1 (SH3-domain kinase binding protein 1) | protein interactions | 58194 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.160e-03 | -5.27 | axon ensheathment | biological process | GO:0008366 | 130 | 3 | 18204 | 49 |
NTRK2,PARD3,QKI |
5.160e-03 | -5.27 | ensheathment of neurons | biological process | GO:0007272 | 130 | 3 | 18204 | 49 |
QKI,NTRK2,PARD3 |
5.276e-03 | -5.24 | cell-cell adhesion via plasma-membrane adhesion molecules | biological process | GO:0098742 | 261 | 4 | 18204 | 49 |
SPARCL1,CDH20,PCDH9,CADM1 |
5.288e-03 | -5.24 | axon development | biological process | GO:0061564 | 420 | 5 | 18204 | 49 |
CTNNA2,NRXN1,BMPR1B,PTPRZ1,PARD3 |
5.302e-03 | -5.24 | lung-left_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-left_upper_lobe-carcinoma-adenocarcinoma | 556 | 6 | 16828 | 49 |
NTRK2,RYR3,TRPS1,CTNND2,FBXL7,SLC4A4 |
5.331e-03 | -5.23 | Calcium-transporting ATPase, cytoplasmic transduction domain A | gene3d domains | 2.70.150.10 | 36 | 2 | 14470 | 44 |
ATP1A2,ATP13A4 |
5.331e-03 | -5.23 | Calcium-transporting ATPase, cytoplasmic domain N | gene3d domains | 3.40.1110.10 | 36 | 2 | 14470 | 44 |
ATP13A4,ATP1A2 |
5.366e-03 | -5.23 | NFIB (nuclear factor I B) | protein interactions | 4781 | 138 | 3 | 19454 | 50 |
SOX5,NFIA,TRPS1 |
5.376e-03 | -5.23 | negative regulation of 3'-UTR-mediated mRNA stabilization | biological process | GO:1905869 | 2 | 1 | 18204 | 49 |
QKI |
5.376e-03 | -5.23 | myofibroblast contraction | biological process | GO:1990764 | 2 | 1 | 18204 | 49 |
QKI |
5.376e-03 | -5.23 | negative regulation of ERBB4 signaling pathway | biological process | GO:0120154 | 2 | 1 | 18204 | 49 |
CADM1 |
5.376e-03 | -5.23 | mesenchymal cell differentiation involved in bone development | biological process | GO:1901706 | 2 | 1 | 18204 | 49 |
RANBP3L |
5.376e-03 | -5.23 | Wnt receptor catabolic process | biological process | GO:0038018 | 2 | 1 | 18204 | 49 |
ZNRF3 |
5.392e-03 | -5.22 | Osteonectin_CS | interpro domains | IPR001999 | 2 | 1 | 18521 | 50 |
SPARCL1 |
5.392e-03 | -5.22 | MSI_RRM2 | interpro domains | IPR034126 | 2 | 1 | 18521 | 50 |
MSI2 |
5.392e-03 | -5.22 | Alpha_CARP_receptor-type | interpro domains | IPR041887 | 2 | 1 | 18521 | 50 |
PTPRZ1 |
5.392e-03 | -5.22 | Distrobrevin | interpro domains | IPR017432 | 2 | 1 | 18521 | 50 |
DTNA |
5.392e-03 | -5.22 | ZNRF-3_ecto | interpro domains | IPR040700 | 2 | 1 | 18521 | 50 |
ZNRF3 |
5.394e-03 | -5.22 | left_upper_lobe | COSMIC cancer mutations | left_upper_lobe | 558 | 6 | 16828 | 49 |
FBXL7,SLC4A4,NTRK2,RYR3,CTNND2,TRPS1 |
5.432e-03 | -5.22 | Ig_I-set | interpro domains | IPR013098 | 132 | 3 | 18521 | 50 |
NTRK2,NTM,LSAMP |
5.440e-03 | -5.21 | sarcoplasmic reticulum membrane | cellular component | GO:0033017 | 43 | 2 | 19108 | 49 |
RYR3,ITPR2 |
5.462e-03 | -5.21 | lung-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-adenocarcinoma | 15133 | 49 | 16828 | 49 |
FBXL7,SLC1A3,LSAMP,ATP1A2,CTNND2,PARD3B,DTNA,CDH20,NEBL,PTPRZ1,ATP13A4,NHSL1,PAMR1,ZBTB20,CADM1,MEIS2,ITPR2,MACF1,GLIS3,NPAS3,RYR3,NFIA,ZNRF3,NKAIN3,GPM6A,SPARCL1,NRXN1,PITPNC1,AHCYL2,RORA,BMPR1B,PARD3,TRPS1,ABLIM1,MSI2,SFXN5,MAML2,NTM,RANBP3L,PCDH9,NTRK2,NRG3,SOX5,PREX2,SLC4A4,QKI,SLC1A2,GPC5,TNIK |
5.468e-03 | -5.21 | regulation of multicellular organismal development | biological process | GO:2000026 | 1484 | 10 | 18204 | 49 |
QKI,TRPS1,SOX5,MACF1,PTPRZ1,BMPR1B,NRXN1,PARD3,NTRK2,MEIS2 |
5.482e-03 | -5.21 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 31 | 16828 | 49 |
ITPR2,MACF1,NTRK2,NRG3,GLIS3,NPAS3,RYR3,CADM1,MAML2,QKI,TNIK,SOX5,PREX2,SLC4A4,ATP1A2,CTNND2,PARD3B,RORA,NKAIN3,SPARCL1,NRXN1,SLC1A3,TRPS1,ATP13A4,PAMR1,ZBTB20,ABLIM1,DTNA,NEBL,PTPRZ1,PARD3 |
5.492e-03 | -5.20 | organic anion transmembrane transporter activity | molecular function | GO:0008514 | 268 | 4 | 18094 | 48 |
SLC1A2,SFXN5,SLC1A3,SLC4A4 |
5.497e-03 | -5.20 | regulation of sequestering of calcium ion | biological process | GO:0051282 | 133 | 3 | 18204 | 49 |
RYR3,ATP1A2,ITPR2 |
5.500e-03 | -5.20 | ZNRF_3_ecto | pfam domains | PF18212 | 2 | 1 | 17795 | 49 |
ZNRF3 |
5.545e-03 | -5.19 | neutral L-amino acid transmembrane transporter activity | molecular function | GO:0015175 | 42 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
5.612e-03 | -5.18 | calcium ion transmembrane transporter activity | molecular function | GO:0015085 | 136 | 3 | 18094 | 48 |
ITPR2,RYR3,GPM6A |
5.706e-03 | -5.17 | Schwann cell development | biological process | GO:0014044 | 42 | 2 | 18204 | 49 |
PARD3,NTRK2 |
5.721e-03 | -5.16 | intracellular monoatomic cation homeostasis | biological process | GO:0030003 | 428 | 5 | 18204 | 49 |
SLC1A3,ATP13A4,SLC4A4,ATP1A2,RYR3 |
5.731e-03 | -5.16 | I-set | pfam domains | PF07679 | 132 | 3 | 17795 | 49 |
NTRK2,LSAMP,NTM |
5.767e-03 | -5.16 | sarcolemma | cellular component | GO:0042383 | 142 | 3 | 19108 | 49 |
ATP1A2,RYR3,DTNA |
5.890e-03 | -5.13 | trans-synaptic signaling | biological process | GO:0099537 | 431 | 5 | 18204 | 49 |
SLC1A3,DTNA,NTRK2,SLC1A2,NRXN1 |
5.913e-03 | -5.13 | Cardiac conduction | REACTOME pathways | R-HSA-5576891 | 142 | 3 | 10285 | 27 |
RYR3,ITPR2,ATP1A2 |
5.922e-03 | -5.13 | SLC6A15 (solute carrier family 6 member 15) | protein interactions | 55117 | 143 | 3 | 19454 | 50 |
PARD3,SFXN5,NTRK2 |
5.929e-03 | -5.13 | postsynapse | cellular component | GO:0098794 | 646 | 6 | 19108 | 49 |
TNIK,GPM6A,CTNND2,ATP1A2,CADM1,NTRK2 |
5.997e-03 | -5.12 | FLOT1 (flotillin 1) | protein interactions | 10211 | 453 | 5 | 19454 | 50 |
DTNA,PARD3,SOX5,ABLIM1,MACF1 |
5.998e-03 | -5.12 | transmembrane transport | biological process | GO:0055085 | 1264 | 9 | 18204 | 49 |
SFXN5,GPM6A,RYR3,SLC1A2,ATP13A4,SLC1A3,SLC4A4,ATP1A2,ITPR2 |
6.037e-03 | -5.11 | Calml3 (calmodulin-like 3) | protein interactions | 70405 | 144 | 3 | 19454 | 50 |
MACF1,ABLIM1,ZBTB20 |
6.044e-03 | -5.11 | inorganic cation transmembrane transport | biological process | GO:0098662 | 618 | 6 | 18204 | 49 |
GPM6A,SLC4A4,SLC1A3,ITPR2,RYR3,ATP1A2 |
6.073e-03 | -5.10 | - | gene3d domains | 6.20.350.10 | 2 | 1 | 14470 | 44 |
RYR3 |
6.073e-03 | -5.10 | Vinculin, Vh2 four-helix bundle | gene3d domains | 1.20.120.810 | 2 | 1 | 14470 | 44 |
CTNNA2 |
6.081e-03 | -5.10 | system process | biological process | GO:0003008 | 2015 | 12 | 18204 | 49 |
SLC1A3,NRXN1,CTNNA2,ABLIM1,NTRK2,ATP1A2,SLC4A4,PTPRZ1,RYR3,SLC1A2,DTNA,MEIS2 |
6.087e-03 | -5.10 | phosphatidylinositol binding | molecular function | GO:0035091 | 276 | 4 | 18094 | 48 |
PARD3B,PARD3,ITPR2,PITPNC1 |
6.174e-03 | -5.09 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 4 | 18204 | 49 |
SLC4A4,SLC1A3,SLC1A2,ATP1A2 |
6.238e-03 | -5.08 | intracellular monoatomic ion homeostasis | biological process | GO:0006873 | 437 | 5 | 18204 | 49 |
ATP13A4,SLC1A3,SLC4A4,ATP1A2,RYR3 |
6.257e-03 | -5.07 | active transmembrane transporter activity | molecular function | GO:0022804 | 444 | 5 | 18094 | 48 |
SLC1A3,SLC4A4,ATP13A4,SLC1A2,ATP1A2 |
6.272e-03 | -5.07 | PARD3 (par-3 family cell polarity regulator) | protein interactions | 56288 | 287 | 4 | 19454 | 50 |
DTNA,NTRK2,PARD3,PARD3B |
6.279e-03 | -5.07 | SLC-mediated transmembrane transport | REACTOME pathways | R-HSA-425407 | 287 | 4 | 10285 | 27 |
AHCYL2,SLC1A3,SLC4A4,SLC1A2 |
6.414e-03 | -5.05 | telencephalon development | biological process | GO:0021537 | 276 | 4 | 18204 | 49 |
ATP1A2,SLC1A2,NRG3,NTRK2 |
6.493e-03 | -5.04 | spleen | COSMIC cancer mutations | spleen | 408 | 5 | 16828 | 49 |
NTM,MEIS2,PARD3B,TNIK,PTPRZ1 |
6.500e-03 | -5.04 | CNTN1 (contactin 1) | protein interactions | 1272 | 47 | 2 | 19454 | 50 |
GPM6A,PTPRZ1 |
6.588e-03 | -5.02 | monoatomic anion transmembrane transport | biological process | GO:0098656 | 142 | 3 | 18204 | 49 |
SLC4A4,SLC1A3,SLC1A2 |
6.624e-03 | -5.02 | metal ion transport | biological process | GO:0030001 | 630 | 6 | 18204 | 49 |
SLC4A4,SLC1A3,GPM6A,ITPR2,ATP1A2,RYR3 |
6.634e-03 | -5.02 | GSE1 (Gse1 coiled-coil protein) | protein interactions | 23199 | 149 | 3 | 19454 | 50 |
NFIA,SOX5,TNIK |
6.812e-03 | -4.99 | regulation of myelination | biological process | GO:0031641 | 46 | 2 | 18204 | 49 |
PTPRZ1,PARD3 |
6.812e-03 | -4.99 | positive regulation of glial cell differentiation | biological process | GO:0045687 | 46 | 2 | 18204 | 49 |
QKI,PTPRZ1 |
6.812e-03 | -4.99 | regulation of oligodendrocyte differentiation | biological process | GO:0048713 | 46 | 2 | 18204 | 49 |
QKI,PTPRZ1 |
6.875e-03 | -4.98 | Ig_3 | pfam domains | PF13927 | 141 | 3 | 17795 | 49 |
LSAMP,NTM,CADM1 |
6.935e-03 | -4.97 | CATATPASE | prints domains | PR00119 | 35 | 2 | 5227 | 19 |
ATP1A2,ATP13A4 |
6.997e-03 | -4.96 | Wnt signaling pathway | biological process | GO:0016055 | 283 | 4 | 18204 | 49 |
MACF1,ZNRF3,TNIK,CTNND2 |
7.045e-03 | -4.96 | OSTEONECTIN_1 | prosite domains | PS00612 | 2 | 1 | 12186 | 43 |
SPARCL1 |
7.045e-03 | -4.96 | OSTEONECTIN_2 | prosite domains | PS00613 | 2 | 1 | 12186 | 43 |
SPARCL1 |
7.064e-03 | -4.95 | SP7 (Sp7 transcription factor) | protein interactions | 121340 | 297 | 4 | 19454 | 50 |
TRPS1,QKI,NFIA,SOX5 |
7.087e-03 | -4.95 | symporter activity | molecular function | GO:0015293 | 148 | 3 | 18094 | 48 |
SLC1A3,SLC4A4,SLC1A2 |
7.101e-03 | -4.95 | ATPASE_E1_E2 | prosite domains | PS00154 | 36 | 2 | 12186 | 43 |
ATP13A4,ATP1A2 |
7.103e-03 | -4.95 | Schwann cell differentiation | biological process | GO:0014037 | 47 | 2 | 18204 | 49 |
PARD3,NTRK2 |
7.103e-03 | -4.95 | regulation of neuron migration | biological process | GO:2001222 | 47 | 2 | 18204 | 49 |
CTNNA2,NRG3 |
7.119e-03 | -4.94 | oligoastrocytoma_Grade_III | COSMIC cancer mutations | oligoastrocytoma_Grade_III | 263 | 4 | 16828 | 49 |
SOX5,PREX2,SLC1A2,RYR3 |
7.135e-03 | -4.94 | SOX6 (SRY-box transcription factor 6) | protein interactions | 55553 | 153 | 3 | 19454 | 50 |
TRPS1,SOX5,NFIA |
7.175e-03 | -4.94 | PDZ | interpro domains | IPR001478 | 146 | 3 | 18521 | 50 |
PARD3,PARD3B,PREX2 |
7.203e-03 | -4.93 | SFN (stratifin) | protein interactions | 2810 | 671 | 6 | 19454 | 50 |
PARD3,TNIK,NFIA,PARD3B,MACF1,ABLIM1 |
7.339e-03 | -4.91 | Hippo signaling pathway | KEGG pathways | ko04390 | 154 | 3 | 7161 | 19 |
PARD3,BMPR1B,CTNNA2 |
7.339e-03 | -4.91 | Hippo signaling pathway | KEGG pathways | hsa04390 | 154 | 3 | 7161 | 19 |
BMPR1B,CTNNA2,PARD3 |
7.364e-03 | -4.91 | alveolar | COSMIC cancer mutations | alveolar | 2414 | 14 | 16828 | 49 |
ZNRF3,PARD3,CDH20,PREX2,PAMR1,NHSL1,TRPS1,SLC1A3,SPARCL1,RYR3,NPAS3,NFIA,PARD3B,MACF1 |
7.364e-03 | -4.91 | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | 2414 | 14 | 16828 | 49 |
SLC1A3,SPARCL1,PARD3B,NPAS3,RYR3,NFIA,MACF1,ZNRF3,PARD3,CDH20,PREX2,PAMR1,TRPS1,NHSL1 |
7.519e-03 | -4.89 | neuromuscular process | biological process | GO:0050905 | 149 | 3 | 18204 | 49 |
SLC1A3,CTNNA2,NRXN1 |
7.587e-03 | -4.88 | PDZ_sf | interpro domains | IPR036034 | 149 | 3 | 18521 | 50 |
PREX2,PARD3B,PARD3 |
7.592e-03 | -4.88 | haematopoietic_and_lymphoid_tissue-small_intestine-lymphoid_neoplasm-enteropathy_type_T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-small_intestine-lymphoid_neoplasm-enteropathy_type_T_cell_lymphoma | 45 | 2 | 16828 | 49 |
MACF1,ZNRF3 |
7.592e-03 | -4.88 | enteropathy_type_T_cell_lymphoma | COSMIC cancer mutations | enteropathy_type_T_cell_lymphoma | 45 | 2 | 16828 | 49 |
ZNRF3,MACF1 |
7.617e-03 | -4.88 | Ndc80 (NDC80 kinetochore complex component) | protein interactions | 67052 | 51 | 2 | 19454 | 50 |
MACF1,NHSL1 |
7.617e-03 | -4.88 | FAM171B (family with sequence similarity 171 member B) | protein interactions | 165215 | 51 | 2 | 19454 | 50 |
PARD3,NTRK2 |
7.631e-03 | -4.88 | human chr8q23.3 | chromosome location | human chr8q23.3 | 4 | 1 | 26134 | 50 |
TRPS1 |
7.640e-03 | -4.87 | synaptic signaling | biological process | GO:0099536 | 459 | 5 | 18204 | 49 |
NTRK2,DTNA,SLC1A3,NRXN1,SLC1A2 |
7.691e-03 | -4.87 | Atg16l1 (autophagy related 16 like 1) | protein interactions | 77040 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | PIGL (phosphatidylinositol glycan anchor biosynthesis class L) | protein interactions | 9487 | 3 | 1 | 19454 | 50 |
MEIS2 |
7.691e-03 | -4.87 | QRFPR (pyroglutamylated RFamide peptide receptor) | protein interactions | 84109 | 3 | 1 | 19454 | 50 |
NTM |
7.691e-03 | -4.87 | Stk35 (serine/threonine kinase 35) | protein interactions | 67333 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Usp45 (ubiquitin specific petidase 45) | protein interactions | 77593 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | BCO1 (beta-carotene oxygenase 1) | protein interactions | 53630 | 3 | 1 | 19454 | 50 |
ABLIM1 |
7.691e-03 | -4.87 | IL34 (interleukin 34) | protein interactions | 146433 | 3 | 1 | 19454 | 50 |
PTPRZ1 |
7.691e-03 | -4.87 | Spop (speckle-type BTB/POZ protein) | protein interactions | 20747 | 3 | 1 | 19454 | 50 |
GLIS3 |
7.691e-03 | -4.87 | Rap2a (RAS related protein 2a) | protein interactions | 76108 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Fbxw5 (F-box and WD-40 domain protein 5) | protein interactions | 30839 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Chn1 (chimerin 1) | protein interactions | 108699 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Plekhb1 (pleckstrin homology domain containing, family B (evectins) member 1) | protein interactions | 27276 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | TULP1 (TUB like protein 1) | protein interactions | 7287 | 3 | 1 | 19454 | 50 |
NRXN1 |
7.691e-03 | -4.87 | Smad6 (SMAD family member 6) | protein interactions | 17130 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.700e-03 | -4.87 | visual learning | biological process | GO:0008542 | 49 | 2 | 18204 | 49 |
ATP1A2,MEIS2 |
7.818e-03 | -4.85 | Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-112310 | 51 | 2 | 10285 | 27 |
SLC1A3,SLC1A2 |
7.923e-03 | -4.84 | haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-follicular_lymphoma | 46 | 2 | 16828 | 49 |
ITPR2,RANBP3L |
7.938e-03 | -4.84 | hydrolase activity, acting on carbon-sulfur bonds | molecular function | GO:0046508 | 3 | 1 | 18094 | 48 |
AHCYL2 |
7.938e-03 | -4.84 | cysteine transmembrane transporter activity | molecular function | GO:0033229 | 3 | 1 | 18094 | 48 |
SLC1A2 |
7.938e-03 | -4.84 | inositol 1,4,5-trisphosphate-gated calcium channel activity | molecular function | GO:0005220 | 3 | 1 | 18094 | 48 |
ITPR2 |
7.938e-03 | -4.84 | adenosylhomocysteinase activity | molecular function | GO:0004013 | 3 | 1 | 18094 | 48 |
AHCYL2 |
8.054e-03 | -4.82 | cysteine transmembrane transport | biological process | GO:1903712 | 3 | 1 | 18204 | 49 |
SLC1A2 |
8.054e-03 | -4.82 | mammary placode formation | biological process | GO:0060596 | 3 | 1 | 18204 | 49 |
NRG3 |
8.054e-03 | -4.82 | neuroligin clustering involved in postsynaptic membrane assembly | biological process | GO:0097118 | 3 | 1 | 18204 | 49 |
NRXN1 |
8.054e-03 | -4.82 | regulation of calcium:sodium antiporter activity | biological process | GO:1903279 | 3 | 1 | 18204 | 49 |
ATP1A2 |
8.054e-03 | -4.82 | cardiac muscle thin filament assembly | biological process | GO:0071691 | 3 | 1 | 18204 | 49 |
NEBL |
8.054e-03 | -4.82 | susceptibility to natural killer cell mediated cytotoxicity | biological process | GO:0042271 | 3 | 1 | 18204 | 49 |
CADM1 |
8.054e-03 | -4.82 | cysteine transport | biological process | GO:0042883 | 3 | 1 | 18204 | 49 |
SLC1A2 |
8.054e-03 | -4.82 | radial glia guided migration of Purkinje cell | biological process | GO:0021942 | 3 | 1 | 18204 | 49 |
CTNNA2 |
8.054e-03 | -4.82 | trans-synaptic signaling by BDNF, modulating synaptic transmission | biological process | GO:0099183 | 3 | 1 | 18204 | 49 |
NTRK2 |
8.065e-03 | -4.82 | SOX5 (SRY-box transcription factor 5) | protein interactions | 6660 | 160 | 3 | 19454 | 50 |
SOX5,NFIA,TRPS1 |
8.078e-03 | -4.82 | NTRK | interpro domains | IPR020777 | 3 | 1 | 18521 | 50 |
NTRK2 |
8.078e-03 | -4.82 | SPRY1_RyR | interpro domains | IPR035761 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Ado_hCys_hydrolase_NAD-bd | interpro domains | IPR015878 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | MAML1-3 | interpro domains | IPR046369 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | Myelin_PLP | interpro domains | IPR001614 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | Ryan_recept | interpro domains | IPR013333 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | SPRY2_RyR | interpro domains | IPR035764 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | NTRK_LRRCT | interpro domains | IPR031635 | 3 | 1 | 18521 | 50 |
NTRK2 |
8.078e-03 | -4.82 | Vinculin_CS | interpro domains | IPR000633 | 3 | 1 | 18521 | 50 |
CTNNA2 |
8.078e-03 | -4.82 | Adenosylhomocysteinase-like | interpro domains | IPR000043 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | S-Ado-L-homoCys_hydrolase_CS | interpro domains | IPR020082 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | RYDR_Jsol | interpro domains | IPR048581 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Mastermind-like_N | interpro domains | IPR019082 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | Myelin_PLP_CS | interpro domains | IPR018237 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | InsP3_rcpt | interpro domains | IPR000493 | 3 | 1 | 18521 | 50 |
ITPR2 |
8.078e-03 | -4.82 | NR_DBD_ROR | interpro domains | IPR044101 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | ROR_rcpt | interpro domains | IPR003079 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | Adenosylhomocyst_ase-like_sf | interpro domains | IPR042172 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | Ryanrecept_TM4-6 | interpro domains | IPR009460 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | SPRY3_RyR | interpro domains | IPR035762 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | MAML_N_sf | interpro domains | IPR046370 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | Neuregulin | interpro domains | IPR040180 | 3 | 1 | 18521 | 50 |
NRG3 |
8.078e-03 | -4.82 | Ryanodine_rcpt | interpro domains | IPR003032 | 3 | 1 | 18521 | 50 |
RYR3 |
8.100e-03 | -4.82 | AFDN (afadin, adherens junction formation factor) | protein interactions | 4301 | 309 | 4 | 19454 | 50 |
MACF1,NRXN1,PARD3,DTNA |
8.135e-03 | -4.81 | urinary_tract-bladder-carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma | 14050 | 47 | 16828 | 49 |
RYR3,GLIS3,NPAS3,NFIA,NTRK2,NRG3,PCDH9,ITPR2,MACF1,MEIS2,RANBP3L,MAML2,NTM,MSI2,CADM1,SFXN5,GPC5,SLC1A2,TNIK,QKI,ZNRF3,SLC4A4,PREX2,SOX5,RORA,PARD3B,AHCYL2,PITPNC1,ATP1A2,CTNND2,SLC1A3,LSAMP,NRXN1,FBXL7,GPM6A,SPARCL1,ABLIM1,PAMR1,ZBTB20,ATP13A4,TRPS1,PTPRZ1,PARD3,CDH20,BMPR1B,NEBL,DTNA |
8.206e-03 | -4.80 | FOXF2 (forkhead box F2) | protein interactions | 2295 | 53 | 2 | 19454 | 50 |
ZBTB20,AHCYL2 |
8.230e-03 | -4.80 | calcium-mediated signaling | biological process | GO:0019722 | 154 | 3 | 18204 | 49 |
ITPR2,RYR3,ATP1A2 |
8.238e-03 | -4.80 | RyR | pfam domains | PF02026 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | SR_plectin_7 | pfam domains | PF21097 | 3 | 1 | 17795 | 49 |
MACF1 |
8.238e-03 | -4.80 | AdoHcyase_NAD | pfam domains | PF00670 | 3 | 1 | 17795 | 49 |
AHCYL2 |
8.238e-03 | -4.80 | LRRCT_2 | pfam domains | PF16920 | 3 | 1 | 17795 | 49 |
NTRK2 |
8.238e-03 | -4.80 | AdoHcyase | pfam domains | PF05221 | 3 | 1 | 17795 | 49 |
AHCYL2 |
8.238e-03 | -4.80 | Myelin_PLP | pfam domains | PF01275 | 3 | 1 | 17795 | 49 |
GPM6A |
8.238e-03 | -4.80 | RR_TM4-6 | pfam domains | PF06459 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | RYDR_Jsol | pfam domains | PF21119 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | MamL-1 | pfam domains | PF09596 | 3 | 1 | 17795 | 49 |
MAML2 |
8.267e-03 | -4.80 | carboxylic acid transport | biological process | GO:0046942 | 297 | 4 | 18204 | 49 |
SLC1A2,NTRK2,SFXN5,SLC1A3 |
8.320e-03 | -4.79 | neuromuscular process controlling balance | biological process | GO:0050885 | 51 | 2 | 18204 | 49 |
SLC1A3,NRXN1 |
8.363e-03 | -4.78 | organic acid transport | biological process | GO:0015849 | 298 | 4 | 18204 | 49 |
SLC1A2,SLC1A3,SFXN5,NTRK2 |
8.546e-03 | -4.76 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 13 | 16828 | 49 |
ATP1A2,TRPS1,NFIA,NTRK2,PARD3B,TNIK,BMPR1B,PREX2,SOX5,CADM1,DTNA,SLC4A4,PTPRZ1 |
8.603e-03 | -4.76 | central_nervous_system-temporoparietal-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-temporoparietal-glioma-astrocytoma_Grade_IV | 48 | 2 | 16828 | 49 |
RYR3,PARD3 |
8.638e-03 | -4.75 | regulation of purine nucleotide catabolic process | biological process | GO:0033121 | 52 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
8.638e-03 | -4.75 | regulation of nucleotide catabolic process | biological process | GO:0030811 | 52 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
8.638e-03 | -4.75 | regulation of glycolytic process | biological process | GO:0006110 | 52 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
8.675e-03 | -4.75 | positive regulation of synaptic transmission | biological process | GO:0050806 | 157 | 3 | 18204 | 49 |
NRXN1,SLC1A3,NTRK2 |
8.712e-03 | -4.74 | ATPase-coupled monoatomic cation transmembrane transporter activity | molecular function | GO:0019829 | 53 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
8.761e-03 | -4.74 | postsynaptic density | cellular component | GO:0014069 | 317 | 4 | 19108 | 49 |
TNIK,CADM1,NTRK2,CTNND2 |
8.771e-03 | -4.74 | EGR2 (early growth response 2) | protein interactions | 1959 | 165 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
8.917e-03 | -4.72 | SCLT1 (sodium channel and clathrin linker 1) | protein interactions | 132320 | 166 | 3 | 19454 | 50 |
NEBL,ATP1A2,ABLIM1 |
8.962e-03 | -4.71 | neutral amino acid transport | biological process | GO:0015804 | 53 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
8.979e-03 | -4.71 | monoatomic anion transport | biological process | GO:0006820 | 159 | 3 | 18204 | 49 |
SLC1A2,SLC1A3,SLC4A4 |
9.053e-03 | -4.70 | CTNNB1 (catenin beta 1) | protein interactions | 1499 | 926 | 7 | 19454 | 50 |
DTNA,PTPRZ1,CTNNA2,PARD3B,CTNND2,PARD3,NHSL1 |
9.087e-03 | -4.70 | metal ion binding | molecular function | GO:0046872 | 4239 | 19 | 18094 | 48 |
RYR3,MACF1,SLC1A3,ATP13A4,GLIS3,BMPR1B,DTNA,ITPR2,ABLIM1,SLC1A2,PCDH9,PAMR1,SPARCL1,NRXN1,ATP1A2,ZBTB20,RORA,ZNRF3,TRPS1 |
9.095e-03 | -4.70 | Adenosylhomocysteinase-like | gene3d domains | 3.40.50.1480 | 3 | 1 | 14470 | 44 |
AHCYL2 |
9.095e-03 | -4.70 | - | gene3d domains | 6.10.250.970 | 3 | 1 | 14470 | 44 |
MAML2 |
9.095e-03 | -4.70 | - | gene3d domains | 1.10.490.160 | 3 | 1 | 14470 | 44 |
RYR3 |
9.095e-03 | -4.70 | - | gene3d domains | 6.10.250.2510 | 3 | 1 | 14470 | 44 |
CTNNA2 |
9.147e-03 | -4.69 | presynaptic membrane | cellular component | GO:0042734 | 168 | 3 | 19108 | 49 |
GPM6A,NRXN1,SLC1A2 |
9.191e-03 | -4.69 | EF-hand | gene3d domains | 1.10.238.10 | 272 | 4 | 14470 | 44 |
SPARCL1,DTNA,RYR3,MACF1 |
9.428e-03 | -4.66 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 10 | 16828 | 49 |
DTNA,PREX2,PTPRZ1,MACF1,PCDH9,NRG3,GPC5,PARD3B,NPAS3,RYR3 |
9.442e-03 | -4.66 | NXPH3 (neurexophilin 3) | protein interactions | 11248 | 57 | 2 | 19454 | 50 |
CTNNA2,NRXN1 |
9.621e-03 | -4.64 | bladder | COSMIC cancer mutations | bladder | 14112 | 47 | 16828 | 49 |
ZBTB20,PAMR1,ATP13A4,PTPRZ1,CDH20,NEBL,DTNA,PARD3B,ATP1A2,CTNND2,SLC1A3,LSAMP,FBXL7,ZNRF3,RYR3,GLIS3,NPAS3,NFIA,ITPR2,MACF1,MEIS2,CADM1,ABLIM1,TRPS1,PARD3,BMPR1B,RORA,PITPNC1,AHCYL2,NRXN1,GPM6A,SPARCL1,GPC5,SLC1A2,TNIK,QKI,SLC4A4,PREX2,SOX5,NTRK2,NRG3,PCDH9,RANBP3L,MAML2,NTM,MSI2,SFXN5 |
9.621e-03 | -4.64 | urinary_tract | COSMIC cancer mutations | urinary_tract | 14112 | 47 | 16828 | 49 |
BMPR1B,PARD3,TRPS1,ABLIM1,GPM6A,SPARCL1,NRXN1,PITPNC1,AHCYL2,RORA,SOX5,PREX2,SLC4A4,QKI,SLC1A2,GPC5,TNIK,MSI2,SFXN5,MAML2,NTM,RANBP3L,PCDH9,NTRK2,NRG3,DTNA,NEBL,CDH20,PTPRZ1,ATP13A4,ZBTB20,PAMR1,FBXL7,SLC1A3,LSAMP,ATP1A2,CTNND2,PARD3B,ZNRF3,CADM1,MEIS2,ITPR2,MACF1,NPAS3,GLIS3,RYR3,NFIA |
9.625e-03 | -4.64 | establishment or maintenance of epithelial cell apical/basal polarity | biological process | GO:0045197 | 55 | 2 | 18204 | 49 |
PARD3,PARD3B |
9.625e-03 | -4.64 | response to cocaine | biological process | GO:0042220 | 55 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
9.634e-03 | -4.64 | biliary_tract | COSMIC cancer mutations | biliary_tract | 15309 | 49 | 16828 | 49 |
DTNA,NEBL,CDH20,PTPRZ1,ATP13A4,NHSL1,PAMR1,ZBTB20,FBXL7,SLC1A3,LSAMP,ATP1A2,CTNND2,PARD3B,ZNRF3,CADM1,MEIS2,ITPR2,MACF1,NPAS3,GLIS3,RYR3,NFIA,BMPR1B,PARD3,TRPS1,ABLIM1,NKAIN3,GPM6A,SPARCL1,NRXN1,AHCYL2,PITPNC1,RORA,SOX5,PREX2,SLC4A4,QKI,SLC1A2,GPC5,TNIK,MSI2,SFXN5,MAML2,NTM,RANBP3L,PCDH9,NTRK2,NRG3 |
9.665e-03 | -4.64 | TLX1 (T cell leukemia homeobox 1) | protein interactions | 3195 | 171 | 3 | 19454 | 50 |
NFIA,TRPS1,MEIS2 |
9.665e-03 | -4.64 | PPFIBP1 (PPFIA binding protein 1) | protein interactions | 8496 | 171 | 3 | 19454 | 50 |
MEIS2,NTRK2,PARD3 |
9.751e-03 | -4.63 | dendritic spine | cellular component | GO:0043197 | 172 | 3 | 19108 | 49 |
ATP1A2,NTRK2,GPM6A |
9.787e-03 | -4.63 | response to light stimulus | biological process | GO:0009416 | 312 | 4 | 18204 | 49 |
SLC1A3,MEIS2,ATP1A2,SLC1A2 |
9.847e-03 | -4.62 | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 6023 | 26 | 16828 | 49 |
ITPR2,MACF1,NTRK2,NRG3,GLIS3,NPAS3,RYR3,CADM1,MAML2,SOX5,PREX2,SLC4A4,ATP1A2,CTNND2,RORA,NKAIN3,SPARCL1,SLC1A3,ATP13A4,PAMR1,ZBTB20,ABLIM1,DTNA,NEBL,PTPRZ1,PARD3 |
9.929e-03 | -4.61 | homophilic cell adhesion via plasma membrane adhesion molecules | biological process | GO:0007156 | 165 | 3 | 18204 | 49 |
CADM1,PCDH9,CDH20 |
9.929e-03 | -4.61 | import across plasma membrane | biological process | GO:0098739 | 165 | 3 | 18204 | 49 |
SLC1A3,ATP1A2,SLC1A2 |
9.950e-03 | -4.61 | CAV1 (caveolin 1) | protein interactions | 857 | 719 | 6 | 19454 | 50 |
AHCYL2,PARD3,TNIK,SLC1A3,DTNA,MACF1 |
9.964e-03 | -4.61 | release of sequestered calcium ion into cytosol | biological process | GO:0051209 | 56 | 2 | 18204 | 49 |
ITPR2,RYR3 |
1.002e-02 | -4.60 | Ion transport by P-type ATPases | REACTOME pathways | R-HSA-936837 | 58 | 2 | 10285 | 27 |
ATP13A4,ATP1A2 |
1.002e-02 | -4.60 | Znf_NHR/GATA | interpro domains | IPR013088 | 56 | 2 | 18521 | 50 |
RORA,TRPS1 |
1.006e-02 | -4.60 | neuron spine | cellular component | GO:0044309 | 174 | 3 | 19108 | 49 |
NTRK2,GPM6A,ATP1A2 |
1.007e-02 | -4.60 | regulation of cell differentiation | biological process | GO:0045595 | 1622 | 10 | 18204 | 49 |
RANBP3L,SOX5,QKI,TRPS1,BMPR1B,RORA,PTPRZ1,MACF1,MEIS2,NTRK2 |
1.008e-02 | -4.60 | cellular homeostasis | biological process | GO:0019725 | 689 | 6 | 18204 | 49 |
ATP1A2,ZBTB20,ATP13A4,SLC1A3,SLC4A4,RYR3 |
1.022e-02 | -4.58 | extrinsic component of membrane | cellular component | GO:0019898 | 175 | 3 | 19108 | 49 |
CTNNA2,DTNA,CDH20 |
1.022e-02 | -4.58 | internode region of axon | cellular component | GO:0033269 | 4 | 1 | 19108 | 49 |
PARD3 |
1.023e-02 | -4.58 | positive regulation of cell differentiation | biological process | GO:0045597 | 906 | 7 | 18204 | 49 |
PTPRZ1,MACF1,BMPR1B,QKI,SOX5,RANBP3L,NTRK2 |
1.024e-02 | -4.58 | Nkiras1 (NFKB inhibitor interacting Ras-like protein 1) | protein interactions | 69721 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Nme2 (NME/NM23 nucleoside diphosphate kinase 2) | protein interactions | 18103 | 4 | 1 | 19454 | 50 |
RORA |
1.024e-02 | -4.58 | Srgap1 (SLIT-ROBO Rho GTPase activating protein 1) | protein interactions | 117600 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Rhebl1 (Ras homolog enriched in brain like 1) | protein interactions | 69159 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Cdk14 (cyclin dependent kinase 14) | protein interactions | 18647 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | CCDC126 (coiled-coil domain containing 126) | protein interactions | 90693 | 4 | 1 | 19454 | 50 |
GPM6A |
1.024e-02 | -4.58 | Ctbp2 (C-terminal binding protein 2) | protein interactions | 13017 | 4 | 1 | 19454 | 50 |
TRPS1 |
1.024e-02 | -4.58 | Ilkap (integrin-linked kinase-associated serine/threonine phosphatase 2C) | protein interactions | 67444 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Naa20 (N(alpha)-acetyltransferase 20, NatB catalytic subunit) | protein interactions | 67877 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Arhgef6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 73341 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Dnaja1 (DnaJ heat shock protein family (Hsp40) member A1) | protein interactions | 15502 | 4 | 1 | 19454 | 50 |
GLIS3 |
1.026e-02 | -4.58 | Axon guidance | KEGG pathways | ko04360 | 174 | 3 | 7161 | 19 |
BMPR1B,ABLIM1,PARD3 |
1.026e-02 | -4.58 | Axon guidance | KEGG pathways | hsa04360 | 174 | 3 | 7161 | 19 |
PARD3,BMPR1B,ABLIM1 |
1.026e-02 | -4.58 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 27 | 16828 | 49 |
NTM,MAML2,CADM1,MACF1,ITPR2,NFIA,RYR3,NRG3,NTRK2,PREX2,SOX5,SLC4A4,ZNRF3,TNIK,GPC5,NRXN1,CTNND2,ATP1A2,RORA,PITPNC1,BMPR1B,PTPRZ1,PARD3,ATP13A4,ABLIM1,ZBTB20,PAMR1 |
1.026e-02 | -4.58 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 27 | 16828 | 49 |
BMPR1B,PARD3,PTPRZ1,ATP13A4,ZBTB20,PAMR1,ABLIM1,NRXN1,CTNND2,ATP1A2,PITPNC1,RORA,SOX5,PREX2,SLC4A4,ZNRF3,TNIK,GPC5,CADM1,NTM,MAML2,MACF1,ITPR2,NRG3,NTRK2,NFIA,RYR3 |
1.029e-02 | -4.58 | LHX3 (LIM homeobox 3) | protein interactions | 8022 | 175 | 3 | 19454 | 50 |
TRPS1,NFIA,SOX5 |
1.030e-02 | -4.58 | modulation of chemical synaptic transmission | biological process | GO:0050804 | 494 | 5 | 18204 | 49 |
NTRK2,SLC1A3,NRXN1,ATP1A2,NRG3 |
1.031e-02 | -4.57 | negative regulation of sequestering of calcium ion | biological process | GO:0051283 | 57 | 2 | 18204 | 49 |
RYR3,ITPR2 |
1.034e-02 | -4.57 | NR3C1 (nuclear receptor subfamily 3 group C member 1) | protein interactions | 2908 | 950 | 7 | 19454 | 50 |
TRPS1,CTNND2,SLC1A3,ZBTB20,ATP13A4,NFIA,CADM1 |
1.036e-02 | -4.57 | asymmetric synapse | cellular component | GO:0032279 | 333 | 4 | 19108 | 49 |
NTRK2,CADM1,TNIK,CTNND2 |
1.039e-02 | -4.57 | regulation of trans-synaptic signaling | biological process | GO:0099177 | 495 | 5 | 18204 | 49 |
ATP1A2,NRXN1,NRG3,SLC1A3,NTRK2 |
1.041e-02 | -4.56 | - | gene3d domains | 2.30.42.10 | 149 | 3 | 14470 | 44 |
PARD3,PREX2,PARD3B |
1.055e-02 | -4.55 | MYELIN_PLP_1 | prosite domains | PS00575 | 3 | 1 | 12186 | 43 |
GPM6A |
1.055e-02 | -4.55 | ADOHCYASE_2 | prosite domains | PS00739 | 3 | 1 | 12186 | 43 |
AHCYL2 |
1.055e-02 | -4.55 | VINCULIN_1 | prosite domains | PS00663 | 3 | 1 | 12186 | 43 |
CTNNA2 |
1.055e-02 | -4.55 | ADOHCYASE_1 | prosite domains | PS00738 | 3 | 1 | 12186 | 43 |
AHCYL2 |
1.055e-02 | -4.55 | MYELIN_PLP_2 | prosite domains | PS01004 | 3 | 1 | 12186 | 43 |
GPM6A |
1.057e-02 | -4.55 | tricarboxylic acid transmembrane transporter activity | molecular function | GO:0015142 | 4 | 1 | 18094 | 48 |
SFXN5 |
1.057e-02 | -4.55 | citrate transmembrane transporter activity | molecular function | GO:0015137 | 4 | 1 | 18094 | 48 |
SFXN5 |
1.057e-02 | -4.55 | brain-derived neurotrophic factor binding | molecular function | GO:0048403 | 4 | 1 | 18094 | 48 |
NTRK2 |
1.057e-02 | -4.55 | ryanodine-sensitive calcium-release channel activity | molecular function | GO:0005219 | 4 | 1 | 18094 | 48 |
RYR3 |
1.061e-02 | -4.55 | GATA3 (GATA binding protein 3) | protein interactions | 2625 | 177 | 3 | 19454 | 50 |
NFIA,QKI,TRPS1 |
1.061e-02 | -4.55 | adrenal_cortical_carcinoma | COSMIC cancer mutations | adrenal_cortical_carcinoma | 2256 | 13 | 16828 | 49 |
ZBTB20,SLC1A2,NHSL1,PTPRZ1,ZNRF3,SOX5,NRG3,NTRK2,CTNND2,ATP1A2,PCDH9,MEIS2,MAML2 |
1.070e-02 | -4.54 | Signaling by BRAF and RAF fusions | REACTOME pathways | R-HSA-6802952 | 60 | 2 | 10285 | 27 |
QKI,MACF1 |
1.070e-02 | -4.54 | chemical homeostasis | biological process | GO:0048878 | 914 | 7 | 18204 | 49 |
RORA,ATP13A4,SLC1A3,SLC4A4,ZBTB20,RYR3,ATP1A2 |
1.072e-02 | -4.54 | positive regulation of cardiac muscle myoblast proliferation | biological process | GO:0110024 | 4 | 1 | 18204 | 49 |
MEIS2 |
1.072e-02 | -4.54 | positive regulation of mesenchymal stem cell differentiation | biological process | GO:2000741 | 4 | 1 | 18204 | 49 |
SOX5 |
1.072e-02 | -4.54 | regulation of amino acid uptake involved in synaptic transmission | biological process | GO:0051941 | 4 | 1 | 18204 | 49 |
ATP1A2 |
1.072e-02 | -4.54 | ovarian cumulus expansion | biological process | GO:0001550 | 4 | 1 | 18204 | 49 |
BMPR1B |
1.072e-02 | -4.54 | regulation of glutamate uptake involved in transmission of nerve impulse | biological process | GO:0051946 | 4 | 1 | 18204 | 49 |
ATP1A2 |
1.072e-02 | -4.54 | response to glycoside | biological process | GO:1903416 | 4 | 1 | 18204 | 49 |
ATP1A2 |
1.072e-02 | -4.54 | trans-synaptic signaling by BDNF | biological process | GO:0099191 | 4 | 1 | 18204 | 49 |
NTRK2 |
1.072e-02 | -4.54 | brain-derived neurotrophic factor receptor signaling pathway | biological process | GO:0031547 | 4 | 1 | 18204 | 49 |
NTRK2 |
1.076e-02 | -4.53 | Desmoplakin_Spectrin-like | interpro domains | IPR041573 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | P5A-ATPase_N | interpro domains | IPR047819 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | CTF/NFI | interpro domains | IPR000647 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd-dom | interpro domains | IPR020604 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_CS | interpro domains | IPR019739 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | P5B-type_ATPase | interpro domains | IPR047821 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | Alpha_catenin | interpro domains | IPR001033 | 4 | 1 | 18521 | 50 |
CTNNA2 |
1.076e-02 | -4.53 | AbLIM_anchor | interpro domains | IPR032402 | 4 | 1 | 18521 | 50 |
ABLIM1 |
1.076e-02 | -4.53 | PCN-like_spectrin-like_rpt | interpro domains | IPR049538 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | PKNOX/Meis_N | interpro domains | IPR032453 | 4 | 1 | 18521 | 50 |
MEIS2 |
1.076e-02 | -4.53 | Na/K-Atpase_Interacting | interpro domains | IPR008516 | 4 | 1 | 18521 | 50 |
NKAIN3 |
1.076e-02 | -4.53 | NHS-like | interpro domains | IPR024845 | 4 | 1 | 18521 | 50 |
NHSL1 |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_N | interpro domains | IPR019548 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | Nebulin_repeat | interpro domains | IPR000900 | 4 | 1 | 18521 | 50 |
NEBL |
1.082e-02 | -4.53 | skeletal system development | biological process | GO:0001501 | 500 | 5 | 18204 | 49 |
BMPR1B,TRPS1,NFIA,RANBP3L,SOX5 |
1.087e-02 | -4.52 | MYELINPLP | prints domains | PR00214 | 3 | 1 | 5227 | 19 |
GPM6A |
1.087e-02 | -4.52 | NTKRECEPTOR | prints domains | PR01939 | 3 | 1 | 5227 | 19 |
NTRK2 |
1.087e-02 | -4.52 | INSP3RECEPTR | prints domains | PR00779 | 3 | 1 | 5227 | 19 |
ITPR2 |
1.087e-02 | -4.52 | RYANODINER | prints domains | PR00795 | 3 | 1 | 5227 | 19 |
RYR3 |
1.087e-02 | -4.52 | RORNUCRECPTR | prints domains | PR01293 | 3 | 1 | 5227 | 19 |
RORA |
1.096e-02 | -4.51 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 12 | 16828 | 49 |
SPARCL1,NRG3,RORA,CTNND2,ATP1A2,PCDH9,PARD3,PREX2,NEBL,BMPR1B,ABLIM1,ATP13A4 |
1.096e-02 | -4.51 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 12 | 16828 | 49 |
SPARCL1,RORA,NRG3,PCDH9,CTNND2,ATP1A2,PARD3,PREX2,BMPR1B,NEBL,ABLIM1,ATP13A4 |
1.097e-02 | -4.51 | NHS | pfam domains | PF15273 | 4 | 1 | 17795 | 49 |
NHSL1 |
1.097e-02 | -4.51 | P5-ATPase | pfam domains | PF12409 | 4 | 1 | 17795 | 49 |
ATP13A4 |
1.097e-02 | -4.51 | Spectrin_4 | pfam domains | PF21020 | 4 | 1 | 17795 | 49 |
MACF1 |
1.097e-02 | -4.51 | NfI_DNAbd_pre-N | pfam domains | PF10524 | 4 | 1 | 17795 | 49 |
NFIA |
1.097e-02 | -4.51 | NKAIN | pfam domains | PF05640 | 4 | 1 | 17795 | 49 |
NKAIN3 |
1.097e-02 | -4.51 | Nebulin | pfam domains | PF00880 | 4 | 1 | 17795 | 49 |
NEBL |
1.097e-02 | -4.51 | CTF_NFI | pfam domains | PF00859 | 4 | 1 | 17795 | 49 |
NFIA |
1.097e-02 | -4.51 | Meis_PKNOX_N | pfam domains | PF16493 | 4 | 1 | 17795 | 49 |
MEIS2 |
1.097e-02 | -4.51 | Spectrin_3 | pfam domains | PF21019 | 4 | 1 | 17795 | 49 |
MACF1 |
1.097e-02 | -4.51 | Spectrin_2 | pfam domains | PF18373 | 4 | 1 | 17795 | 49 |
MACF1 |
1.097e-02 | -4.51 | AbLIM_anchor | pfam domains | PF16182 | 4 | 1 | 17795 | 49 |
ABLIM1 |
1.098e-02 | -4.51 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 49 | 16828 | 49 |
MEIS2,RANBP3L,CADM1,MSI2,SFXN5,MAML2,NTM,NTRK2,NRG3,RYR3,NPAS3,GLIS3,NFIA,ITPR2,MACF1,PCDH9,ZNRF3,SLC4A4,SOX5,PREX2,GPC5,SLC1A2,TNIK,QKI,NRXN1,FBXL7,SLC1A3,LSAMP,NKAIN3,GPM6A,SPARCL1,PARD3B,PITPNC1,AHCYL2,RORA,ATP1A2,CTNND2,PARD3,PTPRZ1,DTNA,CDH20,NEBL,BMPR1B,ZBTB20,PAMR1,ABLIM1,TRPS1,ATP13A4,NHSL1 |
1.101e-02 | -4.51 | establishment or maintenance of apical/basal cell polarity | biological process | GO:0035088 | 59 | 2 | 18204 | 49 |
PARD3,PARD3B |
1.101e-02 | -4.51 | establishment or maintenance of bipolar cell polarity | biological process | GO:0061245 | 59 | 2 | 18204 | 49 |
PARD3,PARD3B |
1.104e-02 | -4.51 | Cell-cell junction organization | REACTOME pathways | R-HSA-421270 | 61 | 2 | 10285 | 27 |
CADM1,PARD3 |
1.110e-02 | -4.50 | MYOD1 (myogenic differentiation 1) | protein interactions | 4654 | 180 | 3 | 19454 | 50 |
TRPS1,RORA,NFIA |
1.110e-02 | -4.50 | EPHA4 (EPH receptor A4) | protein interactions | 2043 | 180 | 3 | 19454 | 50 |
AHCYL2,PARD3,CTNNA2 |
1.126e-02 | -4.49 | monoatomic cation homeostasis | biological process | GO:0055080 | 505 | 5 | 18204 | 49 |
SLC4A4,SLC1A3,ATP13A4,RYR3,ATP1A2 |
1.128e-02 | -4.48 | cartilage development | biological process | GO:0051216 | 173 | 3 | 18204 | 49 |
BMPR1B,SOX5,NFIA |
1.137e-02 | -4.48 | export across plasma membrane | biological process | GO:0140115 | 60 | 2 | 18204 | 49 |
SLC4A4,ATP1A2 |
1.137e-02 | -4.48 | transmission of nerve impulse | biological process | GO:0019226 | 60 | 2 | 18204 | 49 |
NTRK2,ATP1A2 |
1.138e-02 | -4.48 | head_neck | COSMIC cancer mutations | head_neck | 15361 | 49 | 16828 | 49 |
PTPRZ1,NEBL,CDH20,DTNA,PAMR1,ZBTB20,ATP13A4,NHSL1,SLC1A3,LSAMP,FBXL7,PARD3B,ATP1A2,CTNND2,ZNRF3,MEIS2,CADM1,NPAS3,GLIS3,RYR3,NFIA,ITPR2,MACF1,PARD3,BMPR1B,ABLIM1,TRPS1,NRXN1,GPM6A,SPARCL1,NKAIN3,RORA,AHCYL2,PITPNC1,SLC4A4,PREX2,SOX5,GPC5,SLC1A2,TNIK,QKI,RANBP3L,MAML2,NTM,MSI2,SFXN5,NTRK2,NRG3,PCDH9 |
1.143e-02 | -4.47 | human chr4q34.2 | chromosome location | human chr4q34.2 | 6 | 1 | 26134 | 50 |
GPM6A |
1.143e-02 | -4.47 | human chr14q13.1 | chromosome location | human chr14q13.1 | 6 | 1 | 26134 | 50 |
NPAS3 |
1.160e-02 | -4.46 | skin-face-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-face-malignant_melanoma-superficial_spreading | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | skin-lower_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-nodular | 4 | 1 | 16828 | 49 |
PREX2 |
1.165e-02 | -4.45 | Synaptic Vesicle Pathway | WikiPathways | WP2267 | 52 | 2 | 5310 | 17 |
SLC1A3,ATP1A2 |
1.167e-02 | -4.45 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-peripheral_T_cell_lymphoma_unspecified | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-peripheral_T_cell_lymphoma_unspecified | 162 | 3 | 16828 | 49 |
RYR3,MACF1,ITPR2 |
1.169e-02 | -4.45 | postsynaptic specialization | cellular component | GO:0099572 | 345 | 4 | 19108 | 49 |
NTRK2,CADM1,TNIK,CTNND2 |
1.178e-02 | -4.44 | cation binding | molecular function | GO:0043169 | 4341 | 19 | 18094 | 48 |
SPARCL1,DTNA,BMPR1B,PCDH9,ITPR2,SLC1A2,ABLIM1,PAMR1,SLC1A3,ATP13A4,GLIS3,RYR3,MACF1,TRPS1,ZBTB20,RORA,ZNRF3,NRXN1,ATP1A2 |
1.179e-02 | -4.44 | EVA1C (eva-1 homolog C) | protein interactions | 59271 | 64 | 2 | 19454 | 50 |
BMPR1B,PCDH9 |
1.179e-02 | -4.44 | VSX1 (visual system homeobox 1) | protein interactions | 30813 | 64 | 2 | 19454 | 50 |
TRPS1,NFIA |
1.179e-02 | -4.44 | SYNC (syncoilin, intermediate filament protein) | protein interactions | 81493 | 64 | 2 | 19454 | 50 |
DTNA,MAML2 |
1.182e-02 | -4.44 | central nervous system neuron differentiation | biological process | GO:0021953 | 176 | 3 | 18204 | 49 |
NTRK2,RORA,BMPR1B |
1.184e-02 | -4.44 | cadherin binding | molecular function | GO:0045296 | 335 | 4 | 18094 | 48 |
CTNNA2,CDH20,CTNND2,MACF1 |
1.184e-02 | -4.44 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 27 | 16828 | 49 |
MACF1,NRG3,RYR3,NPAS3,SFXN5,MAML2,NTM,QKI,GPC5,SLC1A2,SOX5,PREX2,SLC4A4,CTNND2,PARD3B,PITPNC1,RORA,GPM6A,FBXL7,SLC1A3,TRPS1,NHSL1,ZBTB20,PAMR1,ABLIM1,CDH20,PARD3 |
1.195e-02 | -4.43 | inorganic ion transmembrane transport | biological process | GO:0098660 | 715 | 6 | 18204 | 49 |
RYR3,ATP1A2,ITPR2,GPM6A,SLC1A3,SLC4A4 |
1.209e-02 | -4.42 | kidney | COSMIC cancer mutations | kidney | 15380 | 49 | 16828 | 49 |
TNIK,SLC1A2,GPC5,QKI,SLC4A4,PREX2,SOX5,NRG3,NTRK2,PCDH9,RANBP3L,NTM,MAML2,SFXN5,MSI2,ABLIM1,TRPS1,PARD3,BMPR1B,RORA,AHCYL2,PITPNC1,NRXN1,SPARCL1,GPM6A,NKAIN3,ZNRF3,NFIA,GLIS3,RYR3,NPAS3,MACF1,ITPR2,MEIS2,CADM1,ZBTB20,PAMR1,NHSL1,ATP13A4,PTPRZ1,CDH20,NEBL,DTNA,PARD3B,CTNND2,ATP1A2,LSAMP,SLC1A3,FBXL7 |
1.211e-02 | -4.41 | - | gene3d domains | 1.20.58.1060 | 4 | 1 | 14470 | 44 |
MACF1 |
1.211e-02 | -4.41 | regulation of carbohydrate catabolic process | biological process | GO:0043470 | 62 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
1.218e-02 | -4.41 | monoatomic ion homeostasis | biological process | GO:0050801 | 515 | 5 | 18204 | 49 |
ATP1A2,RYR3,ATP13A4,SLC1A3,SLC4A4 |
1.230e-02 | -4.40 | PLP | smart domains | SM00002 | 3 | 1 | 9717 | 40 |
GPM6A |
1.230e-02 | -4.40 | AdoHcyase | smart domains | SM00996 | 3 | 1 | 9717 | 40 |
AHCYL2 |
1.230e-02 | -4.40 | AdoHcyase_NAD | smart domains | SM00997 | 3 | 1 | 9717 | 40 |
AHCYL2 |
1.230e-02 | -4.40 | MamL-1 | smart domains | SM01275 | 3 | 1 | 9717 | 40 |
MAML2 |
1.245e-02 | -4.39 | camera-type eye development | biological process | GO:0043010 | 335 | 4 | 18204 | 49 |
NFIA,NTRK2,GPM6A,BMPR1B |
1.248e-02 | -4.38 | HNF1B (HNF1 homeobox B) | protein interactions | 6928 | 188 | 3 | 19454 | 50 |
SOX5,NFIA,TRPS1 |
1.250e-02 | -4.38 | MAML1 (mastermind like transcriptional coactivator 1) | protein interactions | 9794 | 66 | 2 | 19454 | 50 |
NFIA,MAML2 |
1.254e-02 | -4.38 | Erythroid Transcription Factor GATA-1, subunit A | gene3d domains | 3.30.50.10 | 56 | 2 | 14470 | 44 |
TRPS1,RORA |
1.266e-02 | -4.37 | peripheral_T_cell_lymphoma_unspecified | COSMIC cancer mutations | peripheral_T_cell_lymphoma_unspecified | 167 | 3 | 16828 | 49 |
MACF1,ITPR2,RYR3 |
1.279e-02 | -4.36 | Rras2 (related RAS viral (r-ras) oncogene 2) | protein interactions | 66922 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rab38 (RAB38, member RAS oncogene family) | protein interactions | 72433 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | SYT13 (synaptotagmin 13) | protein interactions | 57586 | 5 | 1 | 19454 | 50 |
NRXN1 |
1.279e-02 | -4.36 | ARSI (arylsulfatase family member I) | protein interactions | 340075 | 5 | 1 | 19454 | 50 |
AHCYL2 |
1.279e-02 | -4.36 | Cdk4 (cyclin dependent kinase 4) | protein interactions | 12567 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rhobtb1 (Rho-related BTB domain containing 1) | protein interactions | 69288 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rhoj (ras homolog family member J) | protein interactions | 80837 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rab6b (RAB6B, member RAS oncogene family) | protein interactions | 270192 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Wwp2 (WW domain containing E3 ubiquitin protein ligase 2) | protein interactions | 66894 | 5 | 1 | 19454 | 50 |
GLIS3 |
1.296e-02 | -4.35 | regulation of Wnt signaling pathway | biological process | GO:0030111 | 339 | 4 | 18204 | 49 |
CTNND2,GPC5,MACF1,ZNRF3 |
1.300e-02 | -4.34 | functioning | COSMIC cancer mutations | functioning | 1803 | 11 | 16828 | 49 |
NHSL1,ZBTB20,SLC1A2,SOX5,PTPRZ1,ZNRF3,PCDH9,NRG3,NTRK2,MAML2,MEIS2 |
1.300e-02 | -4.34 | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | COSMIC cancer mutations | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | 1803 | 11 | 16828 | 49 |
SOX5,ZNRF3,PTPRZ1,NHSL1,SLC1A2,ZBTB20,MAML2,MEIS2,PCDH9,NTRK2,NRG3 |
1.302e-02 | -4.34 | pancreas-carcinoma | COSMIC cancer mutations | pancreas-carcinoma | 14770 | 48 | 16828 | 49 |
TRPS1,ABLIM1,BMPR1B,PARD3,AHCYL2,PITPNC1,RORA,NKAIN3,SPARCL1,GPM6A,NRXN1,QKI,TNIK,GPC5,SLC1A2,SOX5,PREX2,SLC4A4,PCDH9,NRG3,NTRK2,SFXN5,MSI2,NTM,MAML2,RANBP3L,NHSL1,ATP13A4,ZBTB20,PAMR1,CDH20,NEBL,PTPRZ1,CTNND2,ATP1A2,PARD3B,FBXL7,LSAMP,SLC1A3,ZNRF3,MACF1,ITPR2,NFIA,GLIS3,NPAS3,RYR3,CADM1,MEIS2 |
1.306e-02 | -4.34 | NGF-independant TRKA activation | REACTOME pathways | R-HSA-187024 | 5 | 1 | 10285 | 27 |
NTRK2 |
1.310e-02 | -4.34 | medullomyoblastoma | COSMIC cancer mutations | medullomyoblastoma | 485 | 5 | 16828 | 49 |
LSAMP,RYR3,SLC4A4,ATP13A4,PCDH9 |
1.310e-02 | -4.34 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | 485 | 5 | 16828 | 49 |
ATP13A4,PCDH9,SLC4A4,LSAMP,RYR3 |
1.312e-02 | -4.33 | regulation of carbohydrate metabolic process | biological process | GO:0006109 | 183 | 3 | 18204 | 49 |
ZBTB20,RORA,SLC4A4 |
1.314e-02 | -4.33 | response to growth factor | biological process | GO:0070848 | 525 | 5 | 18204 | 49 |
BMPR1B,MEIS2,NTRK2,NFIA,SOX5 |
1.317e-02 | -4.33 | carboxylic acid transmembrane transporter activity | molecular function | GO:0046943 | 186 | 3 | 18094 | 48 |
SLC1A2,SLC1A3,SFXN5 |
1.318e-02 | -4.33 | main axon | cellular component | GO:0044304 | 68 | 2 | 19108 | 49 |
SLC1A2,PARD3 |
1.320e-02 | -4.33 | neuroligin family protein binding | molecular function | GO:0097109 | 5 | 1 | 18094 | 48 |
NRXN1 |
1.320e-02 | -4.33 | transforming growth factor beta receptor activity, type I | molecular function | GO:0005025 | 5 | 1 | 18094 | 48 |
BMPR1B |
1.320e-02 | -4.33 | neurotrophin receptor activity | molecular function | GO:0005030 | 5 | 1 | 18094 | 48 |
NTRK2 |
1.323e-02 | -4.33 | CXADR (CXADR Ig-like cell adhesion molecule) | protein interactions | 1525 | 357 | 4 | 19454 | 50 |
MACF1,NEBL,TNIK,PARD3 |
1.324e-02 | -4.32 | PLCH1 (phospholipase C eta 1) | protein interactions | 23007 | 68 | 2 | 19454 | 50 |
PARD3,NTRK2 |
1.325e-02 | -4.32 | positive regulation of synapse assembly | biological process | GO:0051965 | 65 | 2 | 18204 | 49 |
NTRK2,NRXN1 |
1.327e-02 | -4.32 | L-amino acid transmembrane transporter activity | molecular function | GO:0015179 | 66 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
1.332e-02 | -4.32 | human chr13q21.32 | chromosome location | human chr13q21.32 | 7 | 1 | 26134 | 50 |
PCDH9 |
1.332e-02 | -4.32 | human chr8q13.2 | chromosome location | human chr8q13.2 | 7 | 1 | 26134 | 50 |
PREX2 |
1.336e-02 | -4.32 | organic acid transmembrane transporter activity | molecular function | GO:0005342 | 187 | 3 | 18094 | 48 |
SLC1A3,SFXN5,SLC1A2 |
1.339e-02 | -4.31 | citrate transport | biological process | GO:0015746 | 5 | 1 | 18204 | 49 |
SFXN5 |
1.339e-02 | -4.31 | tricarboxylic acid transport | biological process | GO:0006842 | 5 | 1 | 18204 | 49 |
SFXN5 |
1.339e-02 | -4.31 | synaptic signaling via neuropeptide | biological process | GO:0099538 | 5 | 1 | 18204 | 49 |
NTRK2 |
1.339e-02 | -4.31 | negative regulation of chondrocyte proliferation | biological process | GO:1902731 | 5 | 1 | 18204 | 49 |
BMPR1B |
1.339e-02 | -4.31 | amygdala development | biological process | GO:0021764 | 5 | 1 | 18204 | 49 |
ATP1A2 |
1.339e-02 | -4.31 | gephyrin clustering involved in postsynaptic density assembly | biological process | GO:0097116 | 5 | 1 | 18204 | 49 |
NRXN1 |
1.343e-02 | -4.31 | Mtc | interpro domains | IPR004686 | 5 | 1 | 18521 | 50 |
SFXN5 |
1.343e-02 | -4.31 | BBP-like | interpro domains | IPR045071 | 5 | 1 | 18521 | 50 |
QKI |
1.343e-02 | -4.31 | Protocadherin | interpro domains | IPR013585 | 5 | 1 | 18521 | 50 |
PCDH9 |
1.343e-02 | -4.31 | P-type_TPase_V | interpro domains | IPR006544 | 5 | 1 | 18521 | 50 |
ATP13A4 |
1.343e-02 | -4.31 | Vinculin/catenin | interpro domains | IPR006077 | 5 | 1 | 18521 | 50 |
CTNNA2 |
1.343e-02 | -4.31 | Na/HCO3_transpt | interpro domains | IPR003024 | 5 | 1 | 18521 | 50 |
SLC4A4 |
1.343e-02 | -4.31 | PI_transfer | interpro domains | IPR001666 | 5 | 1 | 18521 | 50 |
PITPNC1 |
1.343e-02 | -4.31 | Follistatin/Osteonectin_EGF | interpro domains | IPR015369 | 5 | 1 | 18521 | 50 |
SPARCL1 |
1.347e-02 | -4.31 | signaling | biological process | GO:0023052 | 4968 | 21 | 18204 | 49 |
NRG3,CTNND2,RORA,SLC1A3,MACF1,NFIA,SPARCL1,NRXN1,PITPNC1,TNIK,NTRK2,PREX2,ITPR2,ATP1A2,BMPR1B,MAML2,SLC1A2,RYR3,ZNRF3,PARD3,DTNA |
1.352e-02 | -4.30 | NS-malignant_melanoma | COSMIC cancer mutations | NS-malignant_melanoma | 3420 | 17 | 16828 | 49 |
CADM1,NRXN1,MEIS2,ITPR2,ATP1A2,MACF1,CTNND2,PCDH9,PITPNC1,NRG3,GLIS3,NEBL,PREX2,PARD3,PTPRZ1,ATP13A4,GPC5 |
1.363e-02 | -4.30 | temporoparietal | COSMIC cancer mutations | temporoparietal | 61 | 2 | 16828 | 49 |
RYR3,PARD3 |
1.364e-02 | -4.29 | L-alpha-amino acid transmembrane transport | biological process | GO:1902475 | 66 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
1.367e-02 | -4.29 | neoplasm | COSMIC cancer mutations | neoplasm | 14787 | 48 | 16828 | 49 |
ZNRF3,MEIS2,CADM1,NPAS3,GLIS3,RYR3,NFIA,ITPR2,MACF1,PTPRZ1,NEBL,CDH20,DTNA,ZBTB20,PAMR1,ATP13A4,NHSL1,SLC1A3,LSAMP,FBXL7,PARD3B,ATP1A2,CTNND2,SLC4A4,PREX2,SOX5,SLC1A2,GPC5,TNIK,QKI,RANBP3L,MAML2,NTM,MSI2,SFXN5,NTRK2,NRG3,PCDH9,PARD3,BMPR1B,ABLIM1,TRPS1,NRXN1,GPM6A,SPARCL1,NKAIN3,RORA,AHCYL2 |
1.369e-02 | -4.29 | Vinculin | pfam domains | PF01044 | 5 | 1 | 17795 | 49 |
CTNNA2 |
1.369e-02 | -4.29 | IP_trans | pfam domains | PF02121 | 5 | 1 | 17795 | 49 |
PITPNC1 |
1.369e-02 | -4.29 | Protocadherin | pfam domains | PF08374 | 5 | 1 | 17795 | 49 |
PCDH9 |
1.369e-02 | -4.29 | SFXNs | pfam domains | PF03820 | 5 | 1 | 17795 | 49 |
SFXN5 |
1.369e-02 | -4.29 | FOLN | pfam domains | PF09289 | 5 | 1 | 17795 | 49 |
SPARCL1 |
1.384e-02 | -4.28 | Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways | WikiPathways | WP706 | 162 | 3 | 5310 | 17 |
SLC1A3,NTRK2,RORA |
1.385e-02 | -4.28 | positive regulation of biological process | biological process | GO:0048518 | 6326 | 25 | 18204 | 49 |
NFIA,NRXN1,SFXN5,ZBTB20,RANBP3L,NPAS3,CADM1,SLC1A2,GPM6A,PARD3,MEIS2,GPC5,ATP1A2,BMPR1B,SLC4A4,TNIK,NTRK2,QKI,RORA,MACF1,SLC1A3,SOX5,GLIS3,MAML2,PTPRZ1 |
1.386e-02 | -4.28 | PDZ | prosite domains | PS50106 | 143 | 3 | 12186 | 43 |
PREX2,PARD3B,PARD3 |
1.387e-02 | -4.28 | primary_central_nervous_system_lymphoma | COSMIC cancer mutations | primary_central_nervous_system_lymphoma | 683 | 6 | 16828 | 49 |
ZBTB20,NRG3,PARD3B,MACF1,PARD3,NRXN1 |
1.387e-02 | -4.28 | haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-primary_central_nervous_system_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-primary_central_nervous_system_lymphoma | 683 | 6 | 16828 | 49 |
NRXN1,PARD3,PARD3B,NRG3,ZBTB20,MACF1 |
1.400e-02 | -4.27 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 15 | 16828 | 49 |
GPM6A,NTRK2,RYR3,NPAS3,CTNND2,MACF1,PCDH9,PARD3,PTPRZ1,SOX5,CDH20,BMPR1B,NEBL,GPC5,ZBTB20 |
1.404e-02 | -4.27 | NEBULIN | prosite domains | PS51216 | 4 | 1 | 12186 | 43 |
NEBL |
1.404e-02 | -4.27 | CTF_NFI_2 | prosite domains | PS51080 | 4 | 1 | 12186 | 43 |
NFIA |
1.404e-02 | -4.27 | CTF_NFI_1 | prosite domains | PS00349 | 4 | 1 | 12186 | 43 |
NFIA |
1.407e-02 | -4.26 | RAB35 (RAB35, member RAS oncogene family) | protein interactions | 11021 | 559 | 5 | 19454 | 50 |
MACF1,SLC1A3,PARD3,AHCYL2,DTNA |
1.412e-02 | -4.26 | neuron to neuron synapse | cellular component | GO:0098984 | 365 | 4 | 19108 | 49 |
CTNND2,TNIK,CADM1,NTRK2 |
1.418e-02 | -4.26 | liver-carcinoma-hepatocellular_carcinoma | COSMIC cancer mutations | liver-carcinoma-hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
GPM6A,SPARCL1,NKAIN3,SLC1A3,LSAMP,NRXN1,FBXL7,ATP1A2,CTNND2,RORA,PARD3B,PITPNC1,AHCYL2,BMPR1B,CDH20,NEBL,DTNA,PTPRZ1,PARD3,ATP13A4,NHSL1,TRPS1,ABLIM1,PAMR1,ZBTB20,MAML2,NTM,CADM1,SFXN5,MEIS2,RANBP3L,PCDH9,ITPR2,MACF1,RYR3,GLIS3,NPAS3,NFIA,NTRK2,NRG3,PREX2,SOX5,ZNRF3,SLC4A4,QKI,SLC1A2,GPC5,TNIK |
1.418e-02 | -4.26 | hepatocellular_carcinoma | COSMIC cancer mutations | hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
CTNND2,ATP1A2,PARD3B,FBXL7,LSAMP,SLC1A3,NHSL1,ATP13A4,PAMR1,ZBTB20,DTNA,CDH20,NEBL,PTPRZ1,MACF1,ITPR2,NFIA,NPAS3,GLIS3,RYR3,CADM1,MEIS2,ZNRF3,PITPNC1,AHCYL2,RORA,NKAIN3,SPARCL1,GPM6A,NRXN1,TRPS1,ABLIM1,BMPR1B,PARD3,PCDH9,NRG3,NTRK2,SFXN5,NTM,MAML2,RANBP3L,QKI,TNIK,SLC1A2,GPC5,SOX5,PREX2,SLC4A4 |
1.421e-02 | -4.25 | regulation of multicellular organismal process | biological process | GO:0051239 | 3113 | 15 | 18204 | 49 |
PARD3,MEIS2,PTPRZ1,BMPR1B,TRPS1,ATP1A2,SOX5,NTRK2,SFXN5,NRXN1,CADM1,MACF1,RORA,QKI,ZBTB20 |
1.424e-02 | -4.25 | EGF | pfam domains | PF00008 | 66 | 2 | 17795 | 49 |
NRXN1,PAMR1 |
1.425e-02 | -4.25 | DNAJC5 (DnaJ heat shock protein family (Hsp40) member C5) | protein interactions | 80331 | 365 | 4 | 19454 | 50 |
CADM1,MACF1,PARD3,DTNA |
1.433e-02 | -4.25 | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | 323 | 4 | 16828 | 49 |
PTPRZ1,MEIS2,PARD3B,NTM |
1.433e-02 | -4.25 | NFIX (nuclear factor I X) | protein interactions | 4784 | 198 | 3 | 19454 | 50 |
SOX5,NFIA,TRPS1 |
1.437e-02 | -4.24 | ANK2 (ankyrin 2) | protein interactions | 287 | 71 | 2 | 19454 | 50 |
GPM6A,TNIK |
1.437e-02 | -4.24 | AKR7L (aldo-keto reductase family 7 like (gene/pseudogene)) | protein interactions | 246181 | 71 | 2 | 19454 | 50 |
PARD3,MACF1 |
1.437e-02 | -4.24 | UNKL (unk like zinc finger) | protein interactions | 64718 | 71 | 2 | 19454 | 50 |
QKI,AHCYL2 |
1.446e-02 | -4.24 | ALPHACATENIN | prints domains | PR00805 | 4 | 1 | 5227 | 19 |
CTNNA2 |
1.448e-02 | -4.24 | skin-lower_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-superficial_spreading | 5 | 1 | 16828 | 49 |
PREX2 |
1.463e-02 | -4.22 | regulation of developmental process | biological process | GO:0050793 | 2540 | 13 | 18204 | 49 |
PARD3,MEIS2,PTPRZ1,BMPR1B,TRPS1,SOX5,NTRK2,NRXN1,TNIK,MACF1,RORA,QKI,RANBP3L |
1.476e-02 | -4.22 | DPYSL3 (dihydropyrimidinase like 3) | protein interactions | 1809 | 72 | 2 | 19454 | 50 |
TNIK,GPM6A |
1.476e-02 | -4.22 | Ppp1cb (protein phosphatase 1 catalytic subunit beta) | protein interactions | 19046 | 72 | 2 | 19454 | 50 |
PARD3,ABLIM1 |
1.476e-02 | -4.22 | PPP3CC (protein phosphatase 3 catalytic subunit gamma) | protein interactions | 5533 | 72 | 2 | 19454 | 50 |
BMPR1B,PARD3B |
1.485e-02 | -4.21 | cell communication | biological process | GO:0007154 | 5010 | 21 | 18204 | 49 |
ZNRF3,PARD3,DTNA,SLC1A2,RYR3,BMPR1B,MAML2,PREX2,ITPR2,ATP1A2,NTRK2,NFIA,TNIK,PITPNC1,NRXN1,SPARCL1,RORA,SLC1A3,MACF1,CTNND2,NRG3 |
1.486e-02 | -4.21 | Bile secretion | KEGG pathways | ko04976 | 71 | 2 | 7161 | 19 |
SLC4A4,ATP1A2 |
1.486e-02 | -4.21 | Bile secretion | KEGG pathways | hsa04976 | 71 | 2 | 7161 | 19 |
SLC4A4,ATP1A2 |
1.489e-02 | -4.21 | Diseases of signal transduction | REACTOME pathways | R-HSA-5663202 | 369 | 4 | 10285 | 27 |
MAML2,NRG3,MACF1,QKI |
1.493e-02 | -4.20 | presynapse | cellular component | GO:0098793 | 569 | 5 | 19108 | 49 |
TNIK,NTRK2,GPM6A,NRXN1,SLC1A2 |
1.512e-02 | -4.19 | FEV (FEV transcription factor, ETS family member) | protein interactions | 54738 | 202 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
1.520e-02 | -4.19 | ORF3a (ORF3a protein) | protein interactions | 43740569 | 789 | 6 | 19454 | 50 |
SLC4A4,ZNRF3,PARD3,BMPR1B,PCDH9,PARD3B |
1.526e-02 | -4.18 | Adherens junction | KEGG pathways | ko04520 | 72 | 2 | 7161 | 19 |
CTNNA2,PARD3 |
1.526e-02 | -4.18 | Adherens junction | KEGG pathways | hsa04520 | 72 | 2 | 7161 | 19 |
PARD3,CTNNA2 |
1.529e-02 | -4.18 | PAR polarity complex | cellular component | GO:0120157 | 6 | 1 | 19108 | 49 |
PARD3 |
1.532e-02 | -4.18 | GDF6 (growth differentiation factor 6) | protein interactions | 392255 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | DRP2 (dystrophin related protein 2) | protein interactions | 1821 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | Rhod (ras homolog family member D) | protein interactions | 11854 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | Fancl (Fanconi anemia, complementation group L) | protein interactions | 67030 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | DAZ4 (deleted in azoospermia 4) | protein interactions | 57135 | 6 | 1 | 19454 | 50 |
QKI |
1.532e-02 | -4.18 | Map2k3 (mitogen-activated protein kinase kinase 3) | protein interactions | 26397 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | SOX1 (SRY-box transcription factor 1) | protein interactions | 6656 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | RSPO3 (R-spondin 3) | protein interactions | 84870 | 6 | 1 | 19454 | 50 |
ZNRF3 |
1.532e-02 | -4.18 | CYRIA (CYFIP related Rac1 interactor A) | protein interactions | 81553 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | Itch (itchy, E3 ubiquitin protein ligase) | protein interactions | 16396 | 6 | 1 | 19454 | 50 |
GLIS3 |
1.532e-02 | -4.18 | SLC12A5 (solute carrier family 12 member 5) | protein interactions | 57468 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | PBP2 (Pbp2p) | protein interactions | 852533 | 6 | 1 | 19454 | 50 |
QKI |
1.532e-02 | -4.18 | SYTL3 (synaptotagmin like 3) | protein interactions | 94120 | 6 | 1 | 19454 | 50 |
NRXN1 |
1.532e-02 | -4.18 | SOX11 (SRY-box transcription factor 11) | protein interactions | 6664 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | Tiam2 (T cell lymphoma invasion and metastasis 2) | protein interactions | 24001 | 6 | 1 | 19454 | 50 |
DTNA |
1.539e-02 | -4.17 | skin-ankle-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-ankle-malignant_melanoma-acral_lentiginous | 330 | 4 | 16828 | 49 |
NRG3,PARD3,PREX2,ATP13A4 |
1.547e-02 | -4.17 | cell-cell contact zone | cellular component | GO:0044291 | 74 | 2 | 19108 | 49 |
PCDH9,ATP1A2 |
1.550e-02 | -4.17 | LIM | pfam domains | PF00412 | 69 | 2 | 17795 | 49 |
ABLIM1,NEBL |
1.552e-02 | -4.17 | NFIC (nuclear factor I C) | protein interactions | 4782 | 204 | 3 | 19454 | 50 |
TRPS1,NFIA,SOX5 |
1.555e-02 | -4.16 | marginal_zone_lymphoma | COSMIC cancer mutations | marginal_zone_lymphoma | 331 | 4 | 16828 | 49 |
PARD3B,MEIS2,PTPRZ1,NTM |
1.565e-02 | -4.16 | Activation of TRKA receptors | REACTOME pathways | R-HSA-187015 | 6 | 1 | 10285 | 27 |
NTRK2 |
1.576e-02 | -4.15 | Znf_LIM | interpro domains | IPR001781 | 71 | 2 | 18521 | 50 |
NEBL,ABLIM1 |
1.581e-02 | -4.15 | steroid hormone binding | molecular function | GO:1990239 | 6 | 1 | 18094 | 48 |
ATP1A2 |
1.581e-02 | -4.15 | sodium:bicarbonate symporter activity | molecular function | GO:0008510 | 6 | 1 | 18094 | 48 |
SLC4A4 |
1.581e-02 | -4.15 | calcium-induced calcium release activity | molecular function | GO:0048763 | 6 | 1 | 18094 | 48 |
RYR3 |
1.584e-02 | -4.15 | Muscle contraction | REACTOME pathways | R-HSA-397014 | 204 | 3 | 10285 | 27 |
ATP1A2,RYR3,ITPR2 |
1.590e-02 | -4.14 | animal organ morphogenesis | biological process | GO:0009887 | 988 | 7 | 18204 | 49 |
CTNNA2,ABLIM1,SOX5,NRG3,NTRK2,MEIS2,BMPR1B |
1.596e-02 | -4.14 | Oncogenic MAPK signaling | REACTOME pathways | R-HSA-6802957 | 74 | 2 | 10285 | 27 |
QKI,MACF1 |
1.600e-02 | -4.13 | other | COSMIC cancer mutations | other | 14843 | 48 | 16828 | 49 |
SLC4A4,SOX5,PREX2,TNIK,GPC5,SLC1A2,QKI,RANBP3L,SFXN5,MSI2,NTM,MAML2,NRG3,NTRK2,PCDH9,PARD3,BMPR1B,ABLIM1,TRPS1,NRXN1,NKAIN3,SPARCL1,GPM6A,AHCYL2,RORA,ZNRF3,MEIS2,CADM1,NFIA,GLIS3,NPAS3,RYR3,MACF1,ITPR2,PTPRZ1,DTNA,CDH20,NEBL,PAMR1,ZBTB20,NHSL1,ATP13A4,FBXL7,LSAMP,SLC1A3,PARD3B,CTNND2,ATP1A2 |
1.601e-02 | -4.13 | NAD+ Signalling and Aging | SMPDB pathways | SMP0084271 | 11 | 1 | 1369 | 2 |
RORA |
1.604e-02 | -4.13 | gamma-aminobutyric acid biosynthetic process | biological process | GO:0009449 | 6 | 1 | 18204 | 49 |
SLC1A3 |
1.604e-02 | -4.13 | vocal learning | biological process | GO:0042297 | 6 | 1 | 18204 | 49 |
NRXN1 |
1.604e-02 | -4.13 | fused antrum stage | biological process | GO:0048165 | 6 | 1 | 18204 | 49 |
BMPR1B |
1.604e-02 | -4.13 | postsynaptic density protein 95 clustering | biological process | GO:0097119 | 6 | 1 | 18204 | 49 |
NRXN1 |
1.604e-02 | -4.13 | asymmetric neuroblast division | biological process | GO:0055059 | 6 | 1 | 18204 | 49 |
SOX5 |
1.604e-02 | -4.13 | mammary gland formation | biological process | GO:0060592 | 6 | 1 | 18204 | 49 |
NRG3 |
1.604e-02 | -4.13 | imitative learning | biological process | GO:0098596 | 6 | 1 | 18204 | 49 |
NRXN1 |
1.604e-02 | -4.13 | ERBB4-ERBB4 signaling pathway | biological process | GO:0038138 | 6 | 1 | 18204 | 49 |
NRG3 |
1.608e-02 | -4.13 | Thyroid hormone synthesis | KEGG pathways | hsa04918 | 74 | 2 | 7161 | 19 |
ATP1A2,ITPR2 |
1.608e-02 | -4.13 | Thyroid hormone synthesis | KEGG pathways | ko04918 | 74 | 2 | 7161 | 19 |
ITPR2,ATP1A2 |
1.609e-02 | -4.13 | P-type_ATPase_IIC | interpro domains | IPR005775 | 6 | 1 | 18521 | 50 |
ATP1A2 |
1.609e-02 | -4.13 | Glypican | interpro domains | IPR001863 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | GLI-like | interpro domains | IPR043359 | 6 | 1 | 18521 | 50 |
GLIS3 |
1.609e-02 | -4.13 | Desmoplakin_SH3 | interpro domains | IPR041615 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | EF-hand_dom_typ2 | interpro domains | IPR015154 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | GAR_dom_sf | interpro domains | IPR036534 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Syndecan/Neurexin_dom | interpro domains | IPR027789 | 6 | 1 | 18521 | 50 |
NRXN1 |
1.609e-02 | -4.13 | GAR_dom | interpro domains | IPR003108 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Glypican_CS | interpro domains | IPR019803 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | EF-hand_dom_typ1 | interpro domains | IPR015153 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | regulation of ATP metabolic process | biological process | GO:1903578 | 72 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
1.613e-02 | -4.13 | MAGEA9 (MAGE family member A9) | protein interactions | 4108 | 207 | 3 | 19454 | 50 |
MEIS2,ITPR2,NHSL1 |
1.627e-02 | -4.12 | sarcoplasmic reticulum | cellular component | GO:0016529 | 76 | 2 | 19108 | 49 |
ITPR2,RYR3 |
1.630e-02 | -4.12 | IGc2 | smart domains | SM00408 | 239 | 4 | 9717 | 40 |
NTM,CADM1,NTRK2,LSAMP |
1.631e-02 | -4.12 | positive regulation of cellular process | biological process | GO:0048522 | 5719 | 23 | 18204 | 49 |
MEIS2,PARD3,GPM6A,SLC1A2,SLC4A4,BMPR1B,GPC5,NRXN1,NFIA,CADM1,NPAS3,RANBP3L,ZBTB20,PTPRZ1,MAML2,GLIS3,SOX5,NTRK2,TNIK,SLC1A3,MACF1,RORA,QKI |
1.635e-02 | -4.11 | MIR200A (microRNA 200a) | protein interactions | 406983 | 76 | 2 | 19454 | 50 |
MSI2,QKI |
1.637e-02 | -4.11 | NEBU | smart domains | SM00227 | 4 | 1 | 9717 | 40 |
NEBL |
1.641e-02 | -4.11 | EF-hand_3 | pfam domains | PF09069 | 6 | 1 | 17795 | 49 |
DTNA |
1.641e-02 | -4.11 | EF-hand_2 | pfam domains | PF09068 | 6 | 1 | 17795 | 49 |
DTNA |
1.641e-02 | -4.11 | GAS2 | pfam domains | PF02187 | 6 | 1 | 17795 | 49 |
MACF1 |
1.641e-02 | -4.11 | Plectin | pfam domains | PF00681 | 6 | 1 | 17795 | 49 |
MACF1 |
1.641e-02 | -4.11 | SH3_10 | pfam domains | PF17902 | 6 | 1 | 17795 | 49 |
MACF1 |
1.641e-02 | -4.11 | Syndecan | pfam domains | PF01034 | 6 | 1 | 17795 | 49 |
NRXN1 |
1.641e-02 | -4.11 | Glypican | pfam domains | PF01153 | 6 | 1 | 17795 | 49 |
GPC5 |
1.649e-02 | -4.10 | Gastric acid secretion | KEGG pathways | hsa04971 | 75 | 2 | 7161 | 19 |
ITPR2,ATP1A2 |
1.649e-02 | -4.10 | Gastric acid secretion | KEGG pathways | ko04971 | 75 | 2 | 7161 | 19 |
ATP1A2,ITPR2 |
1.652e-02 | -4.10 | vasculogenesis | biological process | GO:0001570 | 73 | 2 | 18204 | 49 |
NTRK2,QKI |
1.668e-02 | -4.09 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 10 | 16828 | 49 |
PTPRZ1,DTNA,CDH20,PREX2,PARD3B,RORA,ABLIM1,MACF1,CTNND2,QKI |
1.668e-02 | -4.09 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 10 | 16828 | 49 |
QKI,MACF1,CTNND2,ABLIM1,RORA,PARD3B,PREX2,CDH20,DTNA,PTPRZ1 |
1.670e-02 | -4.09 | KIF20A (kinesin family member 20A) | protein interactions | 10112 | 1044 | 7 | 19454 | 50 |
ABLIM1,NEBL,MACF1,MSI2,RORA,ITPR2,PARD3 |
1.676e-02 | -4.09 | ADGRL2 (adhesion G protein-coupled receptor L2) | protein interactions | 23266 | 77 | 2 | 19454 | 50 |
NTRK2,PARD3 |
1.690e-02 | -4.08 | Ion channel transport | REACTOME pathways | R-HSA-983712 | 209 | 3 | 10285 | 27 |
RYR3,ATP13A4,ATP1A2 |
1.695e-02 | -4.08 | positive regulation of gliogenesis | biological process | GO:0014015 | 74 | 2 | 18204 | 49 |
QKI,PTPRZ1 |
1.705e-02 | -4.07 | HAD_sf | interpro domains | IPR023214 | 74 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
1.709e-02 | -4.07 | skin-extremity-malignant_melanoma | COSMIC cancer mutations | skin-extremity-malignant_melanoma | 1875 | 11 | 16828 | 49 |
FBXL7,RYR3,NTRK2,PITPNC1,PCDH9,PTPRZ1,PARD3,CDH20,NEBL,PREX2,ATP13A4 |
1.709e-02 | -4.07 | human chr4q22.3 | chromosome location | human chr4q22.3 | 9 | 1 | 26134 | 50 |
BMPR1B |
1.715e-02 | -4.07 | extremity | COSMIC cancer mutations | extremity | 1876 | 11 | 16828 | 49 |
PREX2,CDH20,NEBL,PTPRZ1,PARD3,FBXL7,PCDH9,ATP13A4,PITPNC1,NTRK2,RYR3 |
1.716e-02 | -4.07 | MARCKS (myristoylated alanine rich protein kinase C substrate) | protein interactions | 4082 | 588 | 5 | 19454 | 50 |
MACF1,SLC1A3,ABLIM1,AHCYL2,DTNA |
1.717e-02 | -4.06 | MIR34C (microRNA 34c) | protein interactions | 407042 | 78 | 2 | 19454 | 50 |
QKI,MSI2 |
1.717e-02 | -4.06 | ANKRD40 (ankyrin repeat domain 40) | protein interactions | 91369 | 78 | 2 | 19454 | 50 |
MSI2,SOX5 |
1.717e-02 | -4.06 | Nedd4 (NEDD4 E3 ubiquitin protein ligase) | protein interactions | 25489 | 78 | 2 | 19454 | 50 |
NTRK2,BMPR1B |
1.735e-02 | -4.05 | autonomic_ganglia-paraganglioma-benign | COSMIC cancer mutations | autonomic_ganglia-paraganglioma-benign | 6 | 1 | 16828 | 49 |
NHSL1 |
1.735e-02 | -4.05 | skin-forearm-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-forearm-malignant_melanoma-superficial_spreading | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-head_neck-malignant_melanoma | COSMIC cancer mutations | skin-head_neck-malignant_melanoma | 6 | 1 | 16828 | 49 |
PREX2 |
1.746e-02 | -4.05 | Lactose Intolerance | SMPDB pathways | SMP0000458 | 12 | 1 | 1369 | 2 |
ATP1A2 |
1.746e-02 | -4.05 | Lactose Degradation | SMPDB pathways | SMP0000457 | 12 | 1 | 1369 | 2 |
ATP1A2 |
1.759e-02 | -4.04 | PRDM1 (PR/SET domain 1) | protein interactions | 639 | 79 | 2 | 19454 | 50 |
TRPS1,NFIA |
1.761e-02 | -4.04 | NCK1 (NCK adaptor protein 1) | protein interactions | 4690 | 214 | 3 | 19454 | 50 |
NTRK2,NHSL1,TNIK |
1.768e-02 | -4.04 | ovary-carcinoma | COSMIC cancer mutations | ovary-carcinoma | 933 | 7 | 16828 | 49 |
TNIK,NTRK2,MACF1,ATP1A2,ITPR2,PREX2,BMPR1B |
1.774e-02 | -4.03 | calcium ion transmembrane transport | biological process | GO:0070588 | 205 | 3 | 18204 | 49 |
GPM6A,ITPR2,RYR3 |
1.786e-02 | -4.03 | RGMB (repulsive guidance molecule BMP co-receptor b) | protein interactions | 285704 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | ZBTB45 (zinc finger and BTB domain containing 45) | protein interactions | 84878 | 7 | 1 | 19454 | 50 |
ZBTB20 |
1.786e-02 | -4.03 | SLC16A5 (solute carrier family 16 member 5) | protein interactions | 9121 | 7 | 1 | 19454 | 50 |
PTPRZ1 |
1.786e-02 | -4.03 | Uhmk1 (U2AF homology motif (UHM) kinase 1) | protein interactions | 16589 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Fbxo3 (F-box protein 3) | protein interactions | 57443 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Smad7 (SMAD family member 7) | protein interactions | 17131 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Ahcyl1 (S-adenosylhomocysteine hydrolase-like 1) | protein interactions | 229709 | 7 | 1 | 19454 | 50 |
AHCYL2 |
1.786e-02 | -4.03 | ABCC12 (ATP binding cassette subfamily C member 12) | protein interactions | 94160 | 7 | 1 | 19454 | 50 |
NPAS3 |
1.786e-02 | -4.03 | Pum2 (pumilio RNA-binding family member 2) | protein interactions | 80913 | 7 | 1 | 19454 | 50 |
QKI |
1.786e-02 | -4.03 | Smurf1 (SMAD specific E3 ubiquitin protein ligase 1) | protein interactions | 75788 | 7 | 1 | 19454 | 50 |
GLIS3 |
1.786e-02 | -4.03 | SASH3 (SAM and SH3 domain containing 3) | protein interactions | 54440 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.805e-02 | -4.01 | PITRANSFER | prints domains | PR00391 | 5 | 1 | 5227 | 19 |
PITPNC1 |
1.805e-02 | -4.01 | NAHCO3TRSPRT | prints domains | PR01232 | 5 | 1 | 5227 | 19 |
SLC4A4 |
1.811e-02 | -4.01 | Gas2-like domain | gene3d domains | 3.30.920.20 | 6 | 1 | 14470 | 44 |
MACF1 |
1.811e-02 | -4.01 | Plakin repeat | gene3d domains | 3.90.1290.10 | 6 | 1 | 14470 | 44 |
MACF1 |
1.821e-02 | -4.01 | SMAD binding | molecular function | GO:0046332 | 78 | 2 | 18094 | 48 |
BMPR1B,RANBP3L |
1.824e-02 | -4.00 | Nectin/Necl trans heterodimerization | REACTOME pathways | R-HSA-420597 | 7 | 1 | 10285 | 27 |
CADM1 |
1.826e-02 | -4.00 | GFAP (glial fibrillary acidic protein) | protein interactions | 2670 | 217 | 3 | 19454 | 50 |
NKAIN3,ABLIM1,RORA |
1.827e-02 | -4.00 | positive regulation of axonogenesis | biological process | GO:0050772 | 77 | 2 | 18204 | 49 |
MACF1,NTRK2 |
1.827e-02 | -4.00 | regulation of synaptic transmission, glutamatergic | biological process | GO:0051966 | 77 | 2 | 18204 | 49 |
ATP1A2,NRXN1 |
1.827e-02 | -4.00 | BMP signaling pathway | biological process | GO:0030509 | 77 | 2 | 18204 | 49 |
NFIA,BMPR1B |
1.827e-02 | -4.00 | neural retina development | biological process | GO:0003407 | 77 | 2 | 18204 | 49 |
NTRK2,GPM6A |
1.843e-02 | -3.99 | P-type sodium transporter activity | molecular function | GO:0008554 | 7 | 1 | 18094 | 48 |
ATP1A2 |
1.843e-02 | -3.99 | P-type sodium:potassium-exchanging transporter activity | molecular function | GO:0005391 | 7 | 1 | 18094 | 48 |
ATP1A2 |
1.843e-02 | -3.99 | phosphatidic acid transfer activity | molecular function | GO:1990050 | 7 | 1 | 18094 | 48 |
PITPNC1 |
1.843e-02 | -3.99 | SOX17 (SRY-box transcription factor 17) | protein interactions | 64321 | 81 | 2 | 19454 | 50 |
TRPS1,NFIA |
1.843e-02 | -3.99 | ARNT2 (aryl hydrocarbon receptor nuclear translocator 2) | protein interactions | 9915 | 81 | 2 | 19454 | 50 |
MEIS2,NPAS3 |
1.844e-02 | -3.99 | regulation of neurogenesis | biological process | GO:0050767 | 377 | 4 | 18204 | 49 |
QKI,NTRK2,PTPRZ1,MACF1 |
1.869e-02 | -3.98 | regulation of oligodendrocyte progenitor proliferation | biological process | GO:0070445 | 7 | 1 | 18204 | 49 |
PTPRZ1 |
1.869e-02 | -3.98 | cellular response to magnesium ion | biological process | GO:0071286 | 7 | 1 | 18204 | 49 |
RYR3 |
1.869e-02 | -3.98 | negative regulation of non-canonical Wnt signaling pathway | biological process | GO:2000051 | 7 | 1 | 18204 | 49 |
ZNRF3 |
1.869e-02 | -3.98 | regulation of 3'-UTR-mediated mRNA stabilization | biological process | GO:1905868 | 7 | 1 | 18204 | 49 |
QKI |
1.869e-02 | -3.98 | regulation of cardiac muscle myoblast proliferation | biological process | GO:0110022 | 7 | 1 | 18204 | 49 |
MEIS2 |
1.869e-02 | -3.98 | negative regulation of Arp2/3 complex-mediated actin nucleation | biological process | GO:0034316 | 7 | 1 | 18204 | 49 |
CTNNA2 |
1.869e-02 | -3.98 | observational learning | biological process | GO:0098597 | 7 | 1 | 18204 | 49 |
NRXN1 |
1.869e-02 | -3.98 | S-adenosylmethionine cycle | biological process | GO:0033353 | 7 | 1 | 18204 | 49 |
AHCYL2 |
1.869e-02 | -3.98 | interneuron migration from the subpallium to the cortex | biological process | GO:0021830 | 7 | 1 | 18204 | 49 |
NRG3 |
1.869e-02 | -3.98 | glial cell fate specification | biological process | GO:0021780 | 7 | 1 | 18204 | 49 |
NFIA |
1.869e-02 | -3.98 | positive regulation of transcription of Notch receptor target | biological process | GO:0007221 | 7 | 1 | 18204 | 49 |
MAML2 |
1.872e-02 | -3.98 | positive regulation of carbohydrate metabolic process | biological process | GO:0045913 | 78 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
1.875e-02 | -3.98 | Plakin_repeat_sf | interpro domains | IPR035915 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | Alpha-catenin/vinculin-like_sf | interpro domains | IPR036723 | 7 | 1 | 18521 | 50 |
CTNNA2 |
1.875e-02 | -3.98 | SPARC/Testican_Ca-bd-dom | interpro domains | IPR019577 | 7 | 1 | 18521 | 50 |
SPARCL1 |
1.875e-02 | -3.98 | GS_dom | interpro domains | IPR003605 | 7 | 1 | 18521 | 50 |
BMPR1B |
1.875e-02 | -3.98 | Plectin_repeat | interpro domains | IPR001101 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | Plakophilin/d_Catenin | interpro domains | IPR028435 | 7 | 1 | 18521 | 50 |
CTNND2 |
1.882e-02 | -3.97 | HAD-like_sf | interpro domains | IPR036412 | 78 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
1.891e-02 | -3.97 | Trehalose Degradation | SMPDB pathways | SMP0000467 | 13 | 1 | 1369 | 2 |
ATP1A2 |
1.897e-02 | -3.96 | human chr12p11.23 | chromosome location | human chr12p11.23 | 10 | 1 | 26134 | 50 |
ITPR2 |
1.897e-02 | -3.96 | human chr9p24.2 | chromosome location | human chr9p24.2 | 10 | 1 | 26134 | 50 |
GLIS3 |
1.902e-02 | -3.96 | testis | COSMIC cancer mutations | testis | 733 | 6 | 16828 | 49 |
MACF1,TRPS1,TNIK,NTRK2,PREX2,BMPR1B |
1.912e-02 | -3.96 | TGF_beta_GS | pfam domains | PF08515 | 7 | 1 | 17795 | 49 |
BMPR1B |
1.912e-02 | -3.96 | SPARC_Ca_bdg | pfam domains | PF10591 | 7 | 1 | 17795 | 49 |
SPARCL1 |
1.917e-02 | -3.95 | regulation of glial cell differentiation | biological process | GO:0045685 | 79 | 2 | 18204 | 49 |
QKI,PTPRZ1 |
1.930e-02 | -3.95 | SYT1 (synaptotagmin 1) | protein interactions | 6857 | 83 | 2 | 19454 | 50 |
GPM6A,NRXN1 |
1.930e-02 | -3.95 | PAX2 (paired box 2) | protein interactions | 5076 | 83 | 2 | 19454 | 50 |
TRPS1,NFIA |
1.943e-02 | -3.94 | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
PARD3,SLC1A2,GPC5,PREX2,ATP13A4,MACF1,ITPR2 |
1.943e-02 | -3.94 | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
PREX2,ATP13A4,MACF1,ITPR2,PARD3,SLC1A2,GPC5 |
1.954e-02 | -3.94 | transmembrane receptor protein kinase activity | molecular function | GO:0019199 | 81 | 2 | 18094 | 48 |
BMPR1B,NTRK2 |
1.955e-02 | -3.93 | sensory organ development | biological process | GO:0007423 | 581 | 5 | 18204 | 49 |
NFIA,GPM6A,BMPR1B,MEIS2,NTRK2 |
1.985e-02 | -3.92 | MAPRE3 (microtubule associated protein RP/EB family member 3) | protein interactions | 22924 | 224 | 3 | 19454 | 50 |
MACF1,GPM6A,ABLIM1 |
1.996e-02 | -3.91 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 19 | 16828 | 49 |
CTNND2,MACF1,NFIA,NPAS3,GLIS3,RORA,RYR3,PARD3B,SPARCL1,MAML2,SLC1A3,NHSL1,TRPS1,PAMR1,PREX2,CDH20,PTPRZ1,PARD3,ZNRF3 |
2.008e-02 | -3.91 | KLF3 (KLF transcription factor 3) | protein interactions | 51274 | 225 | 3 | 19454 | 50 |
SOX5,NFIA,TRPS1 |
2.009e-02 | -3.91 | adult locomotory behavior | biological process | GO:0008344 | 81 | 2 | 18204 | 49 |
PREX2,ATP1A2 |
2.021e-02 | -3.90 | skin-upper_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | skin-face-malignant_melanoma-nodular | COSMIC cancer mutations | skin-face-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.034e-02 | -3.90 | HFE-transferrin receptor complex | cellular component | GO:1990712 | 8 | 1 | 19108 | 49 |
BMPR1B |
2.038e-02 | -3.89 | LHB (luteinizing hormone subunit beta) | protein interactions | 3972 | 8 | 1 | 19454 | 50 |
NTM |
2.038e-02 | -3.89 | DEPP1 (DEPP autophagy regulator 1) | protein interactions | 11067 | 8 | 1 | 19454 | 50 |
QKI |
2.038e-02 | -3.89 | Rps27a (ribosomal protein S27A) | protein interactions | 78294 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | BMP15 (bone morphogenetic protein 15) | protein interactions | 9210 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | SCT (secretin) | protein interactions | 6343 | 8 | 1 | 19454 | 50 |
MEIS2 |
2.038e-02 | -3.89 | Rasd2 (RASD family, member 2) | protein interactions | 75141 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.043e-02 | -3.89 | acral_lentiginous | COSMIC cancer mutations | acral_lentiginous | 745 | 6 | 16828 | 49 |
PARD3,NRG3,MACF1,ATP13A4,CDH20,PREX2 |
2.053e-02 | -3.89 | stress fiber | cellular component | GO:0001725 | 86 | 2 | 19108 | 49 |
ABLIM1,NEBL |
2.053e-02 | -3.89 | contractile actin filament bundle | cellular component | GO:0097517 | 86 | 2 | 19108 | 49 |
ABLIM1,NEBL |
2.059e-02 | -3.88 | regulation of cell junction assembly | biological process | GO:1901888 | 217 | 3 | 18204 | 49 |
NRXN1,NTRK2,MACF1 |
2.063e-02 | -3.88 | FAM171A1 (family with sequence similarity 171 member A1) | protein interactions | 221061 | 86 | 2 | 19454 | 50 |
NTRK2,PARD3 |
2.072e-02 | -3.88 | Cysteine Rich Protein | gene3d domains | 2.10.110.10 | 73 | 2 | 14470 | 44 |
NEBL,ABLIM1 |
2.073e-02 | -3.88 | PDZ | smart domains | SM00228 | 143 | 3 | 9717 | 40 |
PARD3B,PREX2,PARD3 |
2.082e-02 | -3.87 | Release of Hh-Np from the secreting cell | REACTOME pathways | R-HSA-5362798 | 8 | 1 | 10285 | 27 |
GPC5 |
2.099e-02 | -3.86 | GAR | prosite domains | PS51460 | 6 | 1 | 12186 | 43 |
MACF1 |
2.099e-02 | -3.86 | GLYPICAN | prosite domains | PS01207 | 6 | 1 | 12186 | 43 |
GPC5 |
2.101e-02 | -3.86 | EF_hand_dom | interpro domains | IPR002048 | 218 | 3 | 18521 | 50 |
MACF1,SPARCL1,RYR3 |
2.103e-02 | -3.86 | P-type potassium transmembrane transporter activity | molecular function | GO:0008556 | 8 | 1 | 18094 | 48 |
ATP1A2 |
2.103e-02 | -3.86 | BMP receptor activity | molecular function | GO:0098821 | 8 | 1 | 18094 | 48 |
BMPR1B |
2.103e-02 | -3.86 | sodium ion binding | molecular function | GO:0031402 | 8 | 1 | 18094 | 48 |
ATP1A2 |
2.103e-02 | -3.86 | glutamate binding | molecular function | GO:0016595 | 8 | 1 | 18094 | 48 |
SLC1A3 |
2.106e-02 | -3.86 | eye-uveal_tract-malignant_melanoma-spindle | COSMIC cancer mutations | eye-uveal_tract-malignant_melanoma-spindle | 363 | 4 | 16828 | 49 |
MACF1,CTNND2,PCDH9,PREX2 |
2.108e-02 | -3.86 | Kctd5 (potassium channel tetramerisation domain containing 5) | protein interactions | 69259 | 87 | 2 | 19454 | 50 |
SLC1A3,TRPS1 |
2.108e-02 | -3.86 | ZNF608 (zinc finger protein 608) | protein interactions | 57507 | 87 | 2 | 19454 | 50 |
NFIA,SOX5 |
2.108e-02 | -3.86 | NHLH1 (nescient helix-loop-helix 1) | protein interactions | 4807 | 87 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.108e-02 | -3.86 | MIR141 (microRNA 141) | protein interactions | 406933 | 87 | 2 | 19454 | 50 |
QKI,MSI2 |
2.125e-02 | -3.85 | HAD superfamily/HAD-like | gene3d domains | 3.40.50.1000 | 74 | 2 | 14470 | 44 |
ATP13A4,ATP1A2 |
2.130e-02 | -3.85 | leg | COSMIC cancer mutations | leg | 969 | 7 | 16828 | 49 |
NTM,NEBL,SLC4A4,PTPRZ1,ATP13A4,NRG3,ZBTB20 |
2.134e-02 | -3.85 | cell proliferation in external granule layer | biological process | GO:0021924 | 8 | 1 | 18204 | 49 |
RORA |
2.134e-02 | -3.85 | gamma-aminobutyric acid metabolic process | biological process | GO:0009448 | 8 | 1 | 18204 | 49 |
SLC1A3 |
2.134e-02 | -3.85 | cerebellar granule cell precursor proliferation | biological process | GO:0021930 | 8 | 1 | 18204 | 49 |
RORA |
2.134e-02 | -3.85 | ERBB4 signaling pathway | biological process | GO:0038130 | 8 | 1 | 18204 | 49 |
NRG3 |
2.134e-02 | -3.85 | regulation of synapse structural plasticity | biological process | GO:0051823 | 8 | 1 | 18204 | 49 |
CTNNA2 |
2.134e-02 | -3.85 | cell proliferation in hindbrain | biological process | GO:0021534 | 8 | 1 | 18204 | 49 |
RORA |
2.134e-02 | -3.85 | regulation of L-glutamate import across plasma membrane | biological process | GO:0002036 | 8 | 1 | 18204 | 49 |
ATP1A2 |
2.140e-02 | -3.84 | Villin_headpiece | interpro domains | IPR003128 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | Villin_headpiece_dom_sf | interpro domains | IPR036886 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | Plakin | interpro domains | IPR043197 | 8 | 1 | 18521 | 50 |
MACF1 |
2.151e-02 | -3.84 | peripheral nervous system development | biological process | GO:0007422 | 84 | 2 | 18204 | 49 |
NTRK2,PARD3 |
2.151e-02 | -3.84 | regulation of sodium ion transport | biological process | GO:0002028 | 84 | 2 | 18204 | 49 |
ATP1A2,NKAIN3 |
2.151e-02 | -3.84 | L-amino acid transport | biological process | GO:0015807 | 84 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
2.153e-02 | -3.84 | RAP2A (RAP2A, member of RAS oncogene family) | protein interactions | 5911 | 88 | 2 | 19454 | 50 |
BMPR1B,TNIK |
2.153e-02 | -3.84 | Ig_sub | interpro domains | IPR003599 | 394 | 4 | 18521 | 50 |
CADM1,NTM,NTRK2,LSAMP |
2.162e-02 | -3.83 | ACTIVIN2R | prints domains | PR00653 | 6 | 1 | 5227 | 19 |
BMPR1B |
2.165e-02 | -3.83 | establishment of localization | biological process | GO:0051234 | 3887 | 17 | 18204 | 49 |
ATP1A2,ITPR2,SLC4A4,SLC1A2,RYR3,GPM6A,PARD3,RANBP3L,QKI,PARD3B,ATP13A4,SLC1A3,MACF1,PITPNC1,NRXN1,SFXN5,NTRK2 |
2.182e-02 | -3.82 | VHP | pfam domains | PF02209 | 8 | 1 | 17795 | 49 |
ABLIM1 |
2.185e-02 | -3.82 | endometrium-carcinoma-serous_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-serous_carcinoma | 1442 | 9 | 16828 | 49 |
RYR3,TNIK,GPC5,CTNND2,TRPS1,LSAMP,PARD3,SLC4A4,NRXN1 |
2.186e-02 | -3.82 | PDZ domain binding | molecular function | GO:0030165 | 86 | 2 | 18094 | 48 |
CADM1,DTNA |
2.199e-02 | -3.82 | chondrocyte differentiation | biological process | GO:0002062 | 85 | 2 | 18204 | 49 |
SOX5,BMPR1B |
2.199e-02 | -3.82 | oligodendrocyte differentiation | biological process | GO:0048709 | 85 | 2 | 18204 | 49 |
PTPRZ1,NTRK2 |
2.199e-02 | -3.82 | PLEKHA2 (pleckstrin homology domain containing A2) | protein interactions | 59339 | 89 | 2 | 19454 | 50 |
AHCYL2,DTNA |
2.199e-02 | -3.82 | SOX10 (SRY-box transcription factor 10) | protein interactions | 6663 | 89 | 2 | 19454 | 50 |
NFIA,TRPS1 |
2.212e-02 | -3.81 | Cell junction organization | REACTOME pathways | R-HSA-446728 | 88 | 2 | 10285 | 27 |
CADM1,PARD3 |
2.219e-02 | -3.81 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-T_cell_large_granular_lymphocytic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-T_cell_large_granular_lymphocytic_leukaemia | 79 | 2 | 16828 | 49 |
MAML2,CADM1 |
2.224e-02 | -3.81 | HMG20A (high mobility group 20A) | protein interactions | 10363 | 234 | 3 | 19454 | 50 |
SOX5,NFIA,DTNA |
2.246e-02 | -3.80 | CTDSPL (CTD small phosphatase like) | protein interactions | 10217 | 90 | 2 | 19454 | 50 |
DTNA,CADM1 |
2.272e-02 | -3.78 | human chr6q26 | chromosome location | human chr6q26 | 12 | 1 | 26134 | 50 |
QKI |
2.285e-02 | -3.78 | platelet dense tubular network membrane | cellular component | GO:0031095 | 9 | 1 | 19108 | 49 |
ITPR2 |
2.290e-02 | -3.78 | Ywhag (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypeptide) | protein interactions | 22628 | 9 | 1 | 19454 | 50 |
QKI |
2.290e-02 | -3.78 | Tyw3 (tRNA-yW synthesizing protein 3 homolog (S. cerevisiae)) | protein interactions | 209584 | 9 | 1 | 19454 | 50 |
CTNNA2 |
2.290e-02 | -3.78 | VEPH1 (ventricular zone expressed PH domain containing 1) | protein interactions | 79674 | 9 | 1 | 19454 | 50 |
BMPR1B |
2.290e-02 | -3.78 | NRXN2 (neurexin 2) | protein interactions | 9379 | 9 | 1 | 19454 | 50 |
MACF1 |
2.292e-02 | -3.78 | DGUOK (deoxyguanosine kinase) | protein interactions | 1716 | 91 | 2 | 19454 | 50 |
GPM6A,NTM |
2.292e-02 | -3.78 | PTPN21 (protein tyrosine phosphatase non-receptor type 21) | protein interactions | 11099 | 91 | 2 | 19454 | 50 |
NRG3,AHCYL2 |
2.292e-02 | -3.78 | FOXI1 (forkhead box I1) | protein interactions | 2299 | 91 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.296e-02 | -3.77 | associative learning | biological process | GO:0008306 | 87 | 2 | 18204 | 49 |
ATP1A2,MEIS2 |
2.299e-02 | -3.77 | CAMK2A (calcium/calmodulin dependent protein kinase II alpha) | protein interactions | 815 | 237 | 3 | 19454 | 50 |
SOX5,ITPR2,GPM6A |
2.306e-02 | -3.77 | skin-chest-malignant_melanoma-nodular | COSMIC cancer mutations | skin-chest-malignant_melanoma-nodular | 8 | 1 | 16828 | 49 |
PREX2 |
2.306e-02 | -3.77 | central_nervous_system-chiasm-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-chiasm-glioma-astrocytoma_Grade_I | 8 | 1 | 16828 | 49 |
QKI |
2.318e-02 | -3.76 | skin-leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-leg-malignant_melanoma-superficial_spreading | 210 | 3 | 16828 | 49 |
ATP13A4,NTM,SLC4A4 |
2.325e-02 | -3.76 | T_cell_large_granular_lymphocytic_leukaemia | COSMIC cancer mutations | T_cell_large_granular_lymphocytic_leukaemia | 81 | 2 | 16828 | 49 |
MAML2,CADM1 |
2.329e-02 | -3.76 | actomyosin | cellular component | GO:0042641 | 92 | 2 | 19108 | 49 |
NEBL,ABLIM1 |
2.330e-02 | -3.76 | RNF43 (ring finger protein 43) | protein interactions | 54894 | 424 | 4 | 19454 | 50 |
ABLIM1,MACF1,QKI,PARD3 |
2.339e-02 | -3.76 | SOX9 (SRY-box transcription factor 9) | protein interactions | 6662 | 92 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.387e-02 | -3.74 | MIR19B2 (microRNA 19b-2) | protein interactions | 406981 | 93 | 2 | 19454 | 50 |
QKI,MSI2 |
2.387e-02 | -3.74 | RBM23 (RNA binding motif protein 23) | protein interactions | 55147 | 93 | 2 | 19454 | 50 |
QKI,AHCYL2 |
2.387e-02 | -3.74 | DMRTB1 (DMRT like family B with proline rich C-terminal 1) | protein interactions | 63948 | 93 | 2 | 19454 | 50 |
MSI2,QKI |
2.387e-02 | -3.74 | ARHGEF6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 9459 | 93 | 2 | 19454 | 50 |
BMPR1B,ABLIM1 |
2.387e-02 | -3.74 | TEX11 (testis expressed 11) | protein interactions | 56159 | 93 | 2 | 19454 | 50 |
SOX5,QKI |
2.397e-02 | -3.73 | hindbrain radial glia guided cell migration | biological process | GO:0021932 | 9 | 1 | 18204 | 49 |
CTNNA2 |
2.397e-02 | -3.73 | activated T cell proliferation | biological process | GO:0050798 | 9 | 1 | 18204 | 49 |
CADM1 |
2.397e-02 | -3.73 | negative regulation of actin nucleation | biological process | GO:0051126 | 9 | 1 | 18204 | 49 |
CTNNA2 |
2.397e-02 | -3.73 | polyamine transmembrane transport | biological process | GO:1902047 | 9 | 1 | 18204 | 49 |
ATP13A4 |
2.397e-02 | -3.73 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | biological process | GO:0014808 | 9 | 1 | 18204 | 49 |
RYR3 |
2.397e-02 | -3.73 | negative regulation of striated muscle contraction | biological process | GO:0045988 | 9 | 1 | 18204 | 49 |
ATP1A2 |
2.397e-02 | -3.73 | positive regulation of synapse maturation | biological process | GO:0090129 | 9 | 1 | 18204 | 49 |
NRXN1 |
2.401e-02 | -3.73 | ERBIN (erbb2 interacting protein) | protein interactions | 55914 | 241 | 3 | 19454 | 50 |
NTRK2,PARD3,CTNND2 |
2.401e-02 | -3.73 | - | gene3d domains | 2.80.10.50 | 79 | 2 | 14470 | 44 |
RYR3,ITPR2 |
2.403e-02 | -3.73 | Post-translational modification: synthesis of GPI-anchored proteins | REACTOME pathways | R-HSA-163125 | 92 | 2 | 10285 | 27 |
NTM,LSAMP |
2.404e-02 | -3.73 | Band3_cytoplasmic_dom | interpro domains | IPR013769 | 9 | 1 | 18521 | 50 |
SLC4A4 |
2.404e-02 | -3.73 | Activin_recp | interpro domains | IPR000472 | 9 | 1 | 18521 | 50 |
BMPR1B |
2.404e-02 | -3.73 | Fol_N | interpro domains | IPR003645 | 9 | 1 | 18521 | 50 |
SPARCL1 |
2.407e-02 | -3.73 | Villin headpiece domain | gene3d domains | 1.10.950.10 | 8 | 1 | 14470 | 44 |
ABLIM1 |
2.408e-02 | -3.73 | ion binding | molecular function | GO:0043167 | 6007 | 23 | 18094 | 48 |
PITPNC1,ZBTB20,TNIK,PAMR1,DTNA,ITPR2,SLC1A2,ATP13A4,GLIS3,RYR3,MACF1,TRPS1,RORA,ZNRF3,NRXN1,ATP1A2,SPARCL1,NTRK2,BMPR1B,ABLIM1,PCDH9,SLC1A3,PARD3 |
2.412e-02 | -3.72 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 19 | 16828 | 49 |
NHSL1,TRPS1,PAMR1,CDH20,PREX2,ZNRF3,PARD3,PTPRZ1,MACF1,CTNND2,NPAS3,RYR3,RORA,GLIS3,NFIA,PARD3B,MAML2,SPARCL1,SLC1A3 |
2.430e-02 | -3.72 | protein binding | molecular function | GO:0005515 | 13983 | 43 | 18094 | 48 |
GPM6A,PARD3,SLC1A3,QKI,NTRK2,FBXL7,BMPR1B,SOX5,ABLIM1,CTNNA2,SPARCL1,CADM1,LSAMP,NRXN1,ATP1A2,GPC5,RORA,ZNRF3,CTNND2,NFIA,NRG3,RANBP3L,TRPS1,MSI2,SLC4A4,MACF1,RYR3,GLIS3,MEIS2,NTM,TNIK,DTNA,ITPR2,SLC1A2,PTPRZ1,PARD3B,NPAS3,MAML2,PITPNC1,SFXN5,NEBL,CDH20,AHCYL2 |
2.435e-02 | -3.72 | QSER1 (glutamine and serine rich 1) | protein interactions | 79832 | 94 | 2 | 19454 | 50 |
SOX5,NFIA |
2.435e-02 | -3.72 | FOXP4 (forkhead box P4) | protein interactions | 116113 | 94 | 2 | 19454 | 50 |
SOX5,NFIA |
2.435e-02 | -3.72 | WWC1 (WW and C2 domain containing 1) | protein interactions | 23286 | 94 | 2 | 19454 | 50 |
TNIK,ABLIM1 |
2.437e-02 | -3.71 | renal_cell_carcinoma | COSMIC cancer mutations | renal_cell_carcinoma | 4535 | 20 | 16828 | 49 |
SOX5,BMPR1B,PREX2,ZNRF3,PTPRZ1,TRPS1,QKI,TNIK,MSI2,MAML2,MEIS2,NRXN1,FBXL7,ITPR2,CTNND2,MACF1,PCDH9,NTRK2,PITPNC1,RORA |
2.437e-02 | -3.71 | kidney-carcinoma-renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma | 4535 | 20 | 16828 | 49 |
MAML2,MSI2,FBXL7,NRXN1,MEIS2,PCDH9,MACF1,CTNND2,ITPR2,RORA,PITPNC1,NTRK2,PREX2,BMPR1B,SOX5,PTPRZ1,ZNRF3,QKI,TRPS1,TNIK |
2.445e-02 | -3.71 | GS | prosite domains | PS51256 | 7 | 1 | 12186 | 43 |
BMPR1B |
2.445e-02 | -3.71 | GAS2 | smart domains | SM00243 | 6 | 1 | 9717 | 40 |
MACF1 |
2.446e-02 | -3.71 | regulation of purine nucleotide metabolic process | biological process | GO:1900542 | 90 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
2.449e-02 | -3.71 | connective tissue development | biological process | GO:0061448 | 232 | 3 | 18204 | 49 |
BMPR1B,SOX5,NFIA |
2.452e-02 | -3.71 | Band_3_cyto | pfam domains | PF07565 | 9 | 1 | 17795 | 49 |
SLC4A4 |
2.452e-02 | -3.71 | Activin_recp | pfam domains | PF01064 | 9 | 1 | 17795 | 49 |
BMPR1B |
2.459e-02 | -3.71 | human chr5p15.1 | chromosome location | human chr5p15.1 | 13 | 1 | 26134 | 50 |
FBXL7 |
2.470e-02 | -3.70 | EGF-like_dom | interpro domains | IPR000742 | 232 | 3 | 18521 | 50 |
PAMR1,NRG3,NRXN1 |
2.487e-02 | -3.69 | response to organic cyclic compound | biological process | GO:0014070 | 843 | 6 | 18204 | 49 |
SLC1A2,ITPR2,ATP1A2,RYR3,RORA,SLC1A3 |
2.496e-02 | -3.69 | response to BMP | biological process | GO:0071772 | 91 | 2 | 18204 | 49 |
BMPR1B,NFIA |
2.496e-02 | -3.69 | regulation of nucleotide metabolic process | biological process | GO:0006140 | 91 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
2.496e-02 | -3.69 | cellular response to BMP stimulus | biological process | GO:0071773 | 91 | 2 | 18204 | 49 |
BMPR1B,NFIA |
2.496e-02 | -3.69 | DNA-binding transcription factor activity, RNA polymerase II-specific | molecular function | GO:0000981 | 1355 | 8 | 18094 | 48 |
SOX5,TRPS1,NPAS3,NFIA,ZBTB20,MEIS2,GLIS3,RORA |
2.519e-02 | -3.68 | chemical synaptic transmission | biological process | GO:0007268 | 415 | 4 | 18204 | 49 |
NRXN1,SLC1A2,DTNA,SLC1A3 |
2.519e-02 | -3.68 | anterograde trans-synaptic signaling | biological process | GO:0098916 | 415 | 4 | 18204 | 49 |
SLC1A2,NRXN1,DTNA,SLC1A3 |
2.521e-02 | -3.68 | actin filament bundle | cellular component | GO:0032432 | 96 | 2 | 19108 | 49 |
NEBL,ABLIM1 |
2.521e-02 | -3.68 | sarcoplasm | cellular component | GO:0016528 | 96 | 2 | 19108 | 49 |
RYR3,ITPR2 |
2.529e-02 | -3.68 | TRIM67 (tripartite motif containing 67) | protein interactions | 440730 | 4804 | 19 | 19454 | 50 |
CADM1,MACF1,SLC1A3,PARD3,NTM,QKI,LSAMP,CTNNA2,ATP1A2,MSI2,PTPRZ1,DTNA,SLC4A4,ITPR2,PITPNC1,GPM6A,TNIK,AHCYL2,CTNND2 |
2.536e-02 | -3.67 | perineuronal net | cellular component | GO:0072534 | 10 | 1 | 19108 | 49 |
PTPRZ1 |
2.541e-02 | -3.67 | SLC8A2 (solute carrier family 8 member A2) | protein interactions | 6543 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | TSHZ1 (teashirt zinc finger homeobox 1) | protein interactions | 10194 | 10 | 1 | 19454 | 50 |
MEIS2 |
2.541e-02 | -3.67 | P2rx7 (purinergic receptor P2X 7) | protein interactions | 29665 | 10 | 1 | 19454 | 50 |
PTPRZ1 |
2.541e-02 | -3.67 | BANK1 (B cell scaffold protein with ankyrin repeats 1) | protein interactions | 55024 | 10 | 1 | 19454 | 50 |
ITPR2 |
2.541e-02 | -3.67 | Hsp90aa1 (heat shock protein 90, alpha (cytosolic), class A member 1) | protein interactions | 15519 | 10 | 1 | 19454 | 50 |
QKI |
2.541e-02 | -3.67 | CALB2 (calbindin 2) | protein interactions | 794 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | Mrpl13 (mitochondrial ribosomal protein L13) | protein interactions | 68537 | 10 | 1 | 19454 | 50 |
QKI |
2.541e-02 | -3.67 | Smurf2 (SMAD specific E3 ubiquitin protein ligase 2) | protein interactions | 66313 | 10 | 1 | 19454 | 50 |
GLIS3 |
2.541e-02 | -3.67 | GSG1 (germ cell associated 1) | protein interactions | 83445 | 10 | 1 | 19454 | 50 |
PITPNC1 |
2.541e-02 | -3.67 | Vbp1 (von Hippel-Lindau binding protein 1) | protein interactions | 22327 | 10 | 1 | 19454 | 50 |
ABLIM1 |
2.551e-02 | -3.67 | lipid binding | molecular function | GO:0008289 | 861 | 6 | 18094 | 48 |
PARD3B,RORA,PITPNC1,ATP1A2,ITPR2,PARD3 |
2.568e-02 | -3.66 | spindle | COSMIC cancer mutations | spindle | 386 | 4 | 16828 | 49 |
PREX2,PCDH9,CTNND2,MACF1 |
2.585e-02 | -3.66 | NCOR2 (nuclear receptor corepressor 2) | protein interactions | 9612 | 248 | 3 | 19454 | 50 |
SOX5,NFIA,TNIK |
2.591e-02 | -3.65 | skin-upper_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | skin-chest-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-chest-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.592e-02 | -3.65 | LIM_DOMAIN_1 | prosite domains | PS00478 | 71 | 2 | 12186 | 43 |
ABLIM1,NEBL |
2.592e-02 | -3.65 | LIM_DOMAIN_2 | prosite domains | PS50023 | 71 | 2 | 12186 | 43 |
NEBL,ABLIM1 |
2.596e-02 | -3.65 | PI3K events in ERBB4 signaling | REACTOME pathways | R-HSA-1250342 | 10 | 1 | 10285 | 27 |
NRG3 |
2.616e-02 | -3.64 | muscle contraction | biological process | GO:0006936 | 238 | 3 | 18204 | 49 |
RYR3,ATP1A2,DTNA |
2.618e-02 | -3.64 | organic substance transport | biological process | GO:0071702 | 1881 | 10 | 18204 | 49 |
QKI,RANBP3L,MACF1,ATP13A4,SLC1A3,SLC4A4,PITPNC1,SLC1A2,SFXN5,NTRK2 |
2.621e-02 | -3.64 | oesophagus-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-carcinoma-adenocarcinoma | 13112 | 44 | 16828 | 49 |
ZBTB20,PAMR1,TRPS1,ATP13A4,NHSL1,PTPRZ1,PARD3,BMPR1B,NEBL,CDH20,PARD3B,AHCYL2,RORA,ATP1A2,CTNND2,NRXN1,FBXL7,SLC1A3,LSAMP,NKAIN3,GPM6A,SPARCL1,SLC1A2,GPC5,TNIK,QKI,ZNRF3,SLC4A4,SOX5,PREX2,NTRK2,NRG3,NPAS3,GLIS3,RYR3,ITPR2,MACF1,PCDH9,MEIS2,RANBP3L,CADM1,SFXN5,MAML2,NTM |
2.622e-02 | -3.64 | phosphatidylinositol transfer activity | molecular function | GO:0008526 | 10 | 1 | 18094 | 48 |
PITPNC1 |
2.622e-02 | -3.64 | neurotrophin binding | molecular function | GO:0043121 | 10 | 1 | 18094 | 48 |
NTRK2 |
2.622e-02 | -3.64 | polyamine transmembrane transporter activity | molecular function | GO:0015203 | 10 | 1 | 18094 | 48 |
ATP13A4 |
2.623e-02 | -3.64 | Methionine degradation | KEGG pathways | hsa_M00035 | 10 | 1 | 7161 | 19 |
AHCYL2 |
2.623e-02 | -3.64 | Methionine degradation | KEGG pathways | M00035 | 10 | 1 | 7161 | 19 |
AHCYL2 |
2.625e-02 | -3.64 | cell surface | cellular component | GO:0009986 | 896 | 6 | 19108 | 49 |
SLC1A2,GPC5,NRXN1,SLC4A4,SLC1A3,ATP1A2 |
2.631e-02 | -3.64 | FRS2 (fibroblast growth factor receptor substrate 2) | protein interactions | 10818 | 98 | 2 | 19454 | 50 |
NTRK2,PARD3 |
2.631e-02 | -3.64 | MED27 (mediator complex subunit 27) | protein interactions | 9442 | 98 | 2 | 19454 | 50 |
QKI,SOX5 |
2.631e-02 | -3.64 | DNAAF2 (dynein axonemal assembly factor 2) | protein interactions | 55172 | 98 | 2 | 19454 | 50 |
LSAMP,GPM6A |
2.646e-02 | -3.63 | human chr2p16.3 | chromosome location | human chr2p16.3 | 14 | 1 | 26134 | 50 |
NRXN1 |
2.646e-02 | -3.63 | human chr2p13.2 | chromosome location | human chr2p13.2 | 14 | 1 | 26134 | 50 |
SFXN5 |
2.658e-02 | -3.63 | response to radiation | biological process | GO:0009314 | 422 | 4 | 18204 | 49 |
SLC1A3,MEIS2,ATP1A2,SLC1A2 |
2.660e-02 | -3.63 | retinal rod cell development | biological process | GO:0046548 | 10 | 1 | 18204 | 49 |
NTRK2 |
2.660e-02 | -3.63 | substrate-independent telencephalic tangential interneuron migration | biological process | GO:0021843 | 10 | 1 | 18204 | 49 |
NRG3 |
2.660e-02 | -3.63 | regulation of mesenchymal stem cell differentiation | biological process | GO:2000739 | 10 | 1 | 18204 | 49 |
SOX5 |
2.660e-02 | -3.63 | postsynaptic density assembly | biological process | GO:0097107 | 10 | 1 | 18204 | 49 |
NRXN1 |
2.660e-02 | -3.63 | substrate-independent telencephalic tangential migration | biological process | GO:0021826 | 10 | 1 | 18204 | 49 |
NRG3 |
2.660e-02 | -3.63 | trans-synaptic signaling, modulating synaptic transmission | biological process | GO:0099550 | 10 | 1 | 18204 | 49 |
NTRK2 |
2.660e-02 | -3.63 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | biological process | GO:1903514 | 10 | 1 | 18204 | 49 |
RYR3 |
2.660e-02 | -3.63 | postsynaptic membrane assembly | biological process | GO:0097104 | 10 | 1 | 18204 | 49 |
NRXN1 |
2.660e-02 | -3.63 | learned vocalization behavior or vocal learning | biological process | GO:0098598 | 10 | 1 | 18204 | 49 |
NRXN1 |
2.660e-02 | -3.63 | cellular response to brain-derived neurotrophic factor stimulus | biological process | GO:1990416 | 10 | 1 | 18204 | 49 |
NTRK2 |
2.668e-02 | -3.62 | HCO3_transpt_euk | interpro domains | IPR003020 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | HCO3_transpt-like_TM_dom | interpro domains | IPR011531 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | PTrfase/Anion_transptr | interpro domains | IPR016152 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 50 |
NPAS3 |
2.680e-02 | -3.62 | ZFHX3 (zinc finger homeobox 3) | protein interactions | 463 | 99 | 2 | 19454 | 50 |
SOX5,TRPS1 |
2.680e-02 | -3.62 | TNKS (tankyrase) | protein interactions | 8658 | 99 | 2 | 19454 | 50 |
PCDH9,TNIK |
2.683e-02 | -3.62 | ATPase-coupled transmembrane transporter activity | molecular function | GO:0042626 | 96 | 2 | 18094 | 48 |
ATP13A4,ATP1A2 |
2.691e-02 | -3.62 | response to abiotic stimulus | biological process | GO:0009628 | 1100 | 7 | 18204 | 49 |
NRXN1,SLC1A2,MEIS2,ITPR2,ATP1A2,SLC1A3,RORA |
2.693e-02 | -3.61 | NCK2 (NCK adaptor protein 2) | protein interactions | 8440 | 252 | 3 | 19454 | 50 |
NTRK2,TNIK,NHSL1 |
2.693e-02 | -3.61 | CRX (cone-rod homeobox) | protein interactions | 1406 | 252 | 3 | 19454 | 50 |
TRPS1,SOX5,NFIA |
2.695e-02 | -3.61 | lung-carcinoma-non_small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-non_small_cell_carcinoma | 5198 | 22 | 16828 | 49 |
TNIK,ABLIM1,TRPS1,ATP13A4,QKI,PARD3,PTPRZ1,SOX5,BMPR1B,PREX2,NTRK2,PITPNC1,RORA,NPAS3,ITPR2,CTNND2,FBXL7,SLC1A3,LSAMP,MSI2,MAML2,SPARCL1 |
2.695e-02 | -3.61 | non_small_cell_carcinoma | COSMIC cancer mutations | non_small_cell_carcinoma | 5198 | 22 | 16828 | 49 |
TNIK,ABLIM1,TRPS1,ATP13A4,QKI,PARD3,PTPRZ1,SOX5,BMPR1B,PREX2,NTRK2,PITPNC1,NPAS3,RORA,ITPR2,CTNND2,FBXL7,SLC1A3,LSAMP,MSI2,MAML2,SPARCL1 |
2.704e-02 | -3.61 | calcium ion transmembrane import into cytosol | biological process | GO:0097553 | 95 | 2 | 18204 | 49 |
RYR3,ITPR2 |
2.720e-02 | -3.60 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 49 |
NPAS3 |
2.720e-02 | -3.60 | HCO3_cotransp | pfam domains | PF00955 | 10 | 1 | 17795 | 49 |
SLC4A4 |
2.731e-02 | -3.60 | ATP4A (ATPase H+/K+ transporting subunit alpha) | protein interactions | 495 | 100 | 2 | 19454 | 50 |
GPM6A,ATP1A2 |
2.731e-02 | -3.60 | APBA1 (amyloid beta precursor protein binding family A member 1) | protein interactions | 320 | 100 | 2 | 19454 | 50 |
NRXN1,ABLIM1 |
2.737e-02 | -3.60 | pancreas-other-adenoma | COSMIC cancer mutations | pancreas-other-adenoma | 224 | 3 | 16828 | 49 |
CTNND2,PCDH9,BMPR1B |
2.741e-02 | -3.60 | uveal_tract | COSMIC cancer mutations | uveal_tract | 587 | 5 | 16828 | 49 |
PREX2,PCDH9,MACF1,CTNND2,RANBP3L |
2.771e-02 | -3.59 | actin binding | molecular function | GO:0003779 | 434 | 4 | 18094 | 48 |
CTNNA2,NEBL,ABLIM1,MACF1 |
2.776e-02 | -3.58 | DYNLL2 (dynein light chain LC8-type 2) | protein interactions | 140735 | 255 | 3 | 19454 | 50 |
NHSL1,TRPS1,NFIA |
2.786e-02 | -3.58 | platelet dense tubular network | cellular component | GO:0031094 | 11 | 1 | 19108 | 49 |
ITPR2 |
2.786e-02 | -3.58 | perisynaptic extracellular matrix | cellular component | GO:0098966 | 11 | 1 | 19108 | 49 |
PTPRZ1 |
2.789e-02 | -3.58 | HP | prosite domains | PS51089 | 8 | 1 | 12186 | 43 |
ABLIM1 |
2.789e-02 | -3.58 | GATA_ZN_FINGER_1 | prosite domains | PS00344 | 8 | 1 | 12186 | 43 |
TRPS1 |
2.792e-02 | -3.58 | DAZ1 (deleted in azoospermia 1) | protein interactions | 1617 | 11 | 1 | 19454 | 50 |
QKI |
2.792e-02 | -3.58 | Batf3 (basic leucine zipper transcription factor, ATF-like 3) | protein interactions | 381319 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | AQP5 (aquaporin 5) | protein interactions | 362 | 11 | 1 | 19454 | 50 |
ATP1A2 |
2.792e-02 | -3.58 | SYN3 (synapsin III) | protein interactions | 8224 | 11 | 1 | 19454 | 50 |
GPM6A |
2.792e-02 | -3.58 | IL7 (interleukin 7) | protein interactions | 3574 | 11 | 1 | 19454 | 50 |
QKI |
2.792e-02 | -3.58 | Wipi2 (WD repeat domain, phosphoinositide interacting 2) | protein interactions | 74781 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | IRAG1 (inositol 1,4,5-triphosphate receptor associated 1) | protein interactions | 10335 | 11 | 1 | 19454 | 50 |
ITPR2 |
2.792e-02 | -3.58 | Cobll1 (Cobl-like 1) | protein interactions | 319876 | 11 | 1 | 19454 | 50 |
ABLIM1 |
2.792e-02 | -3.58 | Gtf2e2 (general transcription factor II E, polypeptide 2 (beta subunit)) | protein interactions | 68153 | 11 | 1 | 19454 | 50 |
NHSL1 |
2.792e-02 | -3.58 | SYTL1 (synaptotagmin like 1) | protein interactions | 84958 | 11 | 1 | 19454 | 50 |
NRXN1 |
2.802e-02 | -3.58 | RNA polymerase II transcription regulatory region sequence-specific DNA binding | molecular function | GO:0000977 | 1385 | 8 | 18094 | 48 |
SOX5,TRPS1,NPAS3,NFIA,ZBTB20,MEIS2,GLIS3,RORA |
2.810e-02 | -3.57 | amino acid transmembrane transport | biological process | GO:0003333 | 97 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
2.831e-02 | -3.56 | ankle | COSMIC cancer mutations | ankle | 398 | 4 | 16828 | 49 |
ATP13A4,PREX2,NRG3,PARD3 |
2.832e-02 | -3.56 | human chr8q12.3 | chromosome location | human chr8q12.3 | 15 | 1 | 26134 | 50 |
NKAIN3 |
2.832e-02 | -3.56 | human chr10p12.31 | chromosome location | human chr10p12.31 | 15 | 1 | 26134 | 50 |
NEBL |
2.832e-02 | -3.56 | MIR7-1 (microRNA 7-1) | protein interactions | 407043 | 102 | 2 | 19454 | 50 |
MSI2,QKI |
2.832e-02 | -3.56 | KRTAP6-1 (keratin associated protein 6-1) | protein interactions | 337966 | 102 | 2 | 19454 | 50 |
GLIS3,MEIS2 |
2.842e-02 | -3.56 | response to wounding | biological process | GO:0009611 | 431 | 4 | 18204 | 49 |
MACF1,SLC1A3,NFIA,SLC1A2 |
2.847e-02 | -3.56 | PLEC | smart domains | SM00250 | 7 | 1 | 9717 | 40 |
MACF1 |
2.847e-02 | -3.56 | GS | smart domains | SM00467 | 7 | 1 | 9717 | 40 |
BMPR1B |
2.873e-02 | -3.55 | GATAZNFINGER | prints domains | PR00619 | 8 | 1 | 5227 | 19 |
TRPS1 |
2.875e-02 | -3.55 | chiasm | COSMIC cancer mutations | chiasm | 10 | 1 | 16828 | 49 |
QKI |
2.875e-02 | -3.55 | skin-back-malignant_melanoma-nodular | COSMIC cancer mutations | skin-back-malignant_melanoma-nodular | 10 | 1 | 16828 | 49 |
PREX2 |
2.880e-02 | -3.55 | acetylcholine receptor binding | molecular function | GO:0033130 | 11 | 1 | 18094 | 48 |
NRXN1 |
2.880e-02 | -3.55 | sulfur amino acid transmembrane transporter activity | molecular function | GO:0000099 | 11 | 1 | 18094 | 48 |
SLC1A2 |
2.884e-02 | -3.55 | ZDHHC5 (zinc finger DHHC-type palmitoyltransferase 5) | protein interactions | 25921 | 103 | 2 | 19454 | 50 |
NTRK2,PARD3 |
2.884e-02 | -3.55 | RAB6B (RAB6B, member RAS oncogene family) | protein interactions | 51560 | 103 | 2 | 19454 | 50 |
BMPR1B,GPM6A |
2.885e-02 | -3.55 | inorganic ion homeostasis | biological process | GO:0098771 | 433 | 4 | 18204 | 49 |
ATP1A2,RYR3,SLC1A3,ATP13A4 |
2.889e-02 | -3.54 | MARK2 (microtubule affinity regulating kinase 2) | protein interactions | 2011 | 259 | 3 | 19454 | 50 |
PARD3B,PARD3,DTNA |
2.893e-02 | -3.54 | amino acid transmembrane transporter activity | molecular function | GO:0015171 | 100 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
2.894e-02 | -3.54 | Ig-like_dom | interpro domains | IPR007110 | 432 | 4 | 18521 | 50 |
NTRK2,NTM,CADM1,LSAMP |
2.920e-02 | -3.53 | LCK (LCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3932 | 455 | 4 | 19454 | 50 |
MACF1,CTNND2,DTNA,PARD3 |
2.922e-02 | -3.53 | polyamine transport | biological process | GO:0015846 | 11 | 1 | 18204 | 49 |
ATP13A4 |
2.922e-02 | -3.53 | negative regulation of neuron migration | biological process | GO:2001223 | 11 | 1 | 18204 | 49 |
NRG3 |
2.922e-02 | -3.53 | antral ovarian follicle growth | biological process | GO:0001547 | 11 | 1 | 18204 | 49 |
BMPR1B |
2.922e-02 | -3.53 | establishment or maintenance of transmembrane electrochemical gradient | biological process | GO:0010248 | 11 | 1 | 18204 | 49 |
ATP1A2 |
2.922e-02 | -3.53 | ectodermal placode morphogenesis | biological process | GO:0071697 | 11 | 1 | 18204 | 49 |
NRG3 |
2.922e-02 | -3.53 | ectodermal placode formation | biological process | GO:0060788 | 11 | 1 | 18204 | 49 |
NRG3 |
2.922e-02 | -3.53 | intracellular mRNA localization | biological process | GO:0008298 | 11 | 1 | 18204 | 49 |
QKI |
2.922e-02 | -3.53 | cellular response to caffeine | biological process | GO:0071313 | 11 | 1 | 18204 | 49 |
RYR3 |
2.922e-02 | -3.53 | L-ascorbic acid metabolic process | biological process | GO:0019852 | 11 | 1 | 18204 | 49 |
ATP1A2 |
2.922e-02 | -3.53 | lactone metabolic process | biological process | GO:1901334 | 11 | 1 | 18204 | 49 |
ATP1A2 |
2.922e-02 | -3.53 | glutamate secretion | biological process | GO:0014047 | 11 | 1 | 18204 | 49 |
NTRK2 |
2.931e-02 | -3.53 | RanBP1-like | interpro domains | IPR045255 | 11 | 1 | 18521 | 50 |
RANBP3L |
2.931e-02 | -3.53 | Tyr_kinase_rcpt_2_CS | interpro domains | IPR002011 | 11 | 1 | 18521 | 50 |
NTRK2 |
2.931e-02 | -3.53 | Ran_bind_dom | interpro domains | IPR000156 | 11 | 1 | 18521 | 50 |
RANBP3L |
2.934e-02 | -3.53 | nervous system process | biological process | GO:0050877 | 1376 | 8 | 18204 | 49 |
NRXN1,CTNNA2,ABLIM1,NTRK2,MEIS2,ATP1A2,PTPRZ1,SLC1A3 |
2.936e-02 | -3.53 | HUNK (hormonally up-regulated Neu-associated kinase) | protein interactions | 30811 | 104 | 2 | 19454 | 50 |
SPARCL1,ABLIM1 |
2.946e-02 | -3.52 | DIRAS3 (DIRAS family GTPase 3) | protein interactions | 9077 | 261 | 3 | 19454 | 50 |
MACF1,PARD3,DTNA |
2.988e-02 | -3.51 | BEND3 (BEN domain containing 3) | protein interactions | 57673 | 105 | 2 | 19454 | 50 |
TNIK,TRPS1 |
2.988e-02 | -3.51 | ANP32E (acidic nuclear phosphoprotein 32 family member E) | protein interactions | 81611 | 105 | 2 | 19454 | 50 |
AHCYL2,PARD3 |
2.988e-02 | -3.51 | Ran_BP1 | pfam domains | PF00638 | 11 | 1 | 17795 | 49 |
RANBP3L |
2.997e-02 | -3.51 | calcium ion transport | biological process | GO:0006816 | 251 | 3 | 18204 | 49 |
GPM6A,RYR3,ITPR2 |
3.000e-02 | -3.51 | Helical hairpin bin | gene3d domains | 1.10.287.570 | 10 | 1 | 14470 | 44 |
SLC4A4 |
3.035e-02 | -3.49 | positive regulation of developmental process | biological process | GO:0051094 | 1385 | 8 | 18204 | 49 |
BMPR1B,PTPRZ1,MACF1,SOX5,RANBP3L,QKI,NTRK2,NRXN1 |
3.035e-02 | -3.49 | sodium:potassium-exchanging ATPase complex | cellular component | GO:0005890 | 12 | 1 | 19108 | 49 |
ATP1A2 |
3.035e-02 | -3.49 | synapse-associated extracellular matrix | cellular component | GO:0099535 | 12 | 1 | 19108 | 49 |
PTPRZ1 |
3.040e-02 | -3.49 | USP6NL (USP6 N-terminal like) | protein interactions | 9712 | 106 | 2 | 19454 | 50 |
NTRK2,PARD3 |
3.042e-02 | -3.49 | CA4 (carbonic anhydrase 4) | protein interactions | 762 | 12 | 1 | 19454 | 50 |
SLC4A4 |
3.042e-02 | -3.49 | FAM222A (family with sequence similarity 222 member A) | protein interactions | 84915 | 12 | 1 | 19454 | 50 |
MEIS2 |
3.042e-02 | -3.49 | LGR5 (leucine rich repeat containing G protein-coupled receptor 5) | protein interactions | 8549 | 12 | 1 | 19454 | 50 |
ZNRF3 |
3.042e-02 | -3.49 | Pard6b (par-6 family cell polarity regulator beta) | protein interactions | 58220 | 12 | 1 | 19454 | 50 |
PARD3 |
3.042e-02 | -3.49 | BAMBI (BMP and activin membrane bound inhibitor) | protein interactions | 25805 | 12 | 1 | 19454 | 50 |
BMPR1B |
3.042e-02 | -3.49 | ART4 (ADP-ribosyltransferase 4 (inactive) (Dombrock blood group)) | protein interactions | 420 | 12 | 1 | 19454 | 50 |
GPM6A |
3.042e-02 | -3.49 | NTF4 (neurotrophin 4) | protein interactions | 4909 | 12 | 1 | 19454 | 50 |
NTRK2 |
3.042e-02 | -3.49 | LMP-1 (latent membrane protein LMP-1) | protein interactions | 3783750 | 12 | 1 | 19454 | 50 |
TNIK |
3.087e-02 | -3.48 | eye | COSMIC cancer mutations | eye | 606 | 5 | 16828 | 49 |
RANBP3L,PCDH9,PREX2,MACF1,CTNND2 |
3.101e-02 | -3.47 | regulation of neuron projection development | biological process | GO:0010975 | 443 | 4 | 18204 | 49 |
MACF1,NTRK2,CTNNA2,TNIK |
3.107e-02 | -3.47 | Defective EXT1 causes exostoses 1, TRPS2 and CHDS | REACTOME pathways | R-HSA-3656253 | 12 | 1 | 10285 | 27 |
GPC5 |
3.107e-02 | -3.47 | Defective EXT2 causes exostoses 2 | REACTOME pathways | R-HSA-3656237 | 12 | 1 | 10285 | 27 |
GPC5 |
3.114e-02 | -3.47 | Laminin | gene3d domains | 2.10.25.10 | 226 | 3 | 14470 | 44 |
NRXN1,PAMR1,NRG3 |
3.138e-02 | -3.46 | inositol 1,4,5 trisphosphate binding | molecular function | GO:0070679 | 12 | 1 | 18094 | 48 |
ITPR2 |
3.147e-02 | -3.46 | FKBP1A (FKBP prolyl isomerase 1A) | protein interactions | 2280 | 108 | 2 | 19454 | 50 |
MSI2,RYR3 |
3.147e-02 | -3.46 | PAX8 (paired box 8) | protein interactions | 7849 | 108 | 2 | 19454 | 50 |
NFIA,TRPS1 |
3.147e-02 | -3.46 | CAMKV (CaM kinase like vesicle associated) | protein interactions | 79012 | 108 | 2 | 19454 | 50 |
GPM6A,AHCYL2 |
3.158e-02 | -3.46 | skin-back-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-back-malignant_melanoma-superficial_spreading | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | skin-hand-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-hand-malignant_melanoma-acral_lentiginous | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | EGF_3 | prosite domains | PS50026 | 196 | 3 | 12186 | 43 |
NRG3,PAMR1,NRXN1 |
3.184e-02 | -3.45 | sulfur amino acid transport | biological process | GO:0000101 | 12 | 1 | 18204 | 49 |
SLC1A2 |
3.184e-02 | -3.45 | positive regulation of extrinsic apoptotic signaling pathway via death domain receptors | biological process | GO:1902043 | 12 | 1 | 18204 | 49 |
BMPR1B |
3.184e-02 | -3.45 | microglia differentiation | biological process | GO:0014004 | 12 | 1 | 18204 | 49 |
QKI |
3.184e-02 | -3.45 | mammalian oogenesis stage | biological process | GO:0022605 | 12 | 1 | 18204 | 49 |
BMPR1B |
3.193e-02 | -3.44 | MAD_homology1_Dwarfin-type | interpro domains | IPR003619 | 12 | 1 | 18521 | 50 |
NFIA |
3.193e-02 | -3.44 | TGFB_receptor | interpro domains | IPR000333 | 12 | 1 | 18521 | 50 |
BMPR1B |
3.200e-02 | -3.44 | MIR34B (microRNA 34b) | protein interactions | 407041 | 109 | 2 | 19454 | 50 |
QKI,MSI2 |
3.204e-02 | -3.44 | human chr9q21.33 | chromosome location | human chr9q21.33 | 17 | 1 | 26134 | 50 |
NTRK2 |
3.207e-02 | -3.44 | bile_duct | COSMIC cancer mutations | bile_duct | 15095 | 48 | 16828 | 49 |
NTM,MAML2,SFXN5,MSI2,RANBP3L,PCDH9,NRG3,NTRK2,PREX2,SOX5,SLC4A4,QKI,TNIK,GPC5,SLC1A2,SPARCL1,GPM6A,NRXN1,RORA,AHCYL2,PITPNC1,BMPR1B,PARD3,TRPS1,ABLIM1,CADM1,MEIS2,MACF1,ITPR2,NFIA,RYR3,GLIS3,NPAS3,ZNRF3,LSAMP,SLC1A3,FBXL7,CTNND2,ATP1A2,PARD3B,CDH20,NEBL,DTNA,PTPRZ1,NHSL1,ATP13A4,PAMR1,ZBTB20 |
3.207e-02 | -3.44 | biliary_tract-bile_duct-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-bile_duct-carcinoma-adenocarcinoma | 15095 | 48 | 16828 | 49 |
PARD3,BMPR1B,ABLIM1,TRPS1,NRXN1,GPM6A,SPARCL1,RORA,PITPNC1,AHCYL2,SLC4A4,PREX2,SOX5,SLC1A2,GPC5,TNIK,QKI,RANBP3L,MAML2,NTM,MSI2,SFXN5,NTRK2,NRG3,PCDH9,PTPRZ1,NEBL,CDH20,DTNA,PAMR1,ZBTB20,ATP13A4,NHSL1,SLC1A3,LSAMP,FBXL7,PARD3B,ATP1A2,CTNND2,ZNRF3,MEIS2,CADM1,NPAS3,RYR3,GLIS3,NFIA,ITPR2,MACF1 |
3.247e-02 | -3.43 | VHP | smart domains | SM00153 | 8 | 1 | 9717 | 40 |
ABLIM1 |
3.250e-02 | -3.43 | DNA-binding transcription repressor activity, RNA polymerase II-specific | molecular function | GO:0001227 | 263 | 3 | 18094 | 48 |
ZBTB20,TRPS1,GLIS3 |
3.254e-02 | -3.43 | LZTR1 (leucine zipper like post translational regulator 1) | protein interactions | 8216 | 110 | 2 | 19454 | 50 |
PARD3B,BMPR1B |
3.256e-02 | -3.42 | MH1 | pfam domains | PF03165 | 12 | 1 | 17795 | 49 |
NFIA |
3.271e-02 | -3.42 | RDX (radixin) | protein interactions | 5962 | 272 | 3 | 19454 | 50 |
ABLIM1,NEBL,MACF1 |
3.275e-02 | -3.42 | regulation of plasma membrane bounded cell projection organization | biological process | GO:0120035 | 666 | 5 | 18204 | 49 |
TNIK,CTNNA2,NTRK2,MACF1,GPM6A |
3.276e-02 | -3.42 | steroid binding | molecular function | GO:0005496 | 107 | 2 | 18094 | 48 |
ATP1A2,RORA |
3.279e-02 | -3.42 | large_intestine-colon-carcinoma | COSMIC cancer mutations | large_intestine-colon-carcinoma | 2612 | 13 | 16828 | 49 |
PREX2,PARD3,PTPRZ1,TRPS1,GPC5,NRXN1,SLC1A3,ITPR2,MACF1,PCDH9,AHCYL2,NRG3,RORA |
3.281e-02 | -3.42 | distal axon | cellular component | GO:0150034 | 273 | 3 | 19108 | 49 |
PCDH9,GPM6A,NTRK2 |
3.291e-02 | -3.41 | PCDHA2 (protocadherin alpha 2) | protein interactions | 56146 | 13 | 1 | 19454 | 50 |
NFIA |
3.291e-02 | -3.41 | TBCC (tubulin folding cofactor C) | protein interactions | 6903 | 13 | 1 | 19454 | 50 |
NTM |
3.291e-02 | -3.41 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 50 |
GPM6A |
3.291e-02 | -3.41 | PLPPR4 (phospholipid phosphatase related 4) | protein interactions | 9890 | 13 | 1 | 19454 | 50 |
ZNRF3 |
3.291e-02 | -3.41 | JAM2 (junctional adhesion molecule 2) | protein interactions | 58494 | 13 | 1 | 19454 | 50 |
PARD3 |
3.291e-02 | -3.41 | MYO16 (myosin XVI) | protein interactions | 23026 | 13 | 1 | 19454 | 50 |
NRXN1 |
3.291e-02 | -3.41 | MAB21L1 (mab-21 like 1) | protein interactions | 4081 | 13 | 1 | 19454 | 50 |
MEIS2 |
3.291e-02 | -3.41 | Rbm47 (RNA binding motif protein 47) | protein interactions | 245945 | 13 | 1 | 19454 | 50 |
QKI |
3.302e-02 | -3.41 | FLOT2 (flotillin 2) | protein interactions | 2319 | 273 | 3 | 19454 | 50 |
NTRK2,PARD3,SOX5 |
3.361e-02 | -3.39 | Notch-HLH transcription pathway | REACTOME pathways | R-HSA-350054 | 13 | 1 | 10285 | 27 |
MAML2 |
3.361e-02 | -3.39 | CLEC7A (Dectin-1) induces NFAT activation | REACTOME pathways | R-HSA-5607763 | 13 | 1 | 10285 | 27 |
ITPR2 |
3.361e-02 | -3.39 | ERBB2 Activates PTK6 Signaling | REACTOME pathways | R-HSA-8847993 | 13 | 1 | 10285 | 27 |
NRG3 |
3.361e-02 | -3.39 | NOTCH2 intracellular domain regulates transcription | REACTOME pathways | R-HSA-2197563 | 13 | 1 | 10285 | 27 |
MAML2 |
3.363e-02 | -3.39 | CEP170P1 (centrosomal protein 170 pseudogene 1) | protein interactions | 645455 | 112 | 2 | 19454 | 50 |
TRPS1,MACF1 |
3.387e-02 | -3.39 | skin-arm-malignant_melanoma | COSMIC cancer mutations | skin-arm-malignant_melanoma | 1308 | 8 | 16828 | 49 |
ATP1A2,MACF1,TRPS1,PARD3B,ZBTB20,NPAS3,NTM,SLC4A4 |
3.389e-02 | -3.38 | human chr18q21.33 | chromosome location | human chr18q21.33 | 18 | 1 | 26134 | 50 |
CDH20 |
3.389e-02 | -3.38 | human chr7q31.32 | chromosome location | human chr7q31.32 | 18 | 1 | 26134 | 50 |
PTPRZ1 |
3.395e-02 | -3.38 | monoatomic cation:bicarbonate symporter activity | molecular function | GO:0140410 | 13 | 1 | 18094 | 48 |
SLC4A4 |
3.395e-02 | -3.38 | transforming growth factor beta receptor activity | molecular function | GO:0005024 | 13 | 1 | 18094 | 48 |
BMPR1B |
3.395e-02 | -3.38 | potassium ion binding | molecular function | GO:0030955 | 13 | 1 | 18094 | 48 |
ATP1A2 |
3.418e-02 | -3.38 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 2081 | 11 | 16828 | 49 |
NFIA,TNIK,NTRK2,TRPS1,ATP1A2,SLC4A4,PTPRZ1,PREX2,BMPR1B,DTNA,SOX5 |
3.418e-02 | -3.38 | GFI1B (growth factor independent 1B transcriptional repressor) | protein interactions | 8328 | 113 | 2 | 19454 | 50 |
DTNA,ZNRF3 |
3.425e-02 | -3.37 | ZDHHC17 (zinc finger DHHC-type palmitoyltransferase 17) | protein interactions | 23390 | 277 | 3 | 19454 | 50 |
SLC1A3,NEBL,GPM6A |
3.427e-02 | -3.37 | adrenal_gland | COSMIC cancer mutations | adrenal_gland | 2628 | 13 | 16828 | 49 |
PCDH9,CTNND2,ATP1A2,NRG3,NTRK2,MAML2,MEIS2,NHSL1,ZBTB20,SLC1A2,SOX5,PTPRZ1,ZNRF3 |
3.435e-02 | -3.37 | LIM | smart domains | SM00132 | 71 | 2 | 9717 | 40 |
ABLIM1,NEBL |
3.439e-02 | -3.37 | regulation of canonical Wnt signaling pathway | biological process | GO:0060828 | 265 | 3 | 18204 | 49 |
CTNND2,GPC5,ZNRF3 |
3.440e-02 | -3.37 | central_nervous_system-fourth_ventricle-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-fourth_ventricle-glioma-astrocytoma_Grade_I | 12 | 1 | 16828 | 49 |
QKI |
3.440e-02 | -3.37 | skin-abdomen-malignant_melanoma-nodular | COSMIC cancer mutations | skin-abdomen-malignant_melanoma-nodular | 12 | 1 | 16828 | 49 |
PREX2 |
3.440e-02 | -3.37 | DNA-binding transcription factor activity | molecular function | GO:0003700 | 1441 | 8 | 18094 | 48 |
NFIA,ZBTB20,MEIS2,GLIS3,TRPS1,RORA,NPAS3,SOX5 |
3.443e-02 | -3.37 | positive regulation of cell development | biological process | GO:0010720 | 458 | 4 | 18204 | 49 |
MACF1,PTPRZ1,NTRK2,QKI |
3.444e-02 | -3.37 | prepulse inhibition | biological process | GO:0060134 | 13 | 1 | 18204 | 49 |
CTNNA2 |
3.444e-02 | -3.37 | regulation of respiratory gaseous exchange by nervous system process | biological process | GO:0002087 | 13 | 1 | 18204 | 49 |
ATP1A2 |
3.444e-02 | -3.37 | ectodermal placode development | biological process | GO:0071696 | 13 | 1 | 18204 | 49 |
NRG3 |
3.444e-02 | -3.37 | glial cell fate commitment | biological process | GO:0021781 | 13 | 1 | 18204 | 49 |
NFIA |
3.444e-02 | -3.37 | postsynaptic specialization assembly | biological process | GO:0098698 | 13 | 1 | 18204 | 49 |
NRXN1 |
3.444e-02 | -3.37 | cerebellar Purkinje cell differentiation | biological process | GO:0021702 | 13 | 1 | 18204 | 49 |
RORA |
3.444e-02 | -3.37 | T-helper 17 cell differentiation | biological process | GO:0072539 | 13 | 1 | 18204 | 49 |
RORA |
3.444e-02 | -3.37 | negative regulation of cytosolic calcium ion concentration | biological process | GO:0051481 | 13 | 1 | 18204 | 49 |
ATP1A2 |
3.457e-02 | -3.36 | ErbB receptor signaling network | Pathway Interaction DB | erbb_network_pathway | 13 | 1 | 2226 | 6 |
NRG3 |
3.459e-02 | -3.36 | small molecule binding | molecular function | GO:0036094 | 6197 | 23 | 18094 | 48 |
TRPS1,NRXN1,ATP1A2,RORA,ZNRF3,BMPR1B,ABLIM1,PCDH9,NTRK2,SPARCL1,PARD3,SLC1A3,PITPNC1,ZBTB20,DTNA,ITPR2,SLC1A2,PAMR1,TNIK,MACF1,RYR3,GLIS3,ATP13A4 |
3.481e-02 | -3.36 | postsynapse organization | biological process | GO:0099173 | 109 | 2 | 18204 | 49 |
NRXN1,CTNND2 |
3.500e-02 | -3.35 | Ion_trans_dom | interpro domains | IPR005821 | 109 | 2 | 18521 | 50 |
RYR3,ITPR2 |
3.500e-02 | -3.35 | Cadherin_CS | interpro domains | IPR020894 | 109 | 2 | 18521 | 50 |
PCDH9,CDH20 |
3.501e-02 | -3.35 | lower_third | COSMIC cancer mutations | lower_third | 7961 | 30 | 16828 | 49 |
PREX2,SOX5,ZNRF3,SLC4A4,QKI,GPC5,CADM1,MEIS2,RANBP3L,PCDH9,ITPR2,MACF1,NPAS3,RYR3,NTRK2,NRG3,NEBL,CDH20,PARD3,PTPRZ1,ATP13A4,TRPS1,ZBTB20,PAMR1,NRXN1,ATP1A2,CTNND2,RORA,PARD3B,AHCYL2 |
3.530e-02 | -3.34 | TBXT (T-box transcription factor T) | protein interactions | 6862 | 115 | 2 | 19454 | 50 |
NFIA,TRPS1 |
3.530e-02 | -3.34 | DTNA (dystrobrevin alpha) | protein interactions | 1837 | 115 | 2 | 19454 | 50 |
NTRK2,PARD3 |
3.530e-02 | -3.34 | CDH2 (cadherin 2) | protein interactions | 1000 | 115 | 2 | 19454 | 50 |
PARD3,CTNND2 |
3.537e-02 | -3.34 | protein localization to membrane | biological process | GO:0072657 | 462 | 4 | 18204 | 49 |
TNIK,NRXN1,MACF1,PARD3 |
3.538e-02 | -3.34 | DNA-binding transcription repressor activity | molecular function | GO:0001217 | 272 | 3 | 18094 | 48 |
ZBTB20,TRPS1,GLIS3 |
3.539e-02 | -3.34 | positive regulation of cell junction assembly | biological process | GO:1901890 | 110 | 2 | 18204 | 49 |
NRXN1,NTRK2 |
3.539e-02 | -3.34 | HRAS (HRas proto-oncogene, GTPase) | protein interactions | 3265 | 712 | 5 | 19454 | 50 |
PARD3,CADM1,PCDH9,SLC1A3,TNIK |
3.540e-02 | -3.34 | PLXNA4 (plexin A4) | protein interactions | 91584 | 14 | 1 | 19454 | 50 |
GPM6A |
3.540e-02 | -3.34 | SYT5 (synaptotagmin 5) | protein interactions | 6861 | 14 | 1 | 19454 | 50 |
NRXN1 |
3.540e-02 | -3.34 | RHEBL1 (RHEB like 1) | protein interactions | 121268 | 14 | 1 | 19454 | 50 |
BMPR1B |
3.540e-02 | -3.34 | KRTAP22-1 (keratin associated protein 22-1) | protein interactions | 337979 | 14 | 1 | 19454 | 50 |
MEIS2 |
3.540e-02 | -3.34 | VSX2 (visual system homeobox 2) | protein interactions | 338917 | 14 | 1 | 19454 | 50 |
AHCYL2 |
3.540e-02 | -3.34 | MB (myoglobin) | protein interactions | 4151 | 14 | 1 | 19454 | 50 |
MAML2 |
3.540e-02 | -3.34 | SLC1A2 (solute carrier family 1 member 2) | protein interactions | 6506 | 14 | 1 | 19454 | 50 |
SLC1A2 |
3.540e-02 | -3.34 | Asap1 (ArfGAP with SH3 domain, ankyrin repeat and PH domain1) | protein interactions | 13196 | 14 | 1 | 19454 | 50 |
MACF1 |
3.540e-02 | -3.34 | DACT2 (dishevelled binding antagonist of beta catenin 2) | protein interactions | 168002 | 14 | 1 | 19454 | 50 |
ZBTB20 |
3.540e-02 | -3.34 | RSPO1 (R-spondin 1) | protein interactions | 284654 | 14 | 1 | 19454 | 50 |
ZNRF3 |
3.540e-02 | -3.34 | Nedd4 (neural precursor cell expressed, developmentally down-regulated 4) | protein interactions | 17999 | 14 | 1 | 19454 | 50 |
GLIS3 |
3.561e-02 | -3.34 | regulation of membrane potential | biological process | GO:0042391 | 463 | 4 | 18204 | 49 |
SLC4A4,NTRK2,NRXN1,ATP1A2 |
3.574e-02 | -3.33 | human chr6q24.1 | chromosome location | human chr6q24.1 | 19 | 1 | 26134 | 50 |
NHSL1 |
3.574e-02 | -3.33 | human chr11q25 | chromosome location | human chr11q25 | 19 | 1 | 26134 | 50 |
NTM |
3.574e-02 | -3.33 | human chr5p15.2 | chromosome location | human chr5p15.2 | 19 | 1 | 26134 | 50 |
CTNND2 |
3.579e-02 | -3.33 | HCO3TRNSPORT | prints domains | PR01231 | 10 | 1 | 5227 | 19 |
SLC4A4 |
3.581e-02 | -3.33 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | 249 | 3 | 16828 | 49 |
MACF1,PTPRZ1,GLIS3 |
3.586e-02 | -3.33 | SKIL (SKI like proto-oncogene) | protein interactions | 6498 | 116 | 2 | 19454 | 50 |
SPARCL1,MACF1 |
3.590e-02 | -3.33 | Alpha-catenin/vinculin-like | gene3d domains | 1.20.120.230 | 12 | 1 | 14470 | 44 |
CTNNA2 |
3.592e-02 | -3.33 | PRKACA (protein kinase cAMP-activated catalytic subunit alpha) | protein interactions | 5566 | 486 | 4 | 19454 | 50 |
PARD3,SLC4A4,ITPR2,TNIK |
3.593e-02 | -3.33 | regulation of cell projection organization | biological process | GO:0031344 | 683 | 5 | 18204 | 49 |
TNIK,CTNNA2,NTRK2,MACF1,GPM6A |
3.604e-02 | -3.32 | rhythmic process | biological process | GO:0048511 | 270 | 3 | 18204 | 49 |
NTRK2,RORA,BMPR1B |
3.615e-02 | -3.32 | SHC1 events in ERBB4 signaling | REACTOME pathways | R-HSA-1250347 | 14 | 1 | 10285 | 27 |
NRG3 |
3.615e-02 | -3.32 | DCC mediated attractive signaling | REACTOME pathways | R-HSA-418885 | 14 | 1 | 10285 | 27 |
ABLIM1 |
3.617e-02 | -3.32 | small_intestine | COSMIC cancer mutations | small_intestine | 250 | 3 | 16828 | 49 |
TNIK,ZNRF3,MACF1 |
3.619e-02 | -3.32 | cell migration | biological process | GO:0016477 | 921 | 6 | 18204 | 49 |
GPC5,NRG3,CDH20,CTNNA2,NTRK2,GPM6A |
3.627e-02 | -3.32 | Ion_trans | pfam domains | PF00520 | 109 | 2 | 17795 | 49 |
RYR3,ITPR2 |
3.635e-02 | -3.31 | YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) | protein interactions | 7529 | 965 | 6 | 19454 | 50 |
PARD3B,MACF1,ABLIM1,NHSL1,PITPNC1,PARD3 |
3.642e-02 | -3.31 | ELK3 (ETS transcription factor ELK3) | protein interactions | 2004 | 117 | 2 | 19454 | 50 |
TRPS1,NFIA |
3.642e-02 | -3.31 | SYT6 (synaptotagmin 6) | protein interactions | 148281 | 117 | 2 | 19454 | 50 |
NRXN1,AHCYL2 |
3.646e-02 | -3.31 | skin-scalp-malignant_melanoma | COSMIC cancer mutations | skin-scalp-malignant_melanoma | 634 | 5 | 16828 | 49 |
PREX2,NTM,NEBL,NFIA,PTPRZ1 |
3.646e-02 | -3.31 | FOLN | smart domains | SM00274 | 9 | 1 | 9717 | 40 |
SPARCL1 |
3.652e-02 | -3.31 | microtubule minus-end binding | molecular function | GO:0051011 | 14 | 1 | 18094 | 48 |
MACF1 |
3.657e-02 | -3.31 | regulation of gliogenesis | biological process | GO:0014013 | 112 | 2 | 18204 | 49 |
PTPRZ1,QKI |
3.699e-02 | -3.30 | PLCD3 (phospholipase C delta 3) | protein interactions | 113026 | 118 | 2 | 19454 | 50 |
TNIK,AHCYL2 |
3.702e-02 | -3.30 | arm | COSMIC cancer mutations | arm | 1331 | 8 | 16828 | 49 |
NTM,SLC4A4,ATP1A2,MACF1,TRPS1,PARD3B,ZBTB20,NPAS3 |
3.704e-02 | -3.30 | glutathione biosynthetic process | biological process | GO:0006750 | 14 | 1 | 18204 | 49 |
SLC1A2 |
3.704e-02 | -3.30 | cellular response to ethanol | biological process | GO:0071361 | 14 | 1 | 18204 | 49 |
ITPR2 |
3.704e-02 | -3.30 | relaxation of cardiac muscle | biological process | GO:0055119 | 14 | 1 | 18204 | 49 |
ATP1A2 |
3.704e-02 | -3.30 | positive regulation of myoblast proliferation | biological process | GO:2000288 | 14 | 1 | 18204 | 49 |
MEIS2 |
3.704e-02 | -3.30 | cellular response to purine-containing compound | biological process | GO:0071415 | 14 | 1 | 18204 | 49 |
RYR3 |
3.704e-02 | -3.30 | negative regulation of sodium ion transmembrane transporter activity | biological process | GO:2000650 | 14 | 1 | 18204 | 49 |
ATP1A2 |
3.721e-02 | -3.29 | central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_I | 13 | 1 | 16828 | 49 |
QKI |
3.721e-02 | -3.29 | skin-shoulder-malignant_melanoma-nodular | COSMIC cancer mutations | skin-shoulder-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | skin-scalp-malignant_melanoma-nodular | COSMIC cancer mutations | skin-scalp-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.729e-02 | -3.29 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 13 | 16828 | 49 |
ZNRF3,PTPRZ1,PREX2,PARD3B,NPAS3,RORA,RYR3,GLIS3,NFIA,CTNND2,MACF1,MAML2,SPARCL1 |
3.729e-02 | -3.29 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 13 | 16828 | 49 |
PREX2,PTPRZ1,ZNRF3,SPARCL1,MAML2,MACF1,CTNND2,PARD3B,NFIA,RYR3,NPAS3,RORA,GLIS3 |
3.754e-02 | -3.28 | basal plasma membrane | cellular component | GO:0009925 | 288 | 3 | 19108 | 49 |
SLC1A3,SLC4A4,CADM1 |
3.756e-02 | -3.28 | ANKRD26 (ankyrin repeat domain containing 26) | protein interactions | 22852 | 119 | 2 | 19454 | 50 |
PARD3,NTRK2 |
3.764e-02 | -3.28 | Levobupivacaine Action Pathway | SMPDB pathways | SMP0000397 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Proparacaine Action Pathway | SMPDB pathways | SMP0000403 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Hydromorphone Action Pathway | SMPDB pathways | SMP0000410 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Buprenorphine Action Pathway | SMPDB pathways | SMP0000684 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Diphenoxylate Action Pathway | SMPDB pathways | SMP0000675 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Oxybuprocaine Action Pathway | SMPDB pathways | SMP0000400 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Alfentanil Action Pathway | SMPDB pathways | SMP0000413 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Mepivacaine Action Pathway | SMPDB pathways | SMP0000399 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Anileridine Action Pathway | SMPDB pathways | SMP0000674 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Alvimopan Action Pathway | SMPDB pathways | SMP0000685 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Tramadol Action Action Pathway | SMPDB pathways | SMP0000671 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Oxycodone Action Pathway | SMPDB pathways | SMP0000409 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Pentazocine Action Pathway | SMPDB pathways | SMP0000686 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Ethylmorphine Action Pathway | SMPDB pathways | SMP0000681 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Propoxyphene Action Pathway | SMPDB pathways | SMP0000672 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Escitalopram Action Pathway | SMPDB pathways | SMP0000425 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Ketobemidone Action Pathway | SMPDB pathways | SMP0000690 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Bupivacaine Action Pathway | SMPDB pathways | SMP0000393 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Dezocine Action Pathway | SMPDB pathways | SMP0000676 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Sufentanil Action Pathway | SMPDB pathways | SMP0000417 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Dihydromorphine Action Pathway | SMPDB pathways | SMP0000689 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Remifentanil Action Pathway | SMPDB pathways | SMP0000416 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Levomethadyl Acetate Action Action Pathway | SMPDB pathways | SMP0000677 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Oxymorphone Action Pathway | SMPDB pathways | SMP0000412 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Cocaine Action Pathway | SMPDB pathways | SMP0000395 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Procaine Action Pathway | SMPDB pathways | SMP0000402 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Naltrexone Action Pathway | SMPDB pathways | SMP0000687 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | 3-Methylthiofentanyl Action Pathway | SMPDB pathways | SMP0000679 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Chloroprocaine Action Pathway | SMPDB pathways | SMP0000394 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Prilocaine Action Pathway | SMPDB pathways | SMP0000401 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Hydrocodone Action Pathway | SMPDB pathways | SMP0000411 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Carfentanil Action Pathway | SMPDB pathways | SMP0000414 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Levallorphan Action Pathway | SMPDB pathways | SMP0000683 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Methadyl Acetate Action Pathway | SMPDB pathways | SMP0000678 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Ropivacaine Action Pathway | SMPDB pathways | SMP0000404 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Dimethylthiambutene Action Pathway | SMPDB pathways | SMP0000680 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Benzocaine Action Pathway | SMPDB pathways | SMP0000392 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Naloxone Action Pathway | SMPDB pathways | SMP0000688 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Fentanyl Action Pathway | SMPDB pathways | SMP0000415 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Levorphanol Action Pathway | SMPDB pathways | SMP0000673 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Dibucaine Action Pathway | SMPDB pathways | SMP0000396 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.777e-02 | -3.28 | VASP (vasodilator stimulated phosphoprotein) | protein interactions | 7408 | 288 | 3 | 19454 | 50 |
PARD3,NHSL1,NEBL |
3.779e-02 | -3.28 | Bone Morphogenic Protein (BMP) Signalling and Regulation | WikiPathways | WP1425 | 12 | 1 | 5310 | 17 |
BMPR1B |
3.779e-02 | -3.28 | MFAP5-mediated ovarian cancer cell motility and invasiveness | WikiPathways | WP3301 | 12 | 1 | 5310 | 17 |
RYR3 |
3.780e-02 | -3.28 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 49 |
SLC1A2 |
3.788e-02 | -3.27 | TAFA5 (TAFA chemokine like family member 5) | protein interactions | 25817 | 15 | 1 | 19454 | 50 |
NEBL |
3.788e-02 | -3.27 | XIRP1 (xin actin binding repeat containing 1) | protein interactions | 165904 | 15 | 1 | 19454 | 50 |
NEBL |
3.788e-02 | -3.27 | TESPA1 (thymocyte expressed, positive selection associated 1) | protein interactions | 9840 | 15 | 1 | 19454 | 50 |
ITPR2 |
3.788e-02 | -3.27 | IGSF1 (immunoglobulin superfamily member 1) | protein interactions | 3547 | 15 | 1 | 19454 | 50 |
BMPR1B |
3.788e-02 | -3.27 | GATA | pfam domains | PF00320 | 14 | 1 | 17795 | 49 |
TRPS1 |
3.798e-02 | -3.27 | Cadherin-like_dom | interpro domains | IPR002126 | 114 | 2 | 18521 | 50 |
PCDH9,CDH20 |
3.811e-02 | -3.27 | Cadherin | pfam domains | PF00028 | 112 | 2 | 17795 | 49 |
CDH20,PCDH9 |
3.814e-02 | -3.27 | HOXB9 (homeobox B9) | protein interactions | 3219 | 120 | 2 | 19454 | 50 |
AHCYL2,NFIA |
3.815e-02 | -3.27 | RECEPTOR_TYR_KIN_II | prosite domains | PS00239 | 11 | 1 | 12186 | 43 |
NTRK2 |
3.815e-02 | -3.27 | GATA_ZN_FINGER_2 | prosite domains | PS50114 | 11 | 1 | 12186 | 43 |
TRPS1 |
3.815e-02 | -3.27 | RANBD1 | prosite domains | PS50196 | 11 | 1 | 12186 | 43 |
RANBP3L |
3.869e-02 | -3.25 | ERBB2 Regulates Cell Motility | REACTOME pathways | R-HSA-6785631 | 15 | 1 | 10285 | 27 |
NRG3 |
3.872e-02 | -3.25 | MED15 (mediator complex subunit 15) | protein interactions | 51586 | 121 | 2 | 19454 | 50 |
NFIA,QKI |
3.881e-02 | -3.25 | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 107 | 2 | 16828 | 49 |
NEBL,PARD3B |
3.894e-02 | -3.25 | localization | biological process | GO:0051179 | 4474 | 18 | 18204 | 49 |
QKI,RANBP3L,MACF1,SLC1A3,ATP13A4,PARD3B,TNIK,NRXN1,PITPNC1,SFXN5,NTRK2,ATP1A2,ITPR2,SLC4A4,RYR3,SLC1A2,PARD3,GPM6A |
3.900e-02 | -3.24 | germ_cell_tumour | COSMIC cancer mutations | germ_cell_tumour | 867 | 6 | 16828 | 49 |
TNIK,NTRK2,PREX2,BMPR1B,MACF1,TRPS1 |
3.907e-02 | -3.24 | Desipramine Action Pathway | SMPDB pathways | SMP0000423 | 27 | 1 | 1369 | 2 |
ATP1A2 |
3.907e-02 | -3.24 | Nalbuphine Action Pathway | SMPDB pathways | SMP0000691 | 27 | 1 | 1369 | 2 |
ATP1A2 |
3.908e-02 | -3.24 | phosphatidylglycerol binding | molecular function | GO:1901611 | 15 | 1 | 18094 | 48 |
PITPNC1 |
3.908e-02 | -3.24 | filamin binding | molecular function | GO:0031005 | 15 | 1 | 18094 | 48 |
NEBL |
3.908e-02 | -3.24 | tropomyosin binding | molecular function | GO:0005523 | 15 | 1 | 18094 | 48 |
NEBL |
3.914e-02 | -3.24 | skin-leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-leg-malignant_melanoma-nodular | 258 | 3 | 16828 | 49 |
ATP13A4,SLC4A4,PTPRZ1 |
3.920e-02 | -3.24 | Cadherin-like_sf | interpro domains | IPR015919 | 116 | 2 | 18521 | 50 |
PCDH9,CDH20 |
3.930e-02 | -3.24 | BRK1 (BRICK1 subunit of SCAR/WAVE actin nucleating complex) | protein interactions | 55845 | 122 | 2 | 19454 | 50 |
DTNA,NHSL1 |
3.943e-02 | -3.23 | human chr13q31.3 | chromosome location | human chr13q31.3 | 21 | 1 | 26134 | 50 |
GPC5 |
3.943e-02 | -3.23 | human chr10q23.1 | chromosome location | human chr10q23.1 | 21 | 1 | 26134 | 50 |
NRG3 |
3.947e-02 | -3.23 | pleura-pulmonary_blastoma | COSMIC cancer mutations | pleura-pulmonary_blastoma | 648 | 5 | 16828 | 49 |
TRPS1,ATP13A4,NEBL,BMPR1B,NTM |
3.947e-02 | -3.23 | testis-germ_cell_tumour-seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-seminoma | 648 | 5 | 16828 | 49 |
NTRK2,TNIK,BMPR1B,PREX2,TRPS1 |
3.947e-02 | -3.23 | pulmonary_blastoma | COSMIC cancer mutations | pulmonary_blastoma | 648 | 5 | 16828 | 49 |
ATP13A4,BMPR1B,NEBL,NTM,TRPS1 |
3.959e-02 | -3.23 | regulation of synapse assembly | biological process | GO:0051963 | 117 | 2 | 18204 | 49 |
NTRK2,NRXN1 |
3.964e-02 | -3.23 | cerebellar Purkinje cell layer formation | biological process | GO:0021694 | 15 | 1 | 18204 | 49 |
RORA |
3.964e-02 | -3.23 | neuroblast division | biological process | GO:0055057 | 15 | 1 | 18204 | 49 |
SOX5 |
3.964e-02 | -3.23 | regulation of neuron projection arborization | biological process | GO:0150011 | 15 | 1 | 18204 | 49 |
MACF1 |
3.964e-02 | -3.23 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 49 |
SLC1A2 |
3.964e-02 | -3.23 | response to caffeine | biological process | GO:0031000 | 15 | 1 | 18204 | 49 |
RYR3 |
3.964e-02 | -3.23 | peripheral nervous system neuron development | biological process | GO:0048935 | 15 | 1 | 18204 | 49 |
NTRK2 |
3.964e-02 | -3.23 | negative regulation of sodium ion transmembrane transport | biological process | GO:1902306 | 15 | 1 | 18204 | 49 |
ATP1A2 |
3.964e-02 | -3.23 | peripheral nervous system neuron differentiation | biological process | GO:0048934 | 15 | 1 | 18204 | 49 |
NTRK2 |
3.964e-02 | -3.23 | intracellular potassium ion homeostasis | biological process | GO:0030007 | 15 | 1 | 18204 | 49 |
ATP1A2 |
3.964e-02 | -3.23 | synapse maturation | biological process | GO:0060074 | 15 | 1 | 18204 | 49 |
NFIA |
3.964e-02 | -3.23 | exit from mitosis | biological process | GO:0010458 | 15 | 1 | 18204 | 49 |
NFIA |
3.964e-02 | -3.23 | sarcoplasmic reticulum calcium ion transport | biological process | GO:0070296 | 15 | 1 | 18204 | 49 |
RYR3 |
3.970e-02 | -3.23 | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 649 | 5 | 16828 | 49 |
TNIK,ABLIM1,MACF1,QKI,PREX2 |
3.975e-02 | -3.23 | Znf_GATA | interpro domains | IPR000679 | 15 | 1 | 18521 | 50 |
TRPS1 |
3.975e-02 | -3.23 | CNH_dom | interpro domains | IPR001180 | 15 | 1 | 18521 | 50 |
TNIK |
3.975e-02 | -3.23 | ATPase_P-typ_cation-transptr_C | interpro domains | IPR006068 | 15 | 1 | 18521 | 50 |
ATP1A2 |
3.977e-02 | -3.22 | KCNE3 (potassium voltage-gated channel subfamily E regulatory subunit 3) | protein interactions | 10008 | 294 | 3 | 19454 | 50 |
TNIK,PCDH9,ZNRF3 |
3.988e-02 | -3.22 | EF_HAND_2 | prosite domains | PS50222 | 215 | 3 | 12186 | 43 |
SPARCL1,RYR3,MACF1 |
3.988e-02 | -3.22 | PAX7 (paired box 7) | protein interactions | 5081 | 123 | 2 | 19454 | 50 |
NFIA,TRPS1 |
4.008e-02 | -3.22 | transcription cis-regulatory region binding | molecular function | GO:0000976 | 1485 | 8 | 18094 | 48 |
MEIS2,GLIS3,RORA,NFIA,ZBTB20,NPAS3,TRPS1,SOX5 |
4.027e-02 | -3.21 | postsynaptic density, intracellular component | cellular component | GO:0099092 | 16 | 1 | 19108 | 49 |
TNIK |
4.028e-02 | -3.21 | phospholipid binding | molecular function | GO:0005543 | 489 | 4 | 18094 | 48 |
PARD3B,PARD3,ITPR2,PITPNC1 |
4.035e-02 | -3.21 | transcription regulatory region nucleic acid binding | molecular function | GO:0001067 | 1487 | 8 | 18094 | 48 |
TRPS1,SOX5,MEIS2,GLIS3,RORA,NFIA,ZBTB20,NPAS3 |
4.035e-02 | -3.21 | FZD4 (frizzled class receptor 4) | protein interactions | 8322 | 16 | 1 | 19454 | 50 |
ZNRF3 |
4.035e-02 | -3.21 | SAPCD1 (suppressor APC domain containing 1) | protein interactions | 401251 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | SYT4 (synaptotagmin 4) | protein interactions | 6860 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | TWIST2 (twist family bHLH transcription factor 2) | protein interactions | 117581 | 16 | 1 | 19454 | 50 |
ZBTB20 |
4.035e-02 | -3.21 | Sumo3 (small ubiquitin-like modifier 3) | protein interactions | 20610 | 16 | 1 | 19454 | 50 |
ITPR2 |
4.035e-02 | -3.21 | CDH12 (cadherin 12) | protein interactions | 1010 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | GALNT13 (polypeptide N-acetylgalactosaminyltransferase 13) | protein interactions | 114805 | 16 | 1 | 19454 | 50 |
TNIK |
4.035e-02 | -3.21 | SYTL2 (synaptotagmin like 2) | protein interactions | 54843 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | CNTNAP2 (contactin associated protein 2) | protein interactions | 26047 | 16 | 1 | 19454 | 50 |
MACF1 |
4.035e-02 | -3.21 | VGLL1 (vestigial like family member 1) | protein interactions | 51442 | 16 | 1 | 19454 | 50 |
MEIS2 |
4.035e-02 | -3.21 | AMMECR1L (AMMECR1 like) | protein interactions | 83607 | 16 | 1 | 19454 | 50 |
MACF1 |
4.035e-02 | -3.21 | SYT9 (synaptotagmin 9) | protein interactions | 143425 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | FNDC8 (fibronectin type III domain containing 8) | protein interactions | 54752 | 16 | 1 | 19454 | 50 |
SPARCL1 |
4.050e-02 | -3.21 | Lidocaine (Local Anaesthetic) Action Pathway | SMPDB pathways | SMP0000398 | 28 | 1 | 1369 | 2 |
ATP1A2 |
4.053e-02 | -3.21 | CNH | pfam domains | PF00780 | 15 | 1 | 17795 | 49 |
TNIK |
4.053e-02 | -3.21 | Cation_ATPase_C | pfam domains | PF00689 | 15 | 1 | 17795 | 49 |
ATP1A2 |
4.065e-02 | -3.20 | membrane protein complex | cellular component | GO:0098796 | 1261 | 7 | 19108 | 49 |
ATP1A2,SLC1A3,SLC1A2,CDH20,CTNNA2,RYR3,BMPR1B |
4.079e-02 | -3.20 | TJP1 (tight junction protein 1) | protein interactions | 7082 | 297 | 3 | 19454 | 50 |
NEBL,DTNA,PARD3 |
4.087e-02 | -3.20 | Cell-type Dependent Selectivity of CCK2R Signaling | WikiPathways | WP3679 | 13 | 1 | 5310 | 17 |
RYR3 |
4.101e-02 | -3.19 | Ig-like_dom_sf | interpro domains | IPR036179 | 483 | 4 | 18521 | 50 |
NTRK2,CADM1,NTM,LSAMP |
4.112e-02 | -3.19 | export from cell | biological process | GO:0140352 | 485 | 4 | 18204 | 49 |
NRXN1,ATP1A2,NTRK2,SLC4A4 |
4.117e-02 | -3.19 | secondary active transmembrane transporter activity | molecular function | GO:0015291 | 289 | 3 | 18094 | 48 |
SLC4A4,SLC1A3,SLC1A2 |
4.121e-02 | -3.19 | breast-carcinoma-basal_(triple-negative)_carcinoma | COSMIC cancer mutations | breast-carcinoma-basal_(triple-negative)_carcinoma | 2981 | 14 | 16828 | 49 |
BMPR1B,NEBL,SLC4A4,PARD3,MSI2,MAML2,SPARCL1,NTM,MEIS2,ATP1A2,MACF1,NTRK2,NRG3,NPAS3 |
4.121e-02 | -3.19 | basal_(triple-negative)_carcinoma | COSMIC cancer mutations | basal_(triple-negative)_carcinoma | 2981 | 14 | 16828 | 49 |
SLC4A4,PARD3,NEBL,BMPR1B,MEIS2,MAML2,SPARCL1,NTM,MSI2,NPAS3,NTRK2,NRG3,ATP1A2,MACF1 |
4.122e-02 | -3.19 | GRB2 events in ERBB2 signaling | REACTOME pathways | R-HSA-1963640 | 16 | 1 | 10285 | 27 |
NRG3 |
4.122e-02 | -3.19 | PI3K events in ERBB2 signaling | REACTOME pathways | R-HSA-1963642 | 16 | 1 | 10285 | 27 |
NRG3 |
4.144e-02 | -3.18 | regulation of nervous system process | biological process | GO:0031644 | 120 | 2 | 18204 | 49 |
PARD3,NRXN1 |
4.148e-02 | -3.18 | bicellular tight junction | cellular component | GO:0005923 | 126 | 2 | 19108 | 49 |
PARD3B,PARD3 |
4.163e-02 | -3.18 | oxysterol binding | molecular function | GO:0008142 | 16 | 1 | 18094 | 48 |
RORA |
4.166e-02 | -3.18 | SYP (synaptophysin) | protein interactions | 6855 | 126 | 2 | 19454 | 50 |
PITPNC1,GPM6A |
4.193e-02 | -3.17 | Codeine Action Pathway | SMPDB pathways | SMP0000405 | 29 | 1 | 1369 | 2 |
ATP1A2 |
4.223e-02 | -3.16 | regulation of amino acid transmembrane transport | biological process | GO:1903789 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.223e-02 | -3.16 | S-adenosylmethionine metabolic process | biological process | GO:0046500 | 16 | 1 | 18204 | 49 |
AHCYL2 |
4.223e-02 | -3.16 | neuron cell-cell adhesion | biological process | GO:0007158 | 16 | 1 | 18204 | 49 |
NRXN1 |
4.223e-02 | -3.16 | regulation of respiratory system process | biological process | GO:0044065 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.223e-02 | -3.16 | regulation of amino acid import across plasma membrane | biological process | GO:0010958 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.223e-02 | -3.16 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.223e-02 | -3.16 | regulation of Wnt signaling pathway, planar cell polarity pathway | biological process | GO:2000095 | 16 | 1 | 18204 | 49 |
ZNRF3 |
4.223e-02 | -3.16 | nonribosomal peptide biosynthetic process | biological process | GO:0019184 | 16 | 1 | 18204 | 49 |
SLC1A2 |
4.223e-02 | -3.16 | non-proteinogenic amino acid biosynthetic process | biological process | GO:0170043 | 16 | 1 | 18204 | 49 |
SLC1A3 |
4.223e-02 | -3.16 | large_intestine-adenoma | COSMIC cancer mutations | large_intestine-adenoma | 266 | 3 | 16828 | 49 |
CDH20,SOX5,RYR3 |
4.250e-02 | -3.16 | lung-middle_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-middle_lobe-carcinoma-adenocarcinoma | 1368 | 8 | 16828 | 49 |
PARD3B,RYR3,ITPR2,ATP1A2,MACF1,CTNND2,PCDH9,ATP13A4 |
4.267e-02 | -3.15 | neuron projection terminus | cellular component | GO:0044306 | 128 | 2 | 19108 | 49 |
SLC1A2,NTRK2 |
4.271e-02 | -3.15 | muscle cell differentiation | biological process | GO:0042692 | 289 | 3 | 18204 | 49 |
QKI,NEBL,RORA |
4.282e-02 | -3.15 | hypothalamus | COSMIC cancer mutations | hypothalamus | 15 | 1 | 16828 | 49 |
QKI |
4.282e-02 | -3.15 | SEPSECS (Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase) | protein interactions | 51091 | 17 | 1 | 19454 | 50 |
ABLIM1 |
4.282e-02 | -3.15 | NOTCH4 (notch receptor 4) | protein interactions | 4855 | 17 | 1 | 19454 | 50 |
MAML2 |
4.282e-02 | -3.15 | Sqstm1 (sequestosome 1) | protein interactions | 18412 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | PAX4 (paired box 4) | protein interactions | 5078 | 17 | 1 | 19454 | 50 |
NTM |
4.282e-02 | -3.15 | Pef1 (penta-EF hand domain containing 1) | protein interactions | 67898 | 17 | 1 | 19454 | 50 |
QKI |
4.282e-02 | -3.15 | RASL12 (RAS like family 12) | protein interactions | 51285 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | MSANTD2 (Myb/SANT DNA binding domain containing 2) | protein interactions | 79684 | 17 | 1 | 19454 | 50 |
SOX5 |
4.282e-02 | -3.15 | Shcbp1 (Shc SH2-domain binding protein 1) | protein interactions | 20419 | 17 | 1 | 19454 | 50 |
GPC5 |
4.282e-02 | -3.15 | DPP6 (dipeptidyl peptidase like 6) | protein interactions | 1804 | 17 | 1 | 19454 | 50 |
GPM6A |
4.282e-02 | -3.15 | TAGAP (T cell activation RhoGTPase activating protein) | protein interactions | 117289 | 17 | 1 | 19454 | 50 |
DTNA |
4.286e-02 | -3.15 | SYT2 (synaptotagmin 2) | protein interactions | 127833 | 128 | 2 | 19454 | 50 |
AHCYL2,NRXN1 |
4.286e-02 | -3.15 | MYB (MYB proto-oncogene, transcription factor) | protein interactions | 4602 | 128 | 2 | 19454 | 50 |
TRPS1,NFIA |
4.286e-02 | -3.15 | TEAD2 (TEA domain transcription factor 2) | protein interactions | 8463 | 128 | 2 | 19454 | 50 |
TRPS1,ZBTB20 |
4.297e-02 | -3.15 | RAC1 (Rac family small GTPase 1) | protein interactions | 5879 | 1005 | 6 | 19454 | 50 |
MACF1,SLC1A3,DTNA,PREX2,PARD3,AHCYL2 |
4.321e-02 | -3.14 | CARM1 (coactivator associated arginine methyltransferase 1) | protein interactions | 10498 | 304 | 3 | 19454 | 50 |
QKI,DTNA,RORA |
4.336e-02 | -3.14 | Imipramine Action Pathway | SMPDB pathways | SMP0000422 | 30 | 1 | 1369 | 2 |
ATP1A2 |
4.346e-02 | -3.14 | CHD7 (chromodomain helicase DNA binding protein 7) | protein interactions | 55636 | 129 | 2 | 19454 | 50 |
SOX5,ZBTB20 |
4.350e-02 | -3.13 | cellular response to growth factor stimulus | biological process | GO:0071363 | 494 | 4 | 18204 | 49 |
BMPR1B,NTRK2,NFIA,SOX5 |
4.362e-02 | -3.13 | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 891 | 6 | 16828 | 49 |
SPARCL1,PTPRZ1,ITPR2,ATP1A2,NPAS3,ABLIM1 |
4.374e-02 | -3.13 | TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | REACTOME pathways | R-HSA-2173791 | 17 | 1 | 10285 | 27 |
PARD3 |
4.374e-02 | -3.13 | Elevation of cytosolic Ca2+ levels | REACTOME pathways | R-HSA-139853 | 17 | 1 | 10285 | 27 |
ITPR2 |
4.388e-02 | -3.13 | Z disc | cellular component | GO:0030018 | 130 | 2 | 19108 | 49 |
NEBL,RYR3 |
4.389e-02 | -3.13 | actin cytoskeleton | cellular component | GO:0015629 | 520 | 4 | 19108 | 49 |
CTNNA2,MACF1,ABLIM1,NEBL |
4.395e-02 | -3.12 | ERK Pathway in Huntington's Disease | WikiPathways | WP3853 | 14 | 1 | 5310 | 17 |
NTRK2 |
4.397e-02 | -3.12 | action potential | biological process | GO:0001508 | 124 | 2 | 18204 | 49 |
NTRK2,ATP1A2 |
4.400e-02 | -3.12 | basal part of cell | cellular component | GO:0045178 | 307 | 3 | 19108 | 49 |
SLC4A4,SLC1A3,CADM1 |
4.407e-02 | -3.12 | DVL1 (dishevelled segment polarity protein 1) | protein interactions | 1855 | 130 | 2 | 19454 | 50 |
PARD3,ZNRF3 |
4.417e-02 | -3.12 | transmembrane receptor protein tyrosine phosphatase activity | molecular function | GO:0005001 | 17 | 1 | 18094 | 48 |
PTPRZ1 |
4.417e-02 | -3.12 | transmembrane receptor protein phosphatase activity | molecular function | GO:0019198 | 17 | 1 | 18094 | 48 |
PTPRZ1 |
4.424e-02 | -3.12 | Ig-like_fold | interpro domains | IPR013783 | 721 | 5 | 18521 | 50 |
LSAMP,NTRK2,PTPRZ1,NTM,CADM1 |
4.438e-02 | -3.11 | RanBD | smart domains | SM00160 | 11 | 1 | 9717 | 40 |
RANBP3L |
4.449e-02 | -3.11 | tight junction | cellular component | GO:0070160 | 131 | 2 | 19108 | 49 |
PARD3B,PARD3 |
4.468e-02 | -3.11 | ZNF609 (zinc finger protein 609) | protein interactions | 23060 | 131 | 2 | 19454 | 50 |
SOX5,NFIA |
4.468e-02 | -3.11 | TRPS1 (transcriptional repressor GATA binding 1) | protein interactions | 7227 | 131 | 2 | 19454 | 50 |
NFIA,SOX5 |
4.468e-02 | -3.11 | NCOA2 (nuclear receptor coactivator 2) | protein interactions | 10499 | 131 | 2 | 19454 | 50 |
RORA,NFIA |
4.472e-02 | -3.11 | middle_lobe | COSMIC cancer mutations | middle_lobe | 1382 | 8 | 16828 | 49 |
PARD3B,RYR3,MACF1,CTNND2,ITPR2,ATP1A2,PCDH9,ATP13A4 |
4.479e-02 | -3.11 | Fluoxetine Action Pathway | SMPDB pathways | SMP0000426 | 31 | 1 | 1369 | 2 |
ATP1A2 |
4.481e-02 | -3.11 | cell population proliferation | biological process | GO:0008283 | 726 | 5 | 18204 | 49 |
SOX5,NFIA,CADM1,ZNRF3,RORA |
4.481e-02 | -3.11 | retinal rod cell differentiation | biological process | GO:0060221 | 17 | 1 | 18204 | 49 |
NTRK2 |
4.481e-02 | -3.11 | cell communication by electrical coupling involved in cardiac conduction | biological process | GO:0086064 | 17 | 1 | 18204 | 49 |
ATP1A2 |
4.481e-02 | -3.11 | cGMP metabolic process | biological process | GO:0046068 | 17 | 1 | 18204 | 49 |
RORA |
4.481e-02 | -3.11 | membrane depolarization during cardiac muscle cell action potential | biological process | GO:0086012 | 17 | 1 | 18204 | 49 |
ATP1A2 |
4.481e-02 | -3.11 | ureter development | biological process | GO:0072189 | 17 | 1 | 18204 | 49 |
NFIA |
4.481e-02 | -3.11 | microvillus assembly | biological process | GO:0030033 | 17 | 1 | 18204 | 49 |
TNIK |
4.481e-02 | -3.11 | cellular response to ATP | biological process | GO:0071318 | 17 | 1 | 18204 | 49 |
RYR3 |
4.481e-02 | -3.11 | cell migration in hindbrain | biological process | GO:0021535 | 17 | 1 | 18204 | 49 |
CTNNA2 |
4.481e-02 | -3.11 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 49 |
SLC1A2 |
4.481e-02 | -3.11 | T-helper 17 type immune response | biological process | GO:0072538 | 17 | 1 | 18204 | 49 |
RORA |
4.481e-02 | -3.11 | viral genome replication | biological process | GO:0019079 | 17 | 1 | 18204 | 49 |
NFIA |
4.481e-02 | -3.11 | T cell mediated cytotoxicity | biological process | GO:0001913 | 17 | 1 | 18204 | 49 |
CADM1 |
4.493e-02 | -3.10 | CA_dom | interpro domains | IPR001148 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.493e-02 | -3.10 | CA_dom_sf | interpro domains | IPR036398 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.507e-02 | -3.10 | ductal_carcinoma | COSMIC cancer mutations | ductal_carcinoma | 15798 | 49 | 16828 | 49 |
TRPS1,ABLIM1,BMPR1B,PARD3,RORA,AHCYL2,PITPNC1,SPARCL1,GPM6A,NKAIN3,NRXN1,QKI,TNIK,GPC5,SLC1A2,PREX2,SOX5,SLC4A4,PCDH9,NRG3,NTRK2,NTM,MAML2,SFXN5,MSI2,RANBP3L,NHSL1,ATP13A4,PAMR1,ZBTB20,NEBL,CDH20,DTNA,PTPRZ1,CTNND2,ATP1A2,PARD3B,LSAMP,SLC1A3,FBXL7,ZNRF3,MACF1,ITPR2,NFIA,NPAS3,RYR3,GLIS3,CADM1,MEIS2 |
4.529e-02 | -3.09 | NKIRAS1 (NFKB inhibitor interacting Ras like 1) | protein interactions | 28512 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | Cnot2 (CCR4-NOT transcription complex, subunit 2) | protein interactions | 72068 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | KLHL1 (kelch like family member 1) | protein interactions | 57626 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | NECTIN1 (nectin cell adhesion molecule 1) | protein interactions | 5818 | 18 | 1 | 19454 | 50 |
PARD3 |
4.529e-02 | -3.09 | ACAP1 (ArfGAP with coiled-coil, ankyrin repeat and PH domains 1) | protein interactions | 9744 | 18 | 1 | 19454 | 50 |
NEBL |
4.529e-02 | -3.09 | TTC29 (tetratricopeptide repeat domain 29) | protein interactions | 83894 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | OPCML (opioid binding protein/cell adhesion molecule like) | protein interactions | 4978 | 18 | 1 | 19454 | 50 |
NTM |
4.529e-02 | -3.09 | Tgfbr1 (transforming growth factor, beta receptor I) | protein interactions | 21812 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.569e-02 | -3.09 | muscle system process | biological process | GO:0003012 | 297 | 3 | 18204 | 49 |
DTNA,RYR3,ATP1A2 |
4.581e-02 | -3.08 | ZZ | pfam domains | PF00569 | 17 | 1 | 17795 | 49 |
DTNA |
4.581e-02 | -3.08 | Carb_anhydrase | pfam domains | PF00194 | 17 | 1 | 17795 | 49 |
PTPRZ1 |
4.590e-02 | -3.08 | response to amino acid | biological process | GO:0043200 | 127 | 2 | 18204 | 49 |
SLC1A2,NTRK2 |
4.590e-02 | -3.08 | cell-cell junction assembly | biological process | GO:0007043 | 127 | 2 | 18204 | 49 |
CDH20,PARD3 |
4.606e-02 | -3.08 | extraskeletal | COSMIC cancer mutations | extraskeletal | 903 | 6 | 16828 | 49 |
SPARCL1,PTPRZ1,ATP1A2,ITPR2,ABLIM1,NPAS3 |
4.615e-02 | -3.08 | cell cortex | cellular component | GO:0005938 | 313 | 3 | 19108 | 49 |
ITPR2,PARD3B,PARD3 |
4.622e-02 | -3.07 | Methadone Action Pathway | SMPDB pathways | SMP0000408 | 32 | 1 | 1369 | 2 |
ATP1A2 |
4.622e-02 | -3.07 | Nicotine Action Pathway | SMPDB pathways | SMP0000431 | 32 | 1 | 1369 | 2 |
ATP1A2 |
4.622e-02 | -3.07 | Citalopram Action Pathway | SMPDB pathways | SMP0000424 | 32 | 1 | 1369 | 2 |
ATP1A2 |
4.652e-02 | -3.07 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 4 | 18204 | 49 |
SLC1A3,SLC1A2,ITPR2,RYR3 |
4.653e-02 | -3.07 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 2 | 19454 | 50 |
NTM,GPM6A |
4.655e-02 | -3.07 | glial cell development | biological process | GO:0021782 | 128 | 2 | 18204 | 49 |
NTRK2,PARD3 |
4.662e-02 | -3.07 | membrane | cellular component | GO:0016020 | 9220 | 30 | 19108 | 49 |
NTM,SLC4A4,NRXN1,ITPR2,DTNA,PCDH9,SLC1A2,MACF1,LSAMP,ZNRF3,NTRK2,CADM1,BMPR1B,PREX2,ATP1A2,GPM6A,TNIK,CDH20,CTNNA2,PTPRZ1,ATP13A4,RYR3,PARD3B,NRG3,CTNND2,NKAIN3,GPC5,PARD3,SLC1A3,SFXN5 |
4.671e-02 | -3.06 | phosphatidylcholine transporter activity | molecular function | GO:0008525 | 18 | 1 | 18094 | 48 |
PITPNC1 |
4.671e-02 | -3.06 | transmembrane receptor protein tyrosine kinase activator activity | molecular function | GO:0030297 | 18 | 1 | 18094 | 48 |
NRG3 |
4.696e-02 | -3.06 | Cadherins | gene3d domains | 2.60.40.60 | 114 | 2 | 14470 | 44 |
CDH20,PCDH9 |
4.716e-02 | -3.05 | SOX15 (SRY-box transcription factor 15) | protein interactions | 6665 | 135 | 2 | 19454 | 50 |
NFIA,TRPS1 |
4.716e-02 | -3.05 | FOXP1 (forkhead box P1) | protein interactions | 27086 | 135 | 2 | 19454 | 50 |
NFIA,SOX5 |
4.719e-02 | -3.05 | Cell-Cell communication | REACTOME pathways | R-HSA-1500931 | 133 | 2 | 10285 | 27 |
PARD3,CADM1 |
4.720e-02 | -3.05 | response to organophosphorus | biological process | GO:0046683 | 129 | 2 | 18204 | 49 |
ITPR2,RYR3 |
4.722e-02 | -3.05 | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | 15813 | 49 | 16828 | 49 |
NTRK2,NRG3,PCDH9,RANBP3L,MAML2,NTM,MSI2,SFXN5,SLC1A2,GPC5,TNIK,QKI,SLC4A4,PREX2,SOX5,RORA,AHCYL2,PITPNC1,NRXN1,GPM6A,SPARCL1,NKAIN3,ABLIM1,TRPS1,PARD3,BMPR1B,GLIS3,NPAS3,RYR3,NFIA,ITPR2,MACF1,MEIS2,CADM1,ZNRF3,PARD3B,ATP1A2,CTNND2,SLC1A3,LSAMP,FBXL7,PAMR1,ZBTB20,ATP13A4,NHSL1,PTPRZ1,CDH20,NEBL,DTNA |
4.737e-02 | -3.05 | circulatory system process | biological process | GO:0003013 | 508 | 4 | 18204 | 49 |
SLC1A3,SLC4A4,SLC1A2,ATP1A2 |
4.738e-02 | -3.05 | receptor catabolic process | biological process | GO:0032801 | 18 | 1 | 18204 | 49 |
ZNRF3 |
4.738e-02 | -3.05 | negative regulation of sodium ion transport | biological process | GO:0010766 | 18 | 1 | 18204 | 49 |
ATP1A2 |
4.738e-02 | -3.05 | dendritic spine morphogenesis | biological process | GO:0060997 | 18 | 1 | 18204 | 49 |
CTNND2 |
4.738e-02 | -3.05 | negative regulation of anoikis | biological process | GO:2000811 | 18 | 1 | 18204 | 49 |
NTRK2 |
4.738e-02 | -3.05 | cardiac myofibril assembly | biological process | GO:0055003 | 18 | 1 | 18204 | 49 |
NEBL |
4.738e-02 | -3.05 | positive regulation of myelination | biological process | GO:0031643 | 18 | 1 | 18204 | 49 |
PARD3 |
4.738e-02 | -3.05 | positive regulation of circadian rhythm | biological process | GO:0042753 | 18 | 1 | 18204 | 49 |
RORA |
4.752e-02 | -3.05 | Leu-rich_rpt_Cys-con_subtyp | interpro domains | IPR006553 | 18 | 1 | 18521 | 50 |
FBXL7 |
4.754e-02 | -3.05 | ZYX (zyxin) | protein interactions | 7791 | 316 | 3 | 19454 | 50 |
ABLIM1,MACF1,NEBL |
4.764e-02 | -3.04 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 1 | 19108 | 49 |
GPM6A |
4.764e-02 | -3.04 | postsynaptic specialization, intracellular component | cellular component | GO:0099091 | 19 | 1 | 19108 | 49 |
TNIK |
4.764e-02 | -3.04 | cation-transporting ATPase complex | cellular component | GO:0090533 | 19 | 1 | 19108 | 49 |
ATP1A2 |
4.764e-02 | -3.04 | astrocyte projection | cellular component | GO:0097449 | 19 | 1 | 19108 | 49 |
SLC1A2 |
4.774e-02 | -3.04 | SYT7 (synaptotagmin 7) | protein interactions | 9066 | 19 | 1 | 19454 | 50 |
NRXN1 |
4.774e-02 | -3.04 | GCHFR (GTP cyclohydrolase I feedback regulator) | protein interactions | 2644 | 19 | 1 | 19454 | 50 |
NEBL |
4.774e-02 | -3.04 | NLGN1 (neuroligin 1) | protein interactions | 22871 | 19 | 1 | 19454 | 50 |
NRXN1 |
4.774e-02 | -3.04 | PHYHIPL (phytanoyl-CoA 2-hydroxylase interacting protein like) | protein interactions | 84457 | 19 | 1 | 19454 | 50 |
GPM6A |
4.774e-02 | -3.04 | CNTNAP4 (contactin associated protein family member 4) | protein interactions | 85445 | 19 | 1 | 19454 | 50 |
MACF1 |
4.774e-02 | -3.04 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | TNR (tenascin R) | protein interactions | 7143 | 19 | 1 | 19454 | 50 |
PTPRZ1 |
4.774e-02 | -3.04 | SPZ1 (spermatogenic leucine zipper 1) | protein interactions | 84654 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | C3orf62 (chromosome 3 open reading frame 62) | protein interactions | 375341 | 19 | 1 | 19454 | 50 |
ATP1A2 |
4.774e-02 | -3.04 | INKA1 (inka box actin regulator 1) | protein interactions | 389119 | 19 | 1 | 19454 | 50 |
ZBTB20 |
4.793e-02 | -3.04 | skin-back-malignant_melanoma | COSMIC cancer mutations | skin-back-malignant_melanoma | 280 | 3 | 16828 | 49 |
TNIK,ATP1A2,PREX2 |
4.832e-02 | -3.03 | DWA | smart domains | SM00523 | 12 | 1 | 9717 | 40 |
NFIA |
4.832e-02 | -3.03 | ZnF_GATA | smart domains | SM00401 | 12 | 1 | 9717 | 40 |
TRPS1 |
4.839e-02 | -3.03 | central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I | 17 | 1 | 16828 | 49 |
QKI |
4.839e-02 | -3.03 | optic_nerve | COSMIC cancer mutations | optic_nerve | 17 | 1 | 16828 | 49 |
QKI |
4.842e-02 | -3.03 | TBL1X (transducin beta like 1 X-linked) | protein interactions | 6907 | 137 | 2 | 19454 | 50 |
SOX5,NFIA |
4.843e-02 | -3.03 | oligoastrocytoma_Grade_II | COSMIC cancer mutations | oligoastrocytoma_Grade_II | 121 | 2 | 16828 | 49 |
DTNA,CDH20 |
4.852e-02 | -3.03 | carboxylic acid transmembrane transport | biological process | GO:1905039 | 131 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
4.859e-02 | -3.02 | human chr18q12.1 | chromosome location | human chr18q12.1 | 26 | 1 | 26134 | 50 |
DTNA |
4.876e-02 | -3.02 | Defective B3GALT6 causes EDSP2 and SEMDJL1 | REACTOME pathways | R-HSA-4420332 | 19 | 1 | 10285 | 27 |
GPC5 |
4.876e-02 | -3.02 | Defective B3GAT3 causes JDSSDHD | REACTOME pathways | R-HSA-3560801 | 19 | 1 | 10285 | 27 |
GPC5 |
4.876e-02 | -3.02 | Defective B4GALT7 causes EDS, progeroid type | REACTOME pathways | R-HSA-3560783 | 19 | 1 | 10285 | 27 |
GPC5 |
4.879e-02 | -3.02 | transport | biological process | GO:0006810 | 3615 | 15 | 18204 | 49 |
SLC4A4,ITPR2,ATP1A2,GPM6A,SLC1A2,RYR3,ATP13A4,MACF1,SLC1A3,RANBP3L,QKI,NTRK2,SFXN5,PITPNC1,NRXN1 |
4.881e-02 | -3.02 | cytoskeleton organization | biological process | GO:0007010 | 1251 | 7 | 18204 | 49 |
ABLIM1,CTNNA2,TNIK,PARD3B,MACF1,NEBL,PARD3 |
4.907e-02 | -3.01 | Cystinuria | SMPDB pathways | SMP0000723 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Hartnup Disorder | SMPDB pathways | SMP0000189 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Bendroflumethiazide Action Pathway | SMPDB pathways | SMP0000090 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Methyclothiazide Action Pathway | SMPDB pathways | SMP0000081 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Amiloride Action Pathway | SMPDB pathways | SMP0000133 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Furosemide Action Pathway | SMPDB pathways | SMP0000115 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Lysinuric Protein Intolerance (LPI) | SMPDB pathways | SMP0000585 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Metolazone Action Pathway | SMPDB pathways | SMP0000105 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Ethacrynic Acid Action Pathway | SMPDB pathways | SMP0000097 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Chlorothiazide Action Pathway | SMPDB pathways | SMP0000078 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Polythiazide Action Pathway | SMPDB pathways | SMP0000080 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Quinethazone Action Pathway | SMPDB pathways | SMP0000091 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Lysinuric Protein Intolerance | SMPDB pathways | SMP0000197 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Glucose Transporter Defect (SGLT2) | SMPDB pathways | SMP0000184 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Torsemide Action Pathway | SMPDB pathways | SMP0000118 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Trichlormethiazide Action Pathway | SMPDB pathways | SMP0000121 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Hydroflumethiazide Action Pathway | SMPDB pathways | SMP0000108 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Bumetanide Action Pathway | SMPDB pathways | SMP0000088 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Hydrochlorothiazide Action Pathway | SMPDB pathways | SMP0000100 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Chlorthalidone Action Pathway | SMPDB pathways | SMP0000122 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Cyclothiazide Action Pathway | SMPDB pathways | SMP0000103 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Triamterene Action Pathway | SMPDB pathways | SMP0000132 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Blue Diaper Syndrome | SMPDB pathways | SMP0000583 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Indapamide Action Pathway | SMPDB pathways | SMP0000110 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Eplerenone Action Pathway | SMPDB pathways | SMP0000135 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Kidney Function | SMPDB pathways | SMP0000483 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Spironolactone Action Pathway | SMPDB pathways | SMP0000134 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Iminoglycinuria | SMPDB pathways | SMP0000193 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.911e-02 | -3.01 | sequence-specific double-stranded DNA binding | molecular function | GO:1990837 | 1547 | 8 | 18094 | 48 |
NPAS3,ZBTB20,NFIA,RORA,GLIS3,MEIS2,SOX5,TRPS1 |
4.924e-02 | -3.01 | alkali metal ion binding | molecular function | GO:0031420 | 19 | 1 | 18094 | 48 |
ATP1A2 |
4.924e-02 | -3.01 | transmembrane receptor protein serine/threonine kinase activity | molecular function | GO:0004675 | 19 | 1 | 18094 | 48 |
BMPR1B |
4.966e-02 | -3.00 | cell division | biological process | GO:0051301 | 516 | 4 | 18204 | 49 |
PARD3,PARD3B,FBXL7,SOX5 |
4.968e-02 | -3.00 | DUSP22 (dual specificity phosphatase 22) | protein interactions | 56940 | 139 | 2 | 19454 | 50 |
QKI,CTNNA2 |
4.983e-02 | -3.00 | PK_Tyr_Ser-Thr | pfam domains | PF07714 | 130 | 2 | 17795 | 49 |
BMPR1B,NTRK2 |
4.987e-02 | -3.00 | ligand-gated monoatomic cation channel activity | molecular function | GO:0099094 | 135 | 2 | 18094 | 48 |
RYR3,ITPR2 |
4.995e-02 | -3.00 | excitatory synapse assembly | biological process | GO:1904861 | 19 | 1 | 18204 | 49 |
NRXN1 |
4.995e-02 | -3.00 | regulation of neurotransmitter uptake | biological process | GO:0051580 | 19 | 1 | 18204 | 49 |
ATP1A2 |
4.995e-02 | -3.00 | vascular associated smooth muscle cell differentiation | biological process | GO:0035886 | 19 | 1 | 18204 | 49 |
QKI |
4.995e-02 | -3.00 | negative regulation of peptidyl-threonine phosphorylation | biological process | GO:0010801 | 19 | 1 | 18204 | 49 |
PARD3 |
4.995e-02 | -3.00 | cerebellar Purkinje cell layer morphogenesis | biological process | GO:0021692 | 19 | 1 | 18204 | 49 |
RORA |
4.995e-02 | -3.00 | response to potassium ion | biological process | GO:0035864 | 19 | 1 | 18204 | 49 |
ATP1A2 |
4.995e-02 | -3.00 | microvillus organization | biological process | GO:0032528 | 19 | 1 | 18204 | 49 |
TNIK |
4.995e-02 | -3.00 | vocalization behavior | biological process | GO:0071625 | 19 | 1 | 18204 | 49 |
NRXN1 |